Notis Global (NGBL) S-1/A 1 Dec 15 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2015
Document And Entity Information [Abstract]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	AMENDMENT NO. 1 TO FORM S-1
Document Period End Date	Sep. 30, 2015
Trading Symbol	MDBX
Entity Registrant Name	Medbox, Inc.
Entity Central Index Key	1,547,996
Entity Filer Category	Smaller Reporting Company

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$ 346,761	$ 101,182	$ 168,003
Marketable securities	94,817	94,776	184,800
Accounts receivable		8,774	339,735
Notes receivable			115,000
Inventory	187,844	961,236	632,986
Deposits in escrow	15,000	400,476
Prepaid insurance	240,428	31,491	0
Prepaid expenses and other current assets	172,039	34,729	89,241
Total current assets	1,056,889	1,632,664	1,529,765
Property and equipment, net of accumulated depreciation	573,470	158,318	140,658
Land	4,945,000
Assets held for resale		399,594	0
Investments, at cost			1,200,000
Construction in progress	68,959
Intangible assets, net of accumulated amortization	669,086	709,153	682,429
Note receivable, net of allowance	0	0
Goodwill	1,260,037	1,260,037	1,090,037
Deferred Costs	299,018
Deposits and other assets	140,212	104,726	98,726
Total assets	9,012,671	4,264,492	4,741,615
Current liabilities
Accounts payables	3,609,486	1,713,627	305,934
Accrued interest payable	324,330	372,937
Accrued expenses	122,663	610,497	142,380
Deferred revenue, current	219,487	204,091	683,621
Notes payable	431,415	261,434	75,000
Related party notes payable		678,877	111,794
Convertible notes payable, net of discount	4,993,891	2,524,427
Derivative Liability	4,885,286	3,691,853
Customer deposits	1,057,340	1,525,808	785,861
Total current liabilities	16,741,461	11,583,551	2,104,590
Accrued settlement and severance expenses	912,065
Deferred revenue, less current portion	378,041	568,515
Deferred tax liability	160,000	160,000
Total liabilities	$ 21,605,986	$ 12,312,066	$ 2,104,590
Commitments and Contingencies
Stockholders' Equity/(Deficit)
Preferred stock	$ 1,000	$ 3,000	$ 3,000
Common stock	99,250	30,497	29,526
Additional paid-in capital	35,823,112	15,315,110	8,156,358
Common stock subscribed			(15,000)
Treasury stock	(1,209,600)	(1,209,600)
Accumulated deficit	(47,198,689)	(22,078,193)	(5,536,859)
Accumulated other comprehensive loss	(108,388)	(108,388)
Total stockholders' equity/(deficit)	(12,593,315)	(8,047,574)	2,637,025
Total liabilities and stockholders' deficit	9,012,671	4,264,492	$ 4,741,615
Notes Payable, less current portion	4,326,484
Directors [Member]
Current liabilities
Accrued expenses	$ 185,498
As Originally Presented [Member]
Current assets
Prepaid expenses and other current assets		$ 66,220

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Property and equipment, accumulated depreciation (in Dollars)	$ 59,210	$ 50,192	$ 21,123
Intangible assets, accumulated amortization (in Dollars)	123,567	83,500	$ 32,750
Note receivable, allowance	350,000
Convertible notes payable, discount	$ 266,497	$ 1,225,573
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized	10,000,000	10,000,000	10,000,000
Preferred stock, issued	1,000,000	3,000,000	3,000,000
Preferred stock, outstanding	1,000,000	3,000,000	3,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, authorized	100,000,000	100,000,000	100,000,000
Common stock, issued	99,250,518	30,496,909	29,525,750
Common stock, outstanding	99,250,518	30,496,909	29,525,750

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Revenue	$ 288,961	$ 147,884	$ 390,156	$ 534,082	$ 621,106	$ 2,062,083	$ 1,176,829
Revenue, related party	25,192	25,192	74,754	50,110	75,301
Less: allowances and refunds				(60,000)	(67,275)
Net revenue	314,153	173,076	464,910	524,192	629,132	2,062,083	1,176,829
Cost of revenues	656,383	1,813,562	1,837,711	3,492,105	3,796,651	2,660,749	1,051,135
Gross profit/(loss)	(342,230)	(1,640,486)	(1,372,801)	(2,967,913)	(3,167,519)	(598,666)	125,694
Operating expenses
Selling and marketing	103,765	319,204	442,261	749,212	933,627	664,383	806,221
Research and development		61,623		136,656	242,232	74,861	176,964
General and administrative	3,506,029	1,984,303	12,627,644	3,183,382	9,109,205	2,456,435	895,798
Total operating expenses	3,609,794	2,365,130	13,069,905	4,069,250	10,285,064	3,195,679	1,878,983
Loss from operations	(3,952,024)	(4,005,616)	(14,442,706)	(7,037,163)	(13,452,583)	(3,794,345)	(1,753,289)
Other income (expense)
Interest income (expense), net	(195,426)	(123,007)	(289,226)	(71,343)	(1,282,761)	6,905	(4,948)
Financing Costs	(522,379)		(2,822,011)
Change in fair value of derivative liabilities	(2,544,014)	548,315	509,057	548,315	(1,805,990)
Amortization of debt discount	(2,071,898)	(216,224)	(8,121,537)	(216,224)	(935,290)
Other income (expense)	(6,208)		45,927	(26,511)
Total other income (expense)	(5,339,925)	209,084	(10,677,790)	234,237	(3,088,751)	6,905	(4,948)
Loss before provision for income taxes	(9,291,949)	(3,796,532)	(25,120,496)	(6,802,926)	(16,541,334)	(3,787,440)	(1,758,237)
Provision for income taxes	0	0	0	0		4,000
Net loss	$ (9,291,949)	$ (3,796,532)	$ (25,120,496)	$ (6,802,926)	$ (16,541,334)	$ (3,791,440)	$ (1,758,237)
Loss per share attributable to common stockholders
Basic (in Dollars per share)	$ (0.13)	$ (0.13)	$ (0.54)	$ (0.22)	$ (0.55)	$ (0.13)	$ (0.07)
Diluted (in Dollars per share)	$ (0.13)	$ (0.13)	$ (0.54)	$ (0.22)	$ (0.55)	$ (0.13)	$ (0.07)
Weighted average shares outstanding
Basic (in Shares)	73,524,951	30,371,299	46,945,806	30,472,447	30,067,693	28,971,983	25,119,175
Diluted (in Shares)	73,524,951	30,371,299	46,945,806	30,472,447	30,067,693	28,971,983	25,119,175
Other Comprehensive loss
Net loss	$ (9,291,949)	$ (3,796,532)	$ (25,120,496)	$ (6,802,926)	$ (16,541,334)	$ (3,791,440)	$ (1,758,237)
Unrealized loss from marketable securities		(158,507)	0	(158,507)	(108,388)
Comprehensive loss	$ (9,291,949)	$ (3,955,039)	$ (25,120,496)	$ (6,961,433)	$ (16,649,722)	$ (3,791,440)	$ (1,758,237)

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Stockholders' Deficit - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Common Stock Subscribed [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings (Accumulated) (Deficit) [Member]	Accumulated Other Comprehensive Loss [Member]
Balances at Jan. 01, 2012	$ 310,193	$ 6,000	$ 20,830			$ 270,545	$ 12,818
Balances (in Shares) at Jan. 01, 2012		6,000,000	20,829,678		0
Issuance of common stock for acquisition PVMI			$ 4,000			(4,000)
Issuance of common stock for acquisition PVMI (in Shares)			4,000,000
Buyout of PVMI shareholders	(125,000)					(125,000)
Issuance of common stock, net of issuance costs	858,415		$ 2,463			855,952
Issuance of common stock, net of issuance costs (in Shares)			2,463,366
Proceeds from common stock subscribed			$ 74	$ (153,250)		153,176
Proceeds from common stock subscribed (in Shares)			74,100
Capital contributions, related parties	561,000					561,000
Net loss	(1,758,237)						(1,758,237)
Balances at Dec. 31, 2012	(153,629)	$ 6,000	$ 27,367	(153,250)		1,711,673	(1,745,419)
Balances (in Shares) at Dec. 31, 2012		6,000,000	27,367,144
Issuance of common stock, net of issuance costs	4,486,541		$ 2,115			4,484,426
Issuance of common stock, net of issuance costs (in Shares)			2,115,100
Issuance of shares and warrants to settle accounts payable	119,553		$ 44			119,509
Issuance of shares and warrants to settle accounts payable (in shares)			43,506
Issuance of warrants in connection with convertible notes payable	1,166,000					1,166,000
Cancellation of preferred stock		$ (3,000)				3,000
Cancellation of preferred stock (in Shares)		(3,000,000)
Proceeds from common stock subscribed				138,250		(138,250)
Capital contributions, related parties	810,000					810,000
Net loss	(3,791,440)						(3,791,440)
Balances at Dec. 31, 2013	2,637,025	$ 3,000	$ 29,526	(15,000)		8,156,358	(5,536,859)
Balances (in Shares) at Dec. 31, 2013		3,000,000	29,525,750
Issuance of common stock, net of issuance costs	2,427,859		$ 486			2,427,373
Issuance of common stock, net of issuance costs (in Shares)			485,830
Stock-based compensation	4,415,799		$ 178			4,415,621
Stock-based compensation (in Shares)			178,125
Exercise of warrants			$ 253			(253)
Exercise of warrants (in shares)			252,812
Issuance of shares and warrants to settle accounts payable	316,065		$ 54			316,011
Issuance of shares and warrants to settle accounts payable (in shares)			54,392
Proceeds from common stock subscribed	15,000			$ 15,000
Treasury stock	(1,209,600)				$ (1,209,600)
Treasury stock (in Shares)					(60,000)
Unrealized loss from marketable securities	(108,388)							$ (108,388)
Net loss	(16,541,334)						(16,541,334)
Balances at Dec. 31, 2014	(8,047,574)	$ 3,000	$ 30,497		$ (1,209,600)	15,315,110	(22,078,193)	(108,388)
Balances (in Shares) at Dec. 31, 2014		3,000,000	30,496,909		(60,000)
Stock-based compensation	5,331,382		$ 147			5,331,235
Stock-based compensation (in Shares)			147,145
Exercise of warrants	278,951		$ 206			278,745
Exercise of warrants (in shares)			206,480
Issuance of shares and warrants to settle accounts payable	$ 364,728		$ 1,633			363,095
Issuance of shares and warrants to settle accounts payable (in shares)	1,633,047		1,633,047
Conversions of convertible notes payable	$ 10,157,662		$ 67,475			10,090,187
Conversions of convertible notes payable (in shares)			67,475,105
Issuance of warrants in connection with convertible notes payable	4,304,522					4,304,522
Exercise of warrants in connection with convertible notes payable	137,510		$ 2,292			135,218
Exercise of warrants in connection with convertible notes payable (in shares)			2,291,832
Cancellation of preferred stock		$ (2,000)	$ (3,000)			5,000
Share cancelation (in shares)		(2,000,000)	(3,000,000)
Unrealized loss from marketable securities	0							0
Net loss	(25,120,496)						(25,120,496)
Balances at Sep. 30, 2015	$ (12,593,315)	$ 1,000	$ 99,250		$ (1,209,600)	$ 35,823,112	$ (47,198,689)	$ (108,388)
Balances (in Shares) at Sep. 30, 2015		1,000,000	99,250,518		(60,000)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities
Net loss	$ (25,120,496)	$ (6,802,926)	$ (16,541,334)	$ (3,791,440)	$ (1,758,237)
Adjustments to reconcile net income (loss) to net cash
Depreciation and amortization	90,315	59,364	79,819	69,564	29,922
Gain on the sale of property and equipment				(20,682)
Provisions and allowances		60,000	67,275
Gain on sale of investments and property and equipment		(9,600)	(9,600)
Market value of securities received for services			(203,165)
Charges from escrow deposits	280,400
Inventory valuation reserve	497,439
Market value of securities received for services		(190,132)		(1,166,000)
Change in fair value of derivative liability	(509,057)	(548,315)	1,805,990
Amortization of debt discount	8,121,537	216,224	935,290
Financing costs	2,822,011
Stock based compensation	5,331,382	1,031,640	4,415,799
Changes in operating assets and liabilities
Accounts receivable	8,774	213,424	263,686	518,171	(1,042,000)
Inventories	275,953	110,788	(328,250)	(48,180)	(316,254)
Deposits in escrow	55,076		(400,476)
Prepaid insurance	(208,937)
Prepaid expenses and other assets	(172,796)	(896,954)	17,021	(36,725)
Deferred costs	(299,018)
Accounts payables	2,521,976	907,684	1,723,759	(393,458)	190,668
Accrued interest payable	214,886		372,990
Accrued expenses	(487,834)		468,064
Accrued settlement and severance expenses	912,065
Customer deposits	(468,468)	807,347	924,747	675,762
Deferred revenue	(175,078)	390,311	88,985	(716,409)	1,451,030
Net cash used in operating activities	(6,124,372)	(4,651,145)	(6,319,400)	(3,743,397)	(1,444,871)
Cash flows from investing activities
Issuance of note receivable		(115,000)		(115,000)
Receipts on notes receivable, net			115,000		104,650
Purchase of property and equipment	(14,795)	(32,982)	(46,729)	(134,451)
Purchase of real estate	(500,000)	(399,594)	(399,594)
Purchase of intangible assets		(166,183)	(87,474)
Advances for investments				(1,250,000)
Construction in Progress	(68,959)
Net cash used in investing activities	(583,754)	(713,759)	(418,797)	(1,499,451)	104,650
Cash flows from financing activities
Receipts on advances to officer					177,050
Contribution from related parties				810,000	561,000
Payments on a long term debt				(16,307)	(15,771)
Payments on (proceeds from) notes payable	(3,535)	(75,000)	(75,000)	(150,000)	50,000
Dividends paid to subsidary's shareholders					(49,965)
Proceeds from (payments on) Related parties notes payable	(624,888)	379,880	567,083	(746,285)	744,038
Proceeds from issuance of notes payable		299,605	261,434
Proceeds from issuance of common stock		2,442,859	2,442,859	4,486,541	858,415
Proceeds from issuance of convertible notes payable, net	7,432,128	3,500,000	3,475,000
Proceeds from issuance of convertible notes payable from related parties	150,000
Net cash provided by financing activities	6,953,705	6,547,344	6,671,376	4,383,949	2,324,767
Net decrease (increase) in cash	245,579	1,182,440	(66,821)	(858,899)	984,546
Cash and cash equivalents, beginning of period	101,182	168,003	168,003	1,026,902	42,356
Cash and cash equivalents, end of period	346,761	1,350,443	101,182	168,003	1,026,902
Supplemental disclosures of cash flow information:
Cash paid for interest	1,151	37,078	2,834	2,106	4,975
Cash paid for income tax	0	0		10,851	59,141
Non- cash investing and financing activities:
Marketable securities received for accounts receivable			(184,000)	184,800	125,000
Common stock issued upon debt conversion	6,261,474
Liabilities assumed for Vaporfection				73,739
Purchase of land with notes payable	5,000,000
Cancellation of preferred stock				3,000
Treasury stock received for sale of advances on investments			1,200,000
Common stock warrants issued for Vaporfection		$ 190,132		1,166,000
Directors [Member]
Changes in operating assets and liabilities
Accrued expenses	185,498
Repayments Of Debt [Member]
Non- cash investing and financing activities:
Common stock issued				53,500
Stock Issued For Accounts Payable [Member]
Non- cash investing and financing activities:
Common stock issued	$ 364,728		$ 316,065	$ 119,536
Stock Issued For Related Party Notes Payable [Member]
Non- cash investing and financing activities:
Common stock issued					125,000
PVM International Inc. (PVMI) [Member]
Non- cash investing and financing activities:
Common stock issued					$ 2,000

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	9 Months Ended
	Sep. 30, 2015USD ($)
Statement of Cash Flows [Abstract]
Proceeds from issuance of convertible notes payable, net fees	$ 352,000

Business Organization, Nature o

Business Organization, Nature of Operations	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations	NOTE 1 – BUSINESS ORGANIZATION, NATURE OF OPERATIONS Medbox, Inc, which is incorporated in the state of Nevada (the “Company”), provides specialized consulting services to the marijuana industry and sells associated patented products, and medical vaporization devices. The Company works with clients who seek to enter the medical and cultivation marijuana markets in those states where approved. Medbox offers turnkey solutions that assist with licensing and compliance, site selection, design and permitting, safety and security, along with full build-out and operational oversight. The Company’s consulting solutions and technology create structure and process for clients and their respective businesses in this rapidly emerging sector. In addition, through its wholly owned subsidiary, Vaporfection International, Inc. (“VII”), the Company sells a line of vaporizer and accessory products online and through distribution partners. The Company is headquartered in Los Angeles, California. The Company holds the license to operate a dispensary in Portland, Oregon, and a master lease on the property in which the dispensary is located. The Company entered into an Operating Agreement with an unrelated party (the “Operator”) in which the Operator will manage and operate the Dispensary. Per the terms of the Agreement, the Dispensary is “under the exclusive supervision and control of Operator, which shall be responsible for the proper and efficient operation of the Dispensary”. The term of the Agreement includes an initial term, which is five years, and a renewal term for an additional five years. The renewal term is at the discretion of the Operator. The procurement fee for the dispensary was $400,000 (initially classified in Deferred Revenue), of which $50,000 was paid upon execution and delivery of the Agreement, and the remaining $350,000 is to be paid monthly in the amount of gross receipts less payroll and costs of inventories. If the procurement fees are not paid within six months, the payment terms become a minimum monthly payment of $5,000. As of the date of this report, there have been no amounts available under the above calculation to make payments towards the procurement fees. The remaining $350,000 is evidenced by a Note Receivable to the Company. As of June 30, 2015 the Company determined it was not assured of the timing of the collectability of the Note Receivable and therefore has set up an allowance in the amount of $350,000 for the Note Receivable, and has reduced the Deferred Revenue to $50,000. After the Procurement Fee is paid in full, it is the parties’ plan that ownership of the Dispensary (through a new merged corporation) will be apportioned 51% to Operator and 49% to Medbox. The Agreement also includes an annual Licensor Fee of 5% of the annual Gross Revenues, which will begin after the Procurement Fees have been paid in full. The Company has determined that they do not hold the controlling financial interest in the Dispensary and are not the primary beneficiary, and therefore will not consolidate the Dispensary in their financial statements.	NOTE 1 – BUSINESS ORGANIZATION, NATURE OF OPERATIONS Business Description Medbox, Inc. (the “Company”) was incorporated in the state of Nevada on June 16, 1977, originally as Rabatco, Inc., subsequently changing its name on May 12, 2000 to MindfulEye, Inc., and again on August 30, 2011 to Medbox, Inc. Medbox, Inc. provides specialized consulting services to the marijuana industry and sells associated patented products, including its Medbox medical dispensing system and medical vaporization devices. The Company works with clients who seek to enter the medical and cultivation marijuana markets in those states where approved. Medbox offers turnkey solutions that assist with licensing and compliance, site selection, design and permitting, safety and security, along with full build-out and operational oversight. Medbox’s consulting solutions and technology create structure and process for clients and their respective businesses in this rapidly emerging sector. In addition, through its wholly owned subsidiary, Vaporfection International, Inc. (“VII”), the Company sells a line of vaporizer and accessory products online and through distribution partners. The Company is headquartered in Los Angeles, California. On December 31, 2011, Medbox, Inc. entered into a Stock Purchase Agreement with PVM International, Inc. (“PVMI”). Pursuant to two separate closings held on January 1, 2012 and December 31, 2012, the Company acquired from PVMI all of the outstanding shares of common stock in (i) Prescription Vending Machines, Inc., (PVM) (ii) Medicine Dispensing Systems, Inc. (“MDS, Inc.”) (its Arizona subsidiary), and (iii) Medbox, Inc. (its California subsidiary that is currently inactive) (these three listed subsidiaries are hereafter referred to as the “PVMI Named Subsidiaries”), in exchange for two million shares of the Company’s common stock and a $1 million promissory note. The transaction between Medbox, Inc. and PVMI was accounted for as a reverse acquisition, where Medbox, Inc. (the legal acquirer) is considered the accounting acquiree and the PVMI Named Subsidiaries (the legal acquiree) are considered the accounting acquirer. The assets and liabilities are transferred at their historical cost with the capital structure of Medbox, Inc. Medbox, Inc. is deemed a continuation of the business of PVMI Named Subsidiaries and the historical financial statements of PVMI Named Subsidiaries are the historical financial statements of Medbox, Inc. The Company’s PVM subsidiary was incorporated in the state of California in 2008 and its subsidiary, MDS, Inc. was incorporated in the state of Arizona in 2011. On March 22, 2013, the Company entered into a Securities Purchase Agreement with Vapor Systems International, LLC to acquire 100% of the outstanding common stock of VII in exchange for warrants to purchase 260,854 shares of the Company’s common stock. In addition, the Company agreed to provide up to $1,600,000 in working capital to VII at the Company’s sole discretion which included $175,000 paid to the inventor of certain patents including a warrant to purchase 5,000 shares of the Company’s common stock. This transaction was closed in April 2013. Medbox, Inc., a Nevada corporation, operates the business directly and through the utilization of 6 operating subsidiaries, as follows: • Prescription Vending Machines, Inc., a California corporation, d/b/a Medicine Dispensing Systems in the State of California (“MDS”), which distributes our Medbox™ product and provides related consulting services described further below. • Vaporfection International, Inc., a Florida corporation through which we distribute our medical vaporizing products and accessories. • Medbox Property Investments, Inc., a California corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers. • MJ Property Investments, Inc., a Washington corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers in the state of Washington. • Medbox Management Services, Inc., a California corporation specializing in providing management oversight and compliance services to state-licensed dispensaries for cultivation, dispensing, and marijuana infused products (MIPS). • Medicine Dispensing Systems, Inc., an Arizona corporation, which distributes our Medbox dispensing system and provides related consulting services in the State of Arizona. In order to obtain the license for one of the Company’s clients the Company registered an affiliated nonprofit corporation Allied Patient Care, Inc. in the state of Oregon.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The consolidated financial statements include the accounts of Medbox, Inc. and its wholly owned subsidiaries: • Prescription Vending Machines, Inc., a California corporation, d/b/a Medicine Dispensing Systems in the State of California (“MDS”), which distributes our Medbox™ product and provides related consulting services described further below. • Vaporfection International, Inc., a Florida corporation through which we distribute our medical vaporizing products and accessories. • Medbox Property Investments, Inc., a California corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers. • MJ Property Investments, Inc., a Washington corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers in the state of Washington. • Medbox Management Services, Inc., a California corporation specializing in providing management oversight and compliance services to state-licensed dispensaries for cultivation, dispensing, and marijuana infused products (MIPS). • EWSD I, LLC, an Arizona corporation that owns property in Colorado. All intercompany transactions, amounts and balances have been eliminated. Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the condensed consolidated financial statements as well as the reported expenses during the reporting periods. The Company’s significant estimates and assumptions include the valuation of the Company’s common stock used in the valuation of goodwill, accounts receivable and note receivable collectability, inventory, advances on investments, the valuation of restricted stock and warrants received from customers, the amortization and recoverability of capitalized patent costs and useful lives of long-lived assets, the derivative liability, and income tax expense. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from these estimates. Basis of Presentation The accompanying unaudited interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. The results for the three and nine months ended September 30, 2015 are not necessarily indicative of results to be expected for a full year, any other interim periods or any future year or period. The accompanying unaudited interim financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our company’s audited financial statements and related notes included in our company’s Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC on March 26, 2015. The condensed consolidated balance sheet data as of December 31, 2014 was derived from audited consolidated financial statements. The Company has performed a review of all subsequent events through the date the unaudited interim financial statements were issued, and has determined that no additional disclosures are necessary. Concentrations of Credit Risk The Company maintains cash balances at several financial institutions in California, Illinois, and Florida. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. At September 30, 2015 and December 31, 2014, the Company’s uninsured balances totaled $22,504 and $0, respectively. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible. Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred. The Company incurred advertising and marketing costs of approximately $0 and $319,000 for the three months ended September 30, 2015 and 2014, respectively and approximately $0 and $749,000 for the nine months ended September 30, 2015 and 2014, respectively. Fair Value of Financial Instruments Pursuant to ASC No. 825, Financial Instruments Warrants and other financial assets received as a payment for the services provided are recorded as “Marketable securities” under the current assets if they are expected to be realized within 12 months. The Company uses the Black-Scholes model to measure the value of the warrants. At each reporting date the Company will reevaluate the value of marketable securities and record any changes in value to other comprehensive income (loss) under “Unrealized gain or losses from marketable securities”. Embedded derivative – The Company’s convertible notes payable include embedded features that require bifurcation and are accounted for as a separate embedded derivative (see Note 5). The Company has estimated the fair market value of the embedded derivative of the Notes based on a weighted probability model. The key valuation assumptions used consist of the price of the Company’s stock, a risk free interest rate based on the average yield of a one year Treasury note and expected volatility of the Company’s common stock all as of the measurement dates, and various estimated reset exercise prices allocated by probability. The Company considers these inputs Level 3 assumptions. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the liabilities that are measured at fair value on a recurring basis. Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) September 30, 2015 Marketable securities $ 94,817 $ 21,650 $ — $ 73,167 Derivative liability 4,885,286 — — 4,885,286 Total $ 4,980,103 $ 21,650 $ — $ 4,958,453 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the nine months ended September 30, 2015 Total Balance at January 1, 2015 $ 3,691,853 Additions 5,531,201 Reclassified to equity upon conversion (3,828,711 ) Change in fair value of conversion feature (509,057 ) Ending balance $ 4,885,286 Revenue Recognition We enter into transactions with clients who require our expertise and are interested in being granted the right to have us engage exclusively with them in certain territories (which we describe as territory rights) to obtain the necessary licenses to operate a dispensary or cultivation center for the location, and to consult in daily operations of the dispensary or cultivation center. Terms for each deal are varied and the sales arrangements typically include the delivery of our dispensing technology and dispensary location build-out and/or consultation on the location, licensing, build out and operation of a cultivation center. Medbox machines retail for approximately $50,000 for each machine set (including the POS system), and normally our contracts include the sale of the dispensary units within the scope of options to be provided that might also include location build out costs. Currently, our standard contracts have a five year term, call for an upfront, non-refundable consulting fee, and contain options including acquiring a Medbox dispensary machine and having the Company perform the buildouts for the location, at set prices. The Company has determined these optional purchases each constitute a separate purchasing decision, and therefore are considered a separate arrangement for revenue recognition purposes. Revenue on each of these options are evaluated for recognition when and if the customer decides to enter into the arrangement. Based on these contracts, and other auxiliary agreements, our current revenue model consists of the following income streams: Consulting fee revenues and build-outs Consulting fee revenues is a consistent component of our current and anticipated future revenues and is negotiated at the time we enter into a contract. Consulting revenue consists of providing ongoing consulting services over the life of the contract, to the established business in the areas of regulatory compliance, security, operations and other matters to operate the dispensary. The majority of the consulting fees arise from the upfront, non-refundable consulting fee in our standard contract, and is recognized using the straight line method over the life of the contract. Consulting fee revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonably assured. Revenue for the build-outs of the dispensary or cultivation center, if the customer chooses to have it performed by the Company, is recognized after issuance of a certificate of occupancy for the newly completed facility. This consists of a complete interior build-out of the retail store front including necessary construction (not to include installation of plumbing, electrical, HVAC systems and masonry), furniture fixtures and security system. Due to the uncertainties inherent in the emerging industry, the Company deferred recognition of revenue for sale of completed dispensaries with licenses until the issuance of a certificate of occupancy by the municipality. The certificate of occupancy is the final approval to open a dispensary in the customer’s community, at which time all criteria for revenue recognition, including delivery and acceptance, has been met. Additionally, at the time of the issuance of the certificate of occupancy, under the contract terms, all payments owed by the customer have been received by the Company. Similarly, recognition of revenue for sale of completed cultivation center is deferred until all licensing and permitting is completed and approved. Unbilled costs and associated fees related to the build-outs are recorded in inventory and are subject to valuation testing at each quarter end for net realizable value (lower of cost or market) and collectability. Other revenue includes sales of territory, location, and management rights The Company at times enters into specific contracts to assign exclusive location and management rights, for a dispensary, that the Company has been granted through a license approved by local authorities. These rights are transferred under a management rights agreement to an operator for retail, dispensary, or cultivation centers. The Company also has one agreement with a related party in which they granted the related party the exclusive rights to a certain territory. Other revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonably assured. In the sale of the territory rights to the related party, the revenue is being recognized over the term of the agreement. Revenues on VII product sales. Revenue from referral fees. Cost of Revenue Cost of revenue consists primarily of expenses associated with the delivery and distribution of our products and services. These include expenses related to the manufacture of our dispensary units, construction expense related to the customer dispensary, site selection and establishment of licensing requirements, and consulting expense for the continued management of the dispensary unit build out, server and security equipment, rent expense, energy and bandwidth costs, and support and maintenance costs prior to when the client moves in. We only begin capitalizing costs when we have obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses then the excess cost above net realizable value is written off to cost of revenues. In addition, cost of revenue related to our vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfilment, shipping, inventory storage and inventory management costs. Inventory Inventory is stated at the lower of cost or market value. Cost is determined on a cost basis that approximates the first-in, first-out (FIFO) method. Work in process and related capitalized costs includes costs to build out a dispensary in Portland Oregon that opened in the second quarter of 2015. Costs include tenant improvements to the facility, furniture, fixtures and Medbox dispensary units to be used by the licensed operator. The costs related to the Portland dispensary have been classified in deferred costs until the related revenue is recognized. Basic and Fully Diluted Net Income/Loss Per Share Basic net income/loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share includes the effects of any outstanding options, warrants and other potentially dilutive securities. The Company did not consider any potential common shares in the computation of diluted loss per share for the three and nine months ending September 30, 2015 and 2014, due to the net loss, as they would have an anti-dilutive effect on EPS. As of September 30, 2014, the Company had 3,000,000 shares of Series A preferred stock outstanding with par value of $0.001 that could have been converted into 15,000,000 shares of the Company’s common stock. On August 24, 2015, 2 million shares of Series A preferred stock was cancelled, leaving 1 million shares outstanding at September 30, 2015 . Additionally the Company has approximately 14,084,000 warrants to purchase common stock outstanding as of September 30, 2015. The Company also has approximately $4,994,000 in convertible debentures outstanding at September 30, 2015, whose underlying shares were not included that are convertible at the holders’ option at a conversion price of the lower of $0.75 or 51% of the VWAP over the last 40 days prior to conversion (subject to reset upon a future dilutive financing). Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC No. 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorizes. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes. An IRS audit is still open on the year ended December 31, 2011, in which the Company received a notice of deficiency for the amount of approximately $60,000. The Company is in discussions with the IRS to set up a payment plan for the amount owed. Commitments and Contingencies Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. Going Concern The accompanying unaudited interim financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of approximately $47,199,000 as of September 30, 2015. During the nine months ended September 30, 2015, the Company had a net loss of approximately $25,120,000, negative cash flow from operations of approximately $6,124,000 and negative working capital of approximately $15,685,000. The Company will need to raise capital in order to fund its operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement a business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. On August 14, 2015 and August 20, 2015, the Company entered into two Securities Purchase Agreements with two separate investors, in the aggregate principal amount of up to approximately $5,480,000 (collectively the “August 2015 Debentures”), of which approximately $2,729,000 was funded during the third quarter of 2015, with up to a remaining $2,751,000 still to be funded. Management is actively seeking additional financing and expects to complete additional financing arrangements in the next few months. The Company expects that these plans will provide it the necessary liquidity to continue operations for the next 12 months. To address its financing requirements, the Company will continue to execute on its business model by attempting to raise additional capital through the sales of debt or equity securities or other means. It is uncertain the Company can obtain financing to fund operating deficits until profitability is achieved. This need may be adversely impacted by: uncertain market conditions, approval of sites and licenses by regulatory bodies and adverse operating results. The outcome of these matters cannot be predicted at this time. Recent Accounting Pronouncements In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entities Ability to Continue as a Going Concern In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for annual reporting periods for public business entities beginning after December 15, 2017, including interim periods within that reporting period. The new standard permits the use of either the retrospective or cumulative effect transition method. The Company is currently evaluating the effect that ASU 2014-09 will have on its financial statements and related disclosures. The Company has not yet selected a transition method nor determined the effect of the standard on its ongoing financial reporting.	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The consolidated financial statements include the accounts of Medbox, Inc. and its wholly owned subsidiaries, as named in Note 1 above. All intercompany transactions have been eliminated. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the consolidated financial statements as well as the reported expenses during the reporting periods. The Company’s significant estimates and assumptions include the valuation of the Company’s common stock used in the valuation of goodwill, accounts receivable and note receivable collectability, inventory, advances on investments, the valuation of restricted stock and warrants received from customers, the amortization and recoverability of capitalized patent costs and useful lives of long-lived assets the derivative liability, and income tax expense. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from these estimates. Concentrations of Credit Risk The Company maintains cash balances at several financial institutions in the Portland, Oregon, Los Angeles, California area and Florida. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible. Three customers, one of which is a related party through the entity’s stock ownership in the Company (customer C) represented 72.1% of the total revenue of $629,132 for the year ended December 31, 2014. Customer December 31, 2014 January -December 2014 December 31, 2013 January -December 2013 Accounts Receivable Revenue Accounts Receivable Revenue Amount, $ % Amount, $ % Amount, $ % Amount, $ % A $ — — % $ 203,165 32.3 % $ 150,000 44.20 % $ 325,000 15.8 % B — — 175,000 27.8 115,200 33.9 — — C — — 75,301 12.0 — — — — Subtotal — 0.0 453,466 72.1 265,200 78.1 $ 325,000 15.8 % Total $ 8,774 100 % $ 629,132 100.00 % $ 339,735 100 % $ 2,062,083 100.00 % Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred. The Company incurred advertising and marketing costs of $933,627, $644,383 and $806,221 for the years ended December 31, 2014, 2013 and 2012, respectively. Research and Development Research and development expenses are charged to operations as incurred. The Company incurred research and development costs of $242,232, $74,861 and $176,964 for the years ended December 31, 2014 2013 and 2012, respectively. Fair Value of Financial Instruments Pursuant to ASC No. 825, Financial Instruments Warrants and other financial assets received as a payment for the services provided are recorded as “Marketable securities” under the current assets if they are expected to be realized within 12 months. The Company uses the Black-Scholes model to measure the value of the warrants. At each reporting date the Company will reevaluate the value of marketable securities and record any changes in value to other comprehensive income (loss) under “Unrealized gain or losses from marketable securities”. Unrealized gain or loss from marketable securities occurs in the process of the reevaluation of the warrants or other financial assets after their initial recognition valuation. At each reporting date the Company reevaluates the value of marketable securities and reflects the change in the statement of changes in equity under other comprehensive income (loss). Embedded derivative – The Company’s convertible notes payable include embedded features that require bifurcation due to a reset provision and are accounted for as a separate embedded derivative (see Note 13). The Company has estimated the fair market value of the embedded derivative of the Notes based on a weighted probability model. The key valuation assumptions used consist of the price of the Company’s stock, a risk free interest rate based on the average yield of a one year Treasury note and expected volatility of the Company’s common stock all as of the measurement dates, and various estimated reset exercise prices allocated by probability. The Company considers these inputs Level 3 assumptions, based on the application of the estimated probability rate being considered an unobservable input. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring basis. Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2014 Marketable securities $ 94,776 $ $ $ 94,776 Derivative liability 3,691,853 — — 3,691,853 Total $ 3,786,629 $ $ — $ 3,786,629 Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2013 Marketable securities $ 184,800 $ 184,800 $ — $ — Total $ 184,800 $ 184,800 $ — $ — The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the year ended December 31, 2014 Total Beginning balance $ — Initial recognition of conversion feature 1,885,863 Change in fair value of conversion feature 1,805,990 Ending balance $ 3,691,853 Revenue Recognition Our current revenue model consists of the following income streams: Consulting fee revenues. Consulting fee revenues. This revenue stream is a consistent component of our current and anticipated future revenues and is negotiated at the time we enter into a contract. In jurisdictions where there is intense competition for a limited number of dispensing or cultivating licenses, we believe the Medbox model, with its incorporated security measures, promotes a distinct advantage in the application selection process for such licenses, especially in the states where an applicant is graded on the ability to demonstrate compliance with applicable law. Consulting fee revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. Revenues on dispensary unit and vaporizer sales Revenue on dispensary unit sales is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. The contract terms are broken down in specific milestones with specific attributable revenue to be earned upon successful completion of the milestone terms. (i.e. if a milestone is completing construction on a client dispensary, the condition for the revenue to be recorded is after issuance of a certificate of occupancy for the newly completed facility. The Company will record a specified amount of revenue attributable to this milestone based on the contract). Equipment sales not associated with a consulting contract are recognized as the product is shipped and title passes. Vaporizer sales are recognized as the product is shipped. Other revenue includes sales of territory rights, sales/leases of management rights of newly awarded dispensary licenses, and sales/leases of management rights of newly acquired dispensary licenses and physical locations. Other revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. The contract terms are broken down in specific milestones with specific attributable revenue to be earned upon successful completion of the milestone terms. (i.e. if a milestone is completing construction on a client dispensary, the condition for the revenue to be recorded is after issuance of a certificate of occupancy for the newly completed facility. The Company will record a specified amount of revenue attributable to this milestone based on the contract. Advance payments from clients in advance of work performed are recorded as customer deposits on the balance sheet. Revenue from referral fees and revenue sharing from real estate transactions with partners. Referral fee and revenue sharing revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. If all required deliverables are complete, the referral fee will be recognized when the customer closes on the subject transaction. Revenue from providing monthly compliance and accountability support to dispensary operators. Monthly compliance and accountability support revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. Revenue is recognized monthly as the services are delivered to clients. Cost of Revenue Cost of revenue consists primarily of expenses associated with the delivery and distribution of our products and services. These include expenses related to the manufacture of our dispensary units, construction expense related to the customer dispensary, site selection and establishment of licensing requirements, and consulting expense for the continued management of the dispensary unit build out, server and security equipment, rent expense, energy and bandwidth costs, and support and maintenance costs prior to when the client moves in. We only begin capitalizing costs when we have obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses then the excess cost above net realizable value is written off to cost of revenues. In addition, cost of revenue related to our vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfilment, shipping, inventory storage and inventory management costs. Inventory Inventory is stated at the lower of cost or market value. Cost is determined on a cost basis that approximates the first-in, first-out (FIFO) method. Work in process and related capitalized costs includes costs to build out a dispensary in Portland Oregon that is expected to open in the second quarter of 2015. Costs include tenant improvements to the facility, furniture, fixtures and Medbox dispensary units to be used by the licensed operator. It is anticipated this dispensary will be operated by a Medbox licensed operator and revenue and related cost of revenue will be recorded in the statement of operations in the second quarter of 2015. Basic and Diluted Net Loss Per Share Basic net income/loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share include the effects of any outstanding options, warrants and other potentially dilutive securities. The Company did not consider any potential common shares in the computation of diluted loss per share for the periods ending December 31, 2014, 2013 and 2012, due to the net loss, as they would have an anti-dilutive effect on EPS. As of December 31, 2014 and 2013, the Company has 3,000,000 shares of Series A preferred stock outstanding with par value of $0.001 that could be converted into 15,000,000 shares of the Company’s common stock. As of December 31, 2012 there were 6,000,000 shares of Series A preferred stock outstanding, which could be converted into 30,000,000 shares. Additionally the Company has 206,480 warrants to purchase common stock outstanding as of December 31, 2014. The Company also has $3,750,000 in convertible debentures outstanding at December 31, 2014, whose underlying shares were not included as they are convertible at the holders’ option at an initial fixed conversion price of $11.75. Accounts Receivable and Allowance for Bad Debts The Company is subject to credit risk as it extends credit to our customers for work performed as specified in individual contracts. The Company extends credit to its customers, mostly on an unsecured basis after performing certain credit analysis. Our typical terms require the customer to pay a portion of the contract price up front and the rest upon certain agreed milestones. The Company’s management periodically reviews the creditworthiness of its customers and provides for probable uncollectible amounts through a charge to operations and a credit to an allowance for doubtful accounts based on our assessment of the current status of individual accounts. Accounts still outstanding after the Company has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts. As of December 31, 2014 and December 31, 2013, the Company’s management considered all accounts outstanding fully collectible. Property and Equipment Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses accelerated depreciation methods for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows: Vehicles 5 years Furniture and Fixtures 5 years Office equipment 3 years Assets Held for Resale During 2014, the Company has entered into various real estate purchase agreements to support the filing of retail dispensary or cultivation facility licenses in certain states and localities. The cost of the acquired real estate is included in Assets Held for Resale on the consolidated balance sheet. The Company intends to sell the real estate to a long term investor after the license is granted. The Company does not depreciate assets held for resale. Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorizes. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes. Commitments and Contingencies Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. The Company accrues all legal costs expected to be incurred per event, up to the amount of their deductible. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. Generally Accepted Accounting Principles when it becomes effective. The new standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The new standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting. Management’s Evaluation of Subsequent Events The Company evaluates events that have occurred after the balance sheet date of December 31, 2014, through the date which the consolidated financial statements were issued. Based upon the review, other than described in Note 20 – Subsequent Events, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements. Going Concern The Company recently revised its business model and completed a restatement of its financial statements. The revision to the business model which plans for long term contracts to manage dispensaries or cultivation centers tends to defer revenue and cash flow while expensing the costs to develop markets currently. The recently completed restatements and the on-going investigations by the SEC and the Department of Justice have added general and administrative expenses. The Company also operates in a new, emerging industry where business models are still developing and finalizing new deals can take longer than in more mature industries. The financial statements were prepared on a going concern basis. The going concern basis assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the year ended December 31, 2014, the Company had a net loss of approximately $16.5 million, negative cash flow from operations of $6.3 million and negative working capital of $10.0 million. The Company will need to raise capital in order to fund its operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement a business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. As disclosed in our Form 8-K dated January 28, 2015, our lenders have committed to an additional $3.3 million in funding as our annual SEC filings are completed and the Form S-1 filed with the SEC. Due diligence is in process between an investor and our majority shareholder to sell his majority position which would also yield $5 million in new equity capital for the Company over the next 18 months (see Note 20). Management is committed to conducting a road show after the Form S-1 is declared effective to raise additional equity capital in 2015. The Company expects that these plans will provide it the necessary liquidity through the first quarter of 2016. To address its financing requirements, the Company will seek financing through debt and equity financings. It is uncertain the Company can obtain financing to fund operating deficits until profitability is achieved. This need may be adversely impacted by: uncertain market conditions, approval of sites and licenses by regulatory bodies and adverse operating results. The outcome of these matters cannot be predicted at this time.

ACQUISITION

ACQUISITION	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Business Combinations [Abstract]
ACQUISITION	NOTE 3 – ASSET ACQUISITION On July 24, 2015, the Company entered into an Agreement of Purchase and Sale of Membership Interest (the “Acquisition Agreement”) with East West Secured Development, LLC (the “Seller”) to purchase 100% of the membership interest of EWSD I, LLC (“EWSD”) which has entered into an agreement with Southwest Farms, Inc. (“Southwest”) to purchase certain real property comprised of 320-acres of agricultural land in Pueblo, Colorado (the “Acquired Property” or “the Farm”). The purchase price to acquire EWSD consisted of (i) $500,000 paid by the Company as a deposit into the escrow for the Acquired Property, and (ii) the Company’s future payments to Seller of a royalty of 3% of the adjusted gross revenue, if any, from operation of the Acquired Property (including sale of any portion of or interest in the Acquired Property less any applicable expenses) for the three-year period beginning on January 1, 2016. Such royalty payments shall be payable 50% in cash and 50% in Company common stock (the “Royalty Payment”). The Company determined that the royalty payments could not be estimated at the time of acquisition, and therefore the contingent payments have not been recognized as part of the acquisition price. The contingent consideration will be remeasured to fair value each subsequent period until the contingency is resolved, in this case, for the three year period beginning on January 1, 2016, with any changes in fair value recognized in earnings. Per the terms of the agreement, the closing is deemed to have occurred when the Special Warranty Deed is recorded (which occurred on August 7, 2015), all terms of the purchase agreement for the Farm have been complied with, including the Farm closing, which also took place on August 7, 2015. Therefore the acquisition date has been determined to be August 7, 2015. There were no assets or liabilities of EWSD on the acquisition date. In connection with EWSD’s purchase of the Acquired Property, EWSD entered into a secured promissory note (the “Note”) with Southwest in the principal amount of $3,670,000. Interest on the outstanding principal balance of the Note shall accrue at the rate of five percent per annum. The Note shall be payable by EWSD in thirty-five payments of principal and interest, which shall be calculated based upon an amortization period of thirty years, commencing on September 1, 2015 and continuing thereafter on the first day of each calendar month through and including July 1, 2018; and one final balloon payment of all unpaid principal and accrued but unpaid interest on August 1, 2018. The Note is secured by a deed of trust, security agreement, assignment of rents and financing statement encumbering the Acquired Property. In connection with the closing (the “Closing”) on the Farm, EWSD also entered into an unsecured promissory note (the “Unsecured Note”) with the Seller, in respect of earnest money payments previously made by Seller to Southwest, in the principal amount of $830,000. Interest on the outstanding principal balance of the Unsecured Note shall accrue at the rate of six percent per annum. The Unsecured Note shall be payable by EWSD in thirty-five payments of principal and interest, which shall be calculated based upon a hypothetical amortization period of thirty years, commencing on September 1, 2015 and continuing thereafter on the first day of each calendar month through and including July 1, 2018; and one final balloon payment of all unpaid principal and accrued but unpaid interest on August 1, 2018. The balance owing on the two notes is $4,485,763 as of September 30, 2015. Principal payments due on the notes are as follows: Secured Unsecured Total 2015 $ 8,851 301,658 310,509 2016 54,691 27,299 81,990 2017 58,007 30,635 88,642 2018 3,536,670 467,952 4,004,622 Current maturities related to these notes as presented on the accompanying Balance Sheet, amount to $378,278. The Closing occurred on August 7, 2015, as a result of which the Company, through its new, wholly-owned subsidiary, EWSD, became the owner of the Acquired Property. The Company has determined that the Acquired Property is an acquisition of assets and does not constitute a business. Prior to its acquisition by the Company, the Acquired Property was leased to a farmer who cultivated corn on 150 of its 320 acres. The Company intends to engage an independent contractor to manage the operations and hire its own new staff to initially cultivate hemp on the Acquired Property. No employees of the former farm will work in the new operation. The new operation will have an entirely new customer base, sales force and marketing plan as well as new production techniques and a new trade name. Management has determined that the purchase of the Acquired Property and planned operations do not constitute continuation of the prior business and therefore it does not meet the criteria for a business acquisition. The Acquired Property was determined to have a fair value of $5,000,000, based on the $500,000 cash payment and the amounts due under the Secured and Unsecured notes for its purchase from third parties. The purchase price is comprised of: Cash deposit $ 500,000 Note Payable to Southwest 3,670,000 Note Payable to EWSD (Seller) 830,000 $ 5,000,000 The assets acquired included various buildings that were on the land. The Company did not acquire the Farm to obtain or use these buildings, and are replacing two of the buildings with new buildings that will better suit the Company’s planned operations, and renovating the greenhouses to also better serve the Company’s planned operations. The buildings which remain are a mechanics shop and a processing building, which the Company will utilize as is. The fair value of these two buildings has been determined to be $55,000. Therefore the purchase price has been allocated $4,945,000 to Land and $55,000 to Buildings and structures (included in Property and equipment on the accompanying Balance Sheet).	NOTE 3 – ACQUISITION On March 22, 2013, the Company entered into a purchase agreement for 100% of the issued and outstanding common stock of Vaporfection International Inc. (“VII”) owned by Vapor Systems International LLC (“VSI”). The Company closed the transaction on April 1, 2013. The Company issued 260,854 warrants to shareholders of VII allowing them to purchase one (1) share of Medbox common stock at $.001 per share beginning April 1, 2014. These warrants were valued for the Company’s accounting purposes at $4.47 per warrant, determined by the Company’s independent appraiser. In addition, the Company assumed certain liabilities and a 10% convertible note of VII in the aggregate amount of approximately $470,000. The total value of the acquisition was approximately $1,635,000 and the purchase price has been allocated as per the Company’s independent valuation as follows: Machinery and equipment $ 70,000 IP and related technology 287,000 Amortizable intangible assets: Customer contracts and related relationships 314,000 Trade name, trademark, and domain name 46,000 Non-compete covenants 23,000 Goodwill 895,000 Total assets acquired 1,635,000 Fair value of liabilities assumed (469,000 ) Net fair value $ 1,166,000 The amortizable intangible assets have useful lives not exceeding ten years. No amounts have been allocated to in-process research and development and $895,000 was originally allocated to Goodwill. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. From the date of acquisition through March 31, 2014, the purchase price allocation period, the liabilities assumed have been increased by approximately $205,000, as they have been accrued or settled. Accordingly, an additional $10,000 and $195,000 was allocated to Goodwill in the years ended December 31, 2014 and 2013, respectively. The warrants included a standard anti-dilution provision, which was triggered by the stock dividend declared on December 18, 2013. On or about September 17, 2014, some but not all of the holders of certain warrants for the Company’s common stock issued in connection with the Company’s 2013 purchase of Vaporfection International, Inc. filed suit against the Company in Circuit Court in Palm Beach County, Florida. There was a dispute as to the adjustment of the exercise price, and the suit was resolved in a settlement agreement dated December 29, 2014, which maintained the anti-dilution adjustment as well as an additional 50,000 warrants being issued to certain of the former VII shareholders. The additional warrants were valued at approximately $280,000, which has been recognized as legal expense in the accompanying consolidated financial statements. The expense was determined using the Black Scholes Merton model, with key valuation assumptions used that consist of the price of the Company’s stock at settlement date, a risk free interest rate based on the average yield of a 3 year Treasury note and expected volatility of the Company’s common stock all as of the measurement date. As of December 31, 2014, 252,812 of the warrants were exercised by the former owners of VII. In addition to the above warrants, the purchase agreement and associated consulting contract with the prior management company of the business unit calls for additional shares of common stock to be issued in the event that the performance of the business unit exceeds $11,818,140 of accumulated EBITDA over the subsequent 4 year operating period. The performance payout is contingent upon future events and accordingly the Company has treated the obtainment of that performance provision as being remote and consequently has not assigned any future value to the purchase price. The amortizable intangible assets, based on their non-deductibility for tax purposes, gave rise to a deferred tax liability in the amount of $160,000. Goodwill was increased accordingly, the balance after the purchase price allocation adjustments disclosed previously is $1,260,037 at December 31, 2015. The Company evaluated Goodwill at year end, and as the Company determined that based on qualitative factors it was not more likely than not that there was not any impairment, they performed Step 1 of the Goodwill impairment test. Since the fair value, based on undiscounted expected future cash flows, was in excess of the units carrying value, the Company concluded no impairment was necessary to recognize as of December 31, 2014. The Company evaluated the Intangible assets with definite lives for any indications of impairment and determined that the same cash projections used for the Goodwill impairment test resulted in a conclusion that no impairment of Intangible assets was necessary.

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2014
Investments Schedule [Abstract]
INVESTMENTS	NOTE 4 – INVESTMENTS On February 8, 2013, the Company entered into an agreement with Bio-Tech Medical Software, Inc. (“Bio-Tech”) which would allow the Company to purchase 833,333 shares of common stock, which represented 25% of Bio-Tech’s issued and outstanding shares of common stock, for $1,500,000. The Company advanced $600,000 upon execution of this agreement for the right to purchase with the remaining balance of $900,000 due and payable in installments at various dates by August 25, 2013. On June 26, 2013, the Company notified Bio-Tech that it was canceling the agreement. On February 27, 2014, the Company signed a settlement agreement, and in connection therewith, a second amended and restated technology license agreement with Bio-Tech. Pursuant to the second amended and restated technology license agreement, the Company received full licensed right to biometric inventory tracking technology for the term of five years with no additional monies due. All stock transfer between companies was canceled and rescinded. On June 5, 2014 the Company entered into a sale agreement with an affiliate company owned by the co-founder of the Company for the sale of all Bio-Tech rights and claims and a contribution for legal costs of $4,800 in exchange for the return of 30,000 shares of the Company’s common stock with a fair value of $604,800, valued at the market price of the Company’s common shares on the date of the agreement. These shares are treated as treasury stock and can be reissued. On March 12, 2013, the Company entered into an agreement with three members of MedVend Holdings LLC (“MedVend”) whereby the Company would acquire 50% of their equity interest in MedVend. The purchase price of the equity interest was $4,100,000. The Company paid an advance of $300,000 upon execution of the contract for the right to purchase and another $300,000 was disbursed as an additional investment to MedVend. In May 2013, the three members of MedVend were named in a lawsuit by that entity’s minority shareholders alleging improper conveyance of the three members’ ownership interest in MedVend to the Company. Accordingly, also in May 2013, Medbox filed suit against MedVend and the three members of that entity that were involved in the transaction (Note 19). The shares of common stock received for the Bio-Tech and MedVend sales to the affiliate company are recorded as treasury stock at cost of $1,209,600 for 60,000 shares.

INVENTORIES

INVENTORIES	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 4 – INVENTORIES Inventories are stated at the lower of cost or market value. Cost is determined on a standard cost basis that approximates the first-in, first-out (FIFO) method. The consolidated inventories at September 30, 2015 and December 31, 2014 consist of the following: September 30, 2015 December 31, 2014 Work in process and related capitalized costs $ — $ 308,867 Deposits on dispensing machines — 325,973 Vaporizers and accessories 187,844 154,930 Dispensing machines — 171,466 Total inventory, net $ 187,844 $ 961,236 On May 4, 2015, AVT, Inc., the manufacturing partner of the Company, announced that they had commenced a voluntary filing for restructuring and court protection under Chapter 11 of the United States Bankruptcy Code. Dispensing machines and Deposits on dispensing machines noted in schedule above are with AVT. Additionally, during the second quarter of 2015, the Company completed a strategic review of the Medbox machines and concluded that they would take a reduced role in future marketing efforts. As a result of the strategic review, the Company evaluated the inventory and the related deposits in connection with reduced demand and concluded a write down of both assets was required. The bankruptcy of the manufacturing partner further complicates the process to convert the inventory and advances to cash and therefore is an additional factor in the decision to write down the inventory and record a valuation reserve against the deposits. During the three months ended September 30, 2015, the Company ended negotiations with the supplier and bankruptcy counsel advised that collection of deposits and availability of inventory from the supplier was unlikely. Accordingly, the remaining deposit and inventory valued at $142,500 were written off. Work in process and related capitalized costs includes costs to build out a dispensary in Portland, Oregon that opened in the second quarter of 2015 (Note 1). The costs related to the Portland dispensary have been classified in deferred costs until the related revenue is recognized.	NOTE 5 – INVENTORY Inventory at December 31, 2014 and 2013 consists of the following: December 31, 2014 December 31, 2013 Work in process and related capitalized costs $ 308,867 $ 242,488 Deposits on dispensing machines 325,973 138,423 Vaporizers and accessories 154,930 193,575 Dispensing machines 171,466 58,500 Total inventory, net $ 961,236 $ 632,986 Work in process and related capitalized costs includes costs to build out a dispensary in Portland Oregon that is expected to open in the second quarter of 2015. Costs include tenant improvements to the facility, furniture, fixtures and Medbox dispensary units to be used by the licensed operator. It is anticipated this dispensary will be operated by a Medbox licensed operator and revenue and related cost of revenue will be recorded in the statement of operations in the second quarter of 2015. During the year ended December, 31, 2014, the Company wrote down slow moving, older models of vaporizer inventory with a charge to cost of revenue of $329,154. The Company determined there was no obsolete or slow moving inventory as of December 31, 2013 and 2012.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6 – PROPERTY AND EQUIPMENT Property and equipment at December 31, 2014 and 2013 consists of: Property and Equipment December 31, 2014 December 31, 2013 Office equipment $ 22,421 $ 17,192 Furniture and fixtures 74,404 73,567 Website development 46,922 46,922 Product tooling 64,763 24,100 208,510 161,781 Less accumulated depreciation (50,192 ) (21,123 ) Property and equipment, net $ 158,318 $ 140,658 Product tooling costs are related to the tooling of a new product by VII. These tooling costs are accumulated and capitalized until launch date of the new product which is expected to commence in the second quarter of 2015. Depreciation expense for the years ending December 31, 2014, 2013 and 2012 was approximately $29,000, $37,000 and $30,000, respectively.

ASSETS HELD FOR RESALE

ASSETS HELD FOR RESALE	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
ASSETS HELD FOR RESALE	NOTE 7 – ASSETS HELD FOR RESALE In the course of seeking licenses for new locations, the Company has to enter into real estate purchase agreements in order to secure the sites to be developed for clients’ dispensaries and cultivation centers. The Company intends to close on the real estate where purchase agreements have been signed, or to seek partners to replace the Company on each property purchased. During the second quarter of 2014 one of the Company’s subsidiaries entered into a real estate purchase agreement for a Washington state property. The purchase transaction was closed during the third quarter for a total purchase price of $399,594 partially financed by a promissory note for $249,000. The note bears an interest rate of 12% per year and matures on January 30, 2015. The balance of Assets held for resale as of December 31, 2014 is $399,594. There were no such assets as of December 31, 2013.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 8 – INTANGIBLE ASSETS The Company acquired certain intangible assets with its purchase of 100% of the outstanding common stock of VII on April 1, 2013. The Company accounts for intangible assets acquired in a business combination, if any, under the purchase method of accounting at their estimated fair values at the date of acquisition. Intangibles are either amortized over their estimated lives, if a definite life is determined, or are not amortized if their life is considered indefinite. Intangible assets December 31, 2014 December 31, 2013 Distributor relationship $ 314,000 $ 314,000 IP/technology/patents 324,653 332,179 Domain names 131,000 46,000 Non-compete covenants 23,000 23,000 Subtotal 792,653 715,179 Less accumulated amortization (83,500 ) (32,750 ) Intangible assets, net $ 709,153 $ 682,429 The estimated useful lives for significant intangible assets are as follows: Distributor Relationship 10 years Domain Names 10 years IP/Technology/Patents 10 years Non-Compete covenants 3 years The Company’s management has evaluated the intangible assets and does not believe any impairment of intangible assets has occurred as of December 31, 2014 and 2013.

ACCOUNTS AND NOTES RECEIVABLE

ACCOUNTS AND NOTES RECEIVABLE	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
ACCOUNTS AND NOTES RECEIVABLE	NOTE 9 – ACCOUNTS AND NOTES RECEIVABLE Accounts receivables Periodically the Company assesses and reviews the receivables for collectability. As of December 31, 2014 and 2013, the Company’s management considered all outstanding accounts receivables fully collectible. During the year ended December 31, 2014, the Company identified $132,640 of accounts receivable and $75,000 in Notes Receivable where management determined that collection was not likely and therefore the Company recognized bad debt expense of $207,640. The Company will continue to make efforts to collect the full value of the various receivables. Notes Receivable current During December 2013, the Company entered into a multiple advance secured promissory note for $1,000,000 with a Canadian partner. This note is due and payable, together with interest at 5% per annum, on December 10, 2018. As of December 31, 2013 the outstanding balance of this note receivable was $115,000. During 2014 the Company advanced to the Canadian partner an additional $40,000, bringing the total outstanding to $155,000. On October 20, 2014, the note receivable was cancelled and repaid in full, including accrued interest of $6,424. During the third quarter of 2014 one of the Company’s clients signed a Note Receivable for $75,000 as a payment on accounts receivable, with a maturity date of December 31, 2014. However, at December 31, 2014 management determined that collection was not likely, and recognized bad debt expense of $75,000 in connection with the Note Receivable. Periodically the Company assesses and reviews the Notes Receivable for collectability. As of December 31, 2013, the Company’s management considered all remaining accounts outstanding fully collectible.

MARKETABLE SECURITIES

MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]
MARKETABLE SECURITIES	NOTE 10 – MARKETABLE SECURITIES Marketable securities of the Company represent the shares received as a payment from clients for services provided. Marketable securities Value as of December 31, 2014 Value as of December 31, 2013 Shares received as a payment from client $ — $ 184,800 Securities from MJ Holdings, Inc. 94,776 — Total marketable securities $ 94,776 $ 184,800 On September 5, 2014 the Company received as a deposit 7,000,000 restricted shares in a publicly traded entity, currently called Endocan, as payment for $300,000 in accounts receivable billed to a customer. The restriction on the shares lapsed in 2014. The value of these unliquidated shares was held as collateral against the outstanding amounts owed to the Company up to $300,000 (the value of receivable of the client) until such time that the shares are liquidated and only at the time that the cash proceeds are used to pay off the receivable will any excess cash received be returned to the client in accordance with the contract. The fair value of the shares as of December 31, 2013 (with 12% restricted stock discount as of December 31, 2013) was $184,800. At December 31, 2014 the Company evaluated the shares for impairment, and noted that Endocan is not currently making material information publicly available, is delinquent on their SEC filings, and is thinly traded on the OTC pink sheets. Furthermore, the last filed financial statements show minimal assets and liabilities of over $1,000,000. Management concluded these factors were indications of impairment, and determined the shares were fully impaired, with the decline being other-than-temporary. As the shares were being held as a deposit against the receivable balance, the fair value was also recognized as a customer deposit, and the impairment will therefore fully reduce the related customer deposit, and not be recognized as an impairment expense. On May 19, 2014 the Company entered into an agreement with MJ Holdings, Inc., a publicly traded company that provides real estate financing and related solutions to licensed marijuana operators. The Company will market MJ Holdings’ real estate financial products and offerings to its consulting clients and will direct all incoming real estate related opportunities to MJ Holdings. Under the agreement, the Company will receive 50% of management fees and profits realized from the real estate opportunities it presents, in addition to warrants to purchase shares in MJ Holdings. The initial term of the agreement was six months which could have been extended on a month to month basis, but the agreement was terminated at the end of the six month term. MJ Holdings, Inc. agreed to issue to the Company, for this six month term of the contract, 33,333 warrants to purchase common stock on each month’s anniversary of the contract. As of December 31, 2014 the Company received six tranches of warrants for the services provided under the agreement. The following table represents the initial recognition value and subsequent adjustment as of reporting date: Warrants Initial Fair Value Fair Value at Conversion Gain or (Loss) Fair Value as of December 31, 2014 Warrant #1 $ 95,866 $ (94,719 ) $ (1,147 ) $ — Warrant #2 2,666 5,513 8,179 Warrant #3 53,867 (44,947 ) 8,920 Warrant #4 30,600 (20,282 ) 10,318 Warrant #5 7,133 12,920 20,053 Warrant #6 13,033 12,623 25,656 Total $ 203,165 $ (94,719 ) $ (35,320 ) $ 73,126 At initial recognition the value of warrants is recorded as “Marketable securities” and “Revenue” for services provided. Subsequent to initial recognition all valuation adjustments are reflected through other comprehensive income (loss) as “Unrealized gain or losses from marketable securities”. In June 2014, Warrant #1 was converted to 10,825 shares of MJ Holdings common stock through the cashless exercise option. The fair value of the shares as of December 31, 2014 was $21,650, which represents a $73,069 unrealized loss on marketable securities. The Company uses the published closing price of the stock to value the stock held by the Company. The Company uses a Black-Scholes model to measure the value of the warrants. The following assumptions were used by the Company for the Black-Scholes model valuation of the warrants as of their initial valuation: Black-Scholes Calculator Data Initial Valuation and Recognition #1 #2 #3 #4 #5 #6 Warrant Stock price, $ 8.69 4.00 8.00 6.15 2.01 2.02 Exercise price, $ 6.42 8.45 7.87 6.95 3.53 2.56 Time to maturity, Years 0.5 0.5 0.5 0.5 1.0 1.0 Annual risk-free rate, % 0.05 0.05 0.05 0.05 0.04 0.11 Annualized volatility, % 70.0 70.0 70.0 70.0 70.0 70.0 Black-Scholes Value per warrant, $ 2.876 0.080 1.616 0.918 0.214 0.391 Number of warrants/shares 33,333 33,333 33,333 33,333 33,333 33,333 Total value of warrants/shares, $ 95,866 2,666 53,867 30,600 7,133 13,033 The following data were used by the Company for the Black-Scholes model valuation of the warrants as of December 31, 2014: Fair Value of Warrants As of December 31, 2014 #2 #3 #4 #5 #6 Warrant Stock price, $ 2.00 2.00 2.00 2.00 2.00 Exercise price, $ 8.45 7.87 6.95 3.53 2.56 Time to maturity, Years 1.0 1.0 1.0 1.0 1.0 Annual risk-free rate, % 0.22 0.22 0.22 0.22 0.22 Annualized volatility, % 120.0 120.0 120.0 120.0 120.0 Black-Scholes Value per warrant, $ 0.25 0.27 0.31 0.60 0.77 Number of warrants/shares 33,333 33,333 33,333 33,333 33,333 Total value of warrants/shares, $ 8,179 8,920 10,318 20,053 25,656

CUSTOMER DEPOSITS

CUSTOMER DEPOSITS	12 Months Ended
	Dec. 31, 2014
Banking and Thrift [Abstract]
CUSTOMER DEPOSITS	NOTE 11 – CUSTOMER DEPOSITS Advance payments from customers are recorded as customer deposits on the consolidated balance sheet. Customer deposits December 31, 2014 December 31, 2013 Advance payments from customers $ 1,450,770 $ 710,225 Advance payments for vaporizers 75,038 75,636 Total customer deposits $ 1,525,808 $ 785,861

SHORT-TERM DEBT

SHORT-TERM DEBT	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
SHORT-TERM DEBT	NOTE 12 – SHORT-TERM DEBT On July 28, 2014 one of the Company’s subsidiaries executed a promissory note for $249,000 for the purchase of real estate (also see Note 7). The note matures on January 30, 2015 and bears 12.0% interest annually. The interest is payable monthly starting August 1, 2014 with a final, sixth payment on January 1, 2015. In the event of a default, as defined, the interest rate increases to 18%, there is a one-time 5% late charge on the principal balance, and the note can be accelerated. Subsequent to December 31, 2014, the Company was in default of the repayment terms, and the note terms were modified. (see Note 20). The other portion of the notes payable balance represents the outstanding balance in the amount of $12,434 for product liability insurance. The financing of product liability insurance bears 5.99% interest and is payable in monthly payments of $2,524 for nine months with the first payment due on September 5, 2014 and the last payment due on May 5, 2015. The notes payable to related parties bear no interest. The December 31, 2013 balance of the $75,000 note payable to an unrelated third party was paid in full during 2014.

Convertible Notes Payable and D

Convertible Notes Payable and Derivative Liability	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY	NOTE 5 – CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY On July 21, 2014, as amended on September 19, 2014 and October 20, 2014, the Company entered into a Securities Purchase Agreement whereby the Company agreed to issue convertible debentures (“July 2014 Debentures”) in the aggregate principal amount of $3,500,000, in five tranches. The initial closing in the aggregate principal amount of $1,000,000 occurred on July 21, 2014. The second closing in the amount of $1,000,000 occurred on August 26, 2014; the third of $500,000 on September 26, 2014. The fourth and fifth, each in the amount of $500,000, were to occur within 2 and 5 business days, respectively, of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the July 2014 Debentures. The Registration statement was withdrawn and terminated in December 2014, and a new registration statement was filed on April 9, 2015. The July 2014 Debentures bear interest at the rate of 10% per year. The debt is due July 21, 2015, with the original agreement calling for amortization payments, including accrued principal and accrued interest, beginning on the eleventh day of the fourth month after issuance and will continue on the eleventh day of each following eight successive months thereafter. Also on September 19, 2014, as amended on October 20, 2014, the Company entered into a securities purchase agreement pursuant to which it agreed to issue convertible debentures (“September 2014 Debentures”) in the aggregate principal amount of $2,500,000, in two tranches. The initial closing in the principal amount of $1,000,000 occurred on September 19, 2014. The second closing, of $1,500,000, is to occur within 2 days of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the September 2014 Debentures. The September 2014 Debentures bear interest at the rate of 5% per year. The debt is due September 19, 2015, and the original agreement called for amortization payments, including accrued principal and accrued interest, due in nine monthly installments, commencing the fourth month after issuance. Both the original July 2014 Purchase Agreement Debentures and September 2014 Debentures prior to subsequent amendment, share the following significant terms: All amounts are convertible at any time, in whole or in part, at the option of the holders into shares of the Company’s common stock at a conversion price. The Notes were initially convertible into shares of the Company’s common stock at the initial Fixed Conversion Price of $11.75 per share. The Fixed Conversion Price is subject to adjustment for stock splits, combinations or similar events. If the Company makes any subsequent equity sales (subject to certain exceptions), under which an effective price per share is lower than the Fixed Conversion Price, then the conversion price will be reduced to equal such price. The Company may make the amortization payments on the debt in cash, prompting a 30% premium or, subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days. In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement. Through subsequent modifications of the July 2014 Debentures and September 2014 Debentures, the required date to file the registration statement and the effective date of the registration statement have been changed to April 15, 2015 and July 15, 2015, respectively. The registration statement was filed on April 9, 2015, and became effective on June 11, 2015. The conversion feature of the July 2014 Debenture and the September 2014 debenture meets the definition of a derivative and due to the reset provision to occur upon subsequent sales of securities at a price lower than the fixed conversion price, requires bifurcation and is accounted for as a derivative liability. The derivative was initially recognized at its estimated fair value of approximately $1,885,000 and created a discount on the Notes that will be amortized over the life of the Notes using the effective interest rate method. The fair value of the embedded derivative is measured and recognized at fair value each subsequent reporting period and the changes in fair value are recognized in the Statement of Operations as Change in fair value of derivative liability. For the nine months ended September 30, 2015 the Company recognized a gain on the change in fair value of derivative liabilities of approximately $509,000 (including the change in fair value related to the new convertible debentures issued in the first, second and third quarters of 2015 discussed below). See Note 2 Fair value measure for additional information on the fair value and gains or losses on the embedded derivative. On January 30, 2015, the Company and the Investors entered into an Amendment, Modification and Supplement to the Purchase Agreement (the “Purchase Agreement Amendment” or the “Modification”) pursuant to which the Investors agreed to purchase an additional $1,800,000 in seven Modified Closings: (1) $200,000 was funded at the Closing of the Purchase Agreement Amendment; (2) $100,000 to be funded within thirty (30) days of the Closing; (3) $100,000 to be funded within two days following the filing of a registration statement with the SEC to register the shares underlying the Debentures (the “Registration Statement”) and of the Company having filed with the SEC a restatement of the Company’s consolidated financial statements as described in the Company’s Current Report on Form 8-K filed with the SEC on December 22, 2014; (4) $100,000 to be funded within two days of receipt of the first comment letter from the SEC with regard to the Registration Statement; (5) $500,000 to be funded within two days of the date that the Registration Statement is declared effective by the SEC; (6) $500,000 to be funded within five days of the date that the Registration Statement is declared effective by the SEC; and (7) $100,000 to be funded within each of 90, 120, 150, and 180 days from the Closing of the Purchase Agreement Amendment. The Modification also eliminated the amortization payments discussed above, and provided for accrued and unpaid interest to be payable upon conversion or maturity rather than on specified payment dates. The Company is also required to open a new dispensary in Portland, Oregon during the first calendar quarter of 2015 (which was later modified to April 30, 2015). The Company must also file the Registration Statement by March 8, 2015 (later amended), and it must be declared effective by June 15, 2015 in order to avoid default and acceleration under the Amended and Restated Debenture. As noted above, the Registration Statement was filed on April 9, 2015, and became effective June 11, 2015. On March 13, 2015 the Company and the Investors entered into a further amendment (“March 2015 Amendment”) to the July 21, 2014, 10% Convertible debentures, as amended January 30, 2015, whereby the reset of the fixed conversion rate to $1.83 caused by recent dilutive issuances was reiterated for all previously issued notes. In addition, the March 2015 Amendment modified the opening date of the Portland, Oregon dispensary to be April 30, 2015. Neither of these modified terms had an impact on the accounting treatment of the Debentures. The July 2014 financing was further modified on March 23, 2015. The closing dates of the financing were again modified, investments by two members of the Board of Director’s (“Board”) was required, and the deadline for filing of the registration statement was changed to no later than April 15, 2015, and its effective date to no later than July 15, 2015. Neither of these modified terms had an impact on the accounting treatment of the Debentures. On April 9, 2015, the Company and their investors entered into an Amendment, Modification and Supplement to the July 2014 convertible debenture, which amends the closings as set forth in the March 23, 2015 Modification, to increase the amounts due in the third tranche, due two days after the filing of the Registration Statement, to $450,000. On January 28, 2015, the Company and the Investors entered into an Amendment, Modification and Supplement to the September 2014 Debenture, pursuant to which the remaining $1,500,000 will be funded in four Modified Closings as set forth in the agreement, and contains other modifications with the same terms as was contained in the January 30, 2015 Modification. The Company considered if the above modifications should be accounted for as an extinguishment or modification of the existing debt. The Company first evaluated if the modification of terms could be considered a troubled debt restructuring, but the modification did not meet the criteria as the Investors did not grant a concession to the Company for economic or legal reasons related to any financial difficulties of the Company. The majority of the modifications related to deadlines being extended for certain required events. The only financial modification was to revise the payment schedule on the Debentures to eliminate the amortization payments and instead require all to be due at maturity. The Company concluded this is not regarded as a concession as it is not the forgiveness of any interest payments, nor reduction of principal, nor change to the maturity date. Therefore, the modification of the terms was evaluated to determine if the changes in the Debentures’ future cash flows were in excess of 10% and considered substantial, which would require the Debentures to be accounted for as extinguished and replaced with new debt. As the modification resulted in a less than 10% estimated change in future cash flows, the Company concluded that the modification of the terms of the July 2014 and September 2014 Debentures was to be accounted for as a modification of the existing Debentures. As part of the January 30, 2015 Modification, the Parties entered into a Modified Debenture Agreement for the $200,000 that was funded at the Closing and agreed to use the same form of Modified Debenture for each of the other foregoing Modified Closings (collectively, the “Modified Debentures”). The fixed conversion price of the Modified Debenture was the lower of $5.00 or 51% of the lowest volume weighted average price for the 20 consecutive trading days prior to the applicable conversion date. This new fixed conversion price was a dilutive issuance to the outstanding July 2014 and September 2014 Debentures, thereby triggering a reset of the older fixed conversion price. As a result of the reset to the conversion price, at January 30, 2015, the derivative liability was remeasured to a fair value of approximately $2,690,000, using a weighted probability model as estimated by management. A decrease in fair value of the derivative liability of approximately $1,072,000 was recognized as a gain on the Statement of Consolidated Comprehensive Loss in the nine months ended September 30, 2015. The additional Modified Debentures under the July 2014 Debentures closed on February 27, 2015 in the amount of $100,000, March 13, 2015 in the amount of $50,000, March 16, 2015 in the amount of $25,000, March 20, 2015 in the amount of $75,000 and on March 26, 2015 in the amount of $150,000. All these Modified Debentures have a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 20 days prior to the conversion. This new fixed conversion price was a dilutive issuance to the outstanding July 2014 and September 2014 Debentures, thereby triggering a reset of the previous $5 fixed conversion price. This reset resulted in the derivative liability being revalued at February 27, 2015, using a weighted probability model for a fair value of $2,720,000, for a decrease in fair value of approximately $334,000, recognized as a gain on the Statement of Consolidated Comprehensive Loss. The additional Modified Debentures under the September 2014 Debentures closed on January 29, 2015 in the amount of $100,000 and February 24, 2015 in the amount of $100,000. These Modified Debentures have a fixed conversion price of the lower of $5.00 or 51% of the VWAP for the last 20 days prior to the conversion. This new fixed conversion price was a dilutive issuance to the outstanding July 2014 and September 2014 Debentures, thereby triggering a reset of the previous $5.00 fixed conversion price. The resulting reset and remeasurement of the fair value of the derivative liability is included in the amounts of the change to fair value discussed above. The additional fundings of the July 2014 Modified Debentures under the closing schedule detailed above resulted in $2,811,500 being received during the second quarter. The first $300,000 had a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 40 days prior to the conversion. The April 17, 2015 closing contained a fixed conversion price of the lower of $0.88 or 51% of the VWAP for the last 40 days prior to the conversion. This new fixed conversion price was a dilutive issuance to the outstanding July 2014 and September 2014 Debentures, thereby triggering a reset of the previous $1.83 fixed conversion price. This reset resulted in the derivative liability being revalued at April 17, 2015, using a weighted probability model for a fair value of $3,287,000, for a increase in fair value of approximately $1,764,000, recognized as a loss on the Statement of Consolidated Comprehensive Loss during the second quarter of 2015. There was additional funding of $1,300,000 of the September 2014 Modified Debentures under the closing schedule detailed above. These Modified Debentures all have a fixed conversion price of the lower of $0.88 or 51% of the VWAP for the last 40 days prior to the conversion. The Directors’ convertible debentures required under the March 23, 2015 Modification, issued in the first quarter of 2015, total $150,000, and have a three year term and an interest rate of 8% per annum. They were originally convertible at a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 20 days prior to conversion. As with the Modified Debentures, the debentures included a reset provision, which resulted in the conversion feature being bifurcated and accounted for as a derivative liability, with an initial fair value of $132,175. The director’s convertible debentures also reset on February 27, 2015 and April 17, 2015, with the changes to fair value included in the amounts disclosed above. The Modified Debentures also included a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, with a three year term. The warrants issued in the nine months ended September 30, 2015 in connection with all the Modified Debentures detailed above, and the August 2015 Securities Purchase Agreement (“August 2015 Debentures”) discussed below, are summarized below: Date issued Number of warrants Exercise price Fair Value July 2014 Modified Debentures January 30, 2015 40,552 $ 4.93 $ 159,601 February 26, 2015 45,537 2.20 79,904 March 13, 2015 21,151 2.36 39,965 March 16, 2015 10,575 2.36 19,981 March 20, 2015 41,946 1.79 59,942 March 27, 2015 75,758 1.98 119,888 April 2, 2015 60,386 1.66 74,025 April 2, 2015 30,193 1.66 37,012 April 10, 2015 107,914 1.39 112,460 April 17, 2015 41,667 1.20 37,680 April 24, 2015 127,119 1.18 112,635 April 24, 2015 21,186 1.18 18,772 May 1, 2015 156,250 .96 113,133 May 7, 2015 134,615 .78 79,234 May 8, 2015 42,000 .75 23,768 May 15, 2015 200,000 .75 113,365 May 22, 2015 250,000 .60 113,366 May 29, 2015 258,621 .58 112,537 June 5, 2015 288,462 .52 120,738 June 12, 2015 930,233 .43 303,246 June 19, 2015 3,448,276 .29 751,159 September 2014 Modified Debentures January 28, 2015 18,038 5.54 80,156 February 13, 2015 57,870 1.73 96,689 April 2, 2015 181,159 1.66 222,109 April 24, 2015 90,579 1.10 80,548 May 15, 2015 200,000 .75 113,365 June 12, 2015 1,744,186 .43 570,248 August 2015 Debentures August 24, 2015 6,666,667 .06 321,757 September 18, 2015 588,235 .17 82,804 Directors January 5, 2015 129,305 .40 39,901 January 30, 2015 129,250 .40 39,916 February 2, 2015 237,778 .22 16,619 Total $ 16,375,508 $ 4,266,522 The Company determined that the warrants were properly classified in equity as there is no cash settlement provision and the warrants have a fixed exercise price and therefore result in an obligation to deliver a known number of shares. Effective September 18, 2015, the holder of the September 2014 Debentures and the Company agreed to amend its September 2014 Warrants, to reduce the exercise price of the warrants to purchase an aggregate of 2,291,832 shares of the Company’s common stock to six cents per share. The holder agreed to exercise in full those warrants in cash within three trading days of the filing with the SEC of a Form 8-K, which occurred on September 18, 2015. During the three months ended September 30, 2015, approximately 2,292,000 warrants were exercised. Effective September 18, 2015, the holder of the July 2014 Debentures and the Company agreed to amend its July 2014 Warrants, to reduce the exercise price of the warrants to purchase an aggregate of 6,332,441 shares of Common Stock to six cents per share. The holder agreed to exercise in full those warrants in cash within three trading days of the filing with the SEC of a Form 8-K, which occurred on September 18, 2015. As of September 30, 2015 the warrants have not yet been exercised, and will be upon the finalization of the increase in authorized shares (Note 8). As a result of the conversion feature being bifurcated and recognized as a derivative liability, the Company evaluated the warrants and determined that they have a sufficient number of authorized and unissued shares as of September 30, 2015, after consideration of the subsequent increased authorized shares, (See Note 10), to settle all existing commitments. The Company adopted a sequencing policy that reclassifies contracts, with the exception of stock options, from equity to assets or liabilities for those with the earliest inception date first. Future issuance of securities will be evaluated as to reclassification as a liability under our sequencing policy of earliest inception date first until either all of the convertible debentures are converted or settled. During the nine months ended September 30, 2015, $4,420,000 principal of the July 2014 Debentures and $1,710,000 principal and approximately $49,000 accrued interest of the September 2014 Debentures, and $150,000 principal of the Directors debentures, in addition to approximately $49,000 accrued interest were converted into approximately 67,475,000 of the Company’s common shares at an average price of $0.09, based on 51% of the calculated VWAP. Upon conversion, the derivative fair value for the amounts converted were remeasured through the date of conversion, with the conversion date fair value reclassified to equity, amounting to $4,519,000 in the nine months ended September 30,2015. As a result of the conversions, the resulting decrease of fair value of approximately $1,730,000 of the related debt discount was recognized on the Statement of Consolidated Comprehensive Loss. August 2015 Debentures On August 14, 2015, the Company entered into a Securities Purchase Agreement whereby the Company agreed to issue convertible debentures in the aggregate principal amount of up $3,979,877. The initial closing in the aggregate principal amount of $650,000 occurred on August 14, 2015. An additional 5 payments were made in the total amount of $1,078,880 through September 30, 2015. The seventh tranche in the amount of $250,000 will occur 8 days after the filing of a registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the August 2015 Debentures, the eighth tranche in the amount of $1,250,000 will occur within 3 business days of the effective date of the registration statement and the ninth tranche, in the amount of $750,000 will occur within 7 business days of the effective date of the registration statement. The August 2015 Debentures bear interest at the rate of 10% per year. On August 20, 2015, the Company also entered into a Securities Purchase Agreement with another investor, in the aggregate principal amount of up to $1,500,000 (collectively the “August 2015 Debentures”), which was amended on September 19, 2015, to increase the principal by an additional $200,000. Through September 30, 2015, two tranches totaling $500,000 have been funded. A third tranche in the amount of $500,000 (after amendment) is to occur within two days after the filing of a registration statement, with the fourth tranche in the amount of $700,000 to occur within 2 days of the effective date of the registration statement. The August 2015 Debentures contain the following significant terms: The debentures all mature in one year from the date of each individual closing. All amounts are convertible at any time, in whole or in part, at the option of the holders into shares of the Company’s common stock at a fixed conversion price. The conversion price is the lower of (a) $0.75, or (b) a 49% discount to the lowest daily VWAP (as reported by Bloomberg) of the Common Stock during the 30 trading days prior to the conversion date. The Fixed Conversion Price is subject to adjustment for stock splits, combinations or similar events. If the Company makes any subsequent equity sales (subject to certain exceptions), under which an effective price per share is lower than the Fixed Conversion Price, then the conversion price will be reset to equal such price. The Company may prepay the Debentures in cash, prompting a 30% premium or, subject to certain conditions, in shares of common stock valued at 51% of the lowest volume weighted average price of the common stock for the 30 prior trading days. The premium will be recognized at such time as the Company may choose to prepay the Debentures. In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement. The pre-effective registration statement was filed with the SEC on October 16, 2015. The conversion feature of the August 2015 Debenture meets the definition of a derivative and due to the reset provision to occur upon subsequent sales of securities at a price lower than the fixed conversion price, requires bifurcation and is accounted for as a derivative liability. The derivative was initially recognized at its estimated fair value of approximately $2,345,000 and created a discount on the Notes that will be amortized over the life of the Notes using the effective interest rate method. The fair value of the embedded derivative is measured and recognized at fair value each subsequent reporting period and the changes in fair value are recognized in the Statement of Operations as Change in fair value of derivative liability (discussed above). See Note 2 Fair value measure for additional information on the fair value and gains or losses on the embedded derivative. The debenture entered into with the second investor on August 20, 2015 included a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Debenture divided by a price equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Debenture, with a three year term. During the three months ending September 30, 2015, there were 7,254,902 warrants issued, with a fair value of $404,561, calculated with the Black Sholes Merton model. There were no conversions of the August 2015 Debentures during the three months ended September 30, 2015. Entry into Security Agreement In connection with entry into the August 20 Purchase Agreement and August 14 Purchase Agreement, the investors party to such agreements and the Company entered into a Security Agreement, dated August 21, 2015, securing the amounts underlying the August 14 Debentures and the August 20 Debentures. The Security Agreement grants a security interest in all assets and personal property of the Company, subject to certain excluded real property assets. The security interests under the Security Agreement shall terminate following the date the registration statement is declared effective. July 2015 Debenture On July 10, 2015, another accredited investor (the “July 2015 Investor”) purchased a separate Convertible Debenture (the “July 2015 Debenture”) in the aggregate principal amount of $500,000, that closed in five weekly tranches between July 10 and August 15, 2015. The July 2015 Debenture is in substantially the same form as the August 14 Debentures, and does not include issuance of warrants . As such, the conversion feature was also determined to require bifurcation, and derivative accounting. All amounts related to the July 2015 derivative liability are included in amounts disclosed above for the August 2015 debentures. On October 14, 2015, the August 14 Investor assigned the right to purchase August 14 Debentures in the principal amount of $100,000 to the July 2015 Investor and the July 2015 Investor purchased such August 15 Debentures on the same day.	NOTE 13 – CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY On July 21, 2014, as amended on September 19, 2014 and October 20, 2014, the Company entered into a Securities Purchase Agreement whereby the Company agreed to issue convertible debentures (“July 2014 Purchase Agreement Debentures”) in the aggregate principal amount of $3,500,000, in five tranches. The initial closing in the aggregate principal amount of $1,000,000 occurred on July 21, 2014. The second closing in the amount of $1,000,000 occurred on August 26, 2014; the third of $500,000 on September 26, 2014; and the fourth of $250,000 on November 24, 2014. The fifth closing was modified in January, 2015 (See Note 20). The July 2014 Purchase Agreement Debentures bear interest at the rate of 10% per year. The debt is due July 21, 2015, with repayment, including accrued principal and accrued interest, beginning on the eleventh day of the fourth month after issuance and will continue on the eleventh day of each following 8 successive months thereafter. Also on September 19, 2014, as amended on October 20, 2014, the Company entered into a securities purchase agreement pursuant to which it agreed to issue convertible debentures (“September 2014 Purchase Agreement Debentures”) (collectively the “Notes”) in the aggregate principal amount of $2,500,000, in two tranches. The initial closing in the principal amount of $1,000,000 occurred on September 19, 2014. The second closing, of $1,500,000, is to occur within 2 days of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the September 2014 Purchase Agreement Debentures. The September 2014 Purchase Agreement Debentures bear interest at the rate of 5% per year. The debt is due September 19, 2015, with repayment, including accrued principal and accrued interest, due in nine monthly installments, commencing the fourth month after issuance. Both the July 2014 Purchase Agreement Debentures and September 2014 Purchase Agreement Debentures, share the following significant terms: Conversion – All amounts are convertible at any time, in whole or in part, at the option of the holders into shares of the Company’s common stock at a conversion price, or Fixed Conversion Price, which is subject to adjustment as described below. The Notes are initially convertible into shares of the Company’s common stock at the initial Fixed Conversion Price of $11.75 per share. The Fixed Conversion Price is subject to adjustment for stock splits, combinations or similar events. If the Company makes any subsequent equity sales (subject to certain exceptions), under which an effective price per share that is lower than the Fixed Conversion Price, then the conversion price will be reduced to equal such price. The July 2014 Securities Purchase Agreement exempts any sales pursuant to the September 2014 Purchase Agreement Debentures from the July 2014 Purchase Agreement Debentures conversion price adjustments. Beginning four months (as subsequently amended) after the initial closing, the Company will begin making amortization payments on the debt in cash, prompting a 30% premium or, at their option and subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days. However, in the event the registration statement filed by the Company in connection with the respective purchase agreements is not effective within 120 days of the initial closing date under the July 2014 Purchase Agreement and 120 days of the initial closing date under the September 2014 Purchase Agreement, the July 2014 Purchase Agreement Debentures’ and the September 2014 Purchase Agreement Debentures’, respectively, conversion rate will be, during the period commencing 120 days after the initial closing date until the registration statement is effective, equal to 63% of the lowest volume weighted average price of the common stock for the 20 prior trading days. If the aforementioned registration statement is not effective within 160 days of the initial closing date, each of the debentures’ conversion rate will be, during the period commencing 160 days after the initial closing date until the registration statement is effective, equal to 60% of the lowest volume weighted average price of the common stock for the 20 prior trading days. In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement. The registration statement was not declared effective within 120 days, and the amortization payment conversion rate was adjusted accordingly. The $3,750,000 million principal amount of the Notes were issued net of $275,000 debt discount. The conversion feature of the notes meets the definition of a derivative under ASC 815 and due to the reset provision upon subsequent sales of securities at a price lower than the fixed conversion price, requires bifurcation and is accounted for as a derivative liability. The derivative was initially recognized at its estimated fair value of $1.885 million and created a discount on the Notes that will be amortized over the life of the Notes using the effective interest rate method. The fair value of the embedded derivative will be measured and recorded at fair value each subsequent reporting period and changes in fair value will be recognized in the statement of operations as a gain or loss on derivative. For the year ended December 31, 2014 the Company recognized a loss on the change in fair value of derivative liabilities of $1,805,990. See Note 2 Fair value measure for additional information on the fair value and gains or losses on the embedded derivative. As a result of a new convertible debentures loan agreements entered into in January 2015 (Note 20), which include a conversion rate equal to the lower of (a) $5.00 or (b) 51% of the lowest VWAP for the 20 consecutive Trading Days ending on the Trading Day that is immediately prior to the applicable Conversion Date, the reset provision terms of the July 2014 and September 2014 convertible debentures were triggered and the original fixed conversion price were adjusted accordingly.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 14 – PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other currents assets consisted of: December 31, 2014 December 31, 2013 Rent $ — $ 3,962 Directors & officers insurance 31,491 — Professional fees 10,000 52,739 Other vendors 24,729 32,540 Prepaid expenses and other current assets $ 66,220 $ 89,241 Deposits in escrow Deposits in escrow consist of amounts paid to open escrow accounts for the purchase of multiple properties to be used to develop retail dispensary or product cultivation facilities.

RESTRICTED STOCK AND RESTRICTED

RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs")	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs")	NOTE 6 – SHARE BASED AWARDS, RESTRICTED STOCK AND RESTRICTED STOCK UNITS (“RSUs”) On July 23, 2014, in connection with the election of a new Chairman, President and CEO, the Company entered into a two year employment contract with the new CEO. Under the employment contract, the CEO received an award of RSU’s, to be issued within 90 days of the effective date of the Employment Agreement, under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant. The Company also agreed to make an equal stock award to the CEO on each anniversary date of the employment agreement. The fair value of the awards, as determined on grant date, was $711,500 which was being amortized over the CEO’s one year service period. On June 30, 2015, Guy Marsala, President, Chief Executive Officer, and director of the Company, tendered his resignation as President and Chief Executive Officer of the Company and as a director on the Company’s board, effective immediately (Note 9). The remaining value of Mr. Marsala’s grants was recorded as expense in the second quarter of 2015. In connection with Mr. Marsala’s separation agreement approximately 2,580,000 options with a 10 year term were granted at an exercise price of $0.13. The fair value of $335,117 was calculated using the Black Sholes Merton model, and was immediately expensed. On August 21, 2014, the Compensation Committee of the Board granted Restricted Stock and RSU’s to two Board members who were elected to the Board on April 9, 2014. Under the award, the Directors received 346,875 shares of restricted stock and 121,875 RSU’s under which the holders have the right to receive 121,875 shares of common stock. The grant date fair value of the restricted stock was $3,607,500 and the grant date fair value of the RSU’s was $1,267,500. The restricted Stock and RSU’s vested over the remaining first year of the new Board members’ term ending on March 31, 2015. The fair value of the grant was amortized over the period from the date of grant, August 21, 2014 to the end of the first year of the Board members’ term, March 31, 2015. Under the Board members’ contracts, additional grants will be made for the second year of the contract. During October 2014, the Compensation Committee of the Board granted 19,452 RSU’s to a new Board member who was elected to the Board on October 22, 2014. The Board member’s contract calls for grants of 100,000 RSU’s for each succeeding year of service beginning on April 1, 2015, which vest quarterly. On September 24, 2015, the same Board member resigned from her positions as a member of the board of directors of the Company, chairperson of the Company’s audit committee and a member of its special committee, effective immediately. Stock compensation expense for this director in the second and third quarter was $353,000 and $197,000, respectively, which completes recognition of stock compensation expense for her service. The remaining 50,000 unvested RSU’s were forfeited upon her resignation. On February 10, 2015, the Compensation Committee of the Board granted 100,174 RSU’s to certain officers and employees of the Company as for retention and bonuses. The grant date fair value of the RSU’s was approximately $114,000. The RSU’s vest every six months through December 31, 2016. The fair value of the grant is being amortized over the period from the date of grant, February 10, 2015 through the vesting dates in six month increments. On January 15, 2015, the Board granted 75,000 RSUs to a consultant, which vest in 25,000 installments quarterly through July 15, 2015, beginning with 25,000 which vested immediately on the grant date. The grant date fair value of the RSU’s was approximately $450,000. On May 11, 2015, the Board granted 38,600 RSUs to various officers and employees, which vested immediately on the grant date. The grant date fair value of the RSU’s was approximately $20,000, which was immediately expensed. On May 11, 2015, the new CEO (Note 9) was awarded 196,078 RSUs in connection with his retention agreement. The grant date fair value of the RSU’s was approximately $100,000. The RSUs vest quarterly through May 11, 2016. On August 26, 2015, the Board granted 79,917 RSUs to various officers and employees, which vested immediately on the grant date. The grant date fair value of the RSU’s was approximately $12,000, which was immediately expensed. On August 31, 2015, the Board granted 156,250 RSUs to the CFO of the Company, which vested immediately on the grant date. The grant date fair value of the RSU’s was approximately $25,000, which was immediately expensed. A summary of the activity related to restricted stock and RSUs for the nine months ended September 30, 2015 is presented below: Restricted stock Total shares Grant date fair value Restricted stock non-vested at January 1, 2015 168,750 $ 10.40 Restricted stock granted 150,000 — Restricted stock vested (206,250 ) 10.40 Restricted stock forfeited — — Restricted stock non-vested at September 30, 2015 112,500 $ 10.40 Restricted stock units (RSU’s) Total shares Grant date fair RSU’s non-vested at January 1, 2015 199,584 $ 10.70 RSU’s granted 698,522 $ 0.51 - $6.07 RSU’s vested (590,502 ) $ 0.51 - $6.07 RSU’s forfeited (50,000 ) RSU’s non-vested September 30, 2015 257,604 $ 0.51 - $10.70 A summary of the expense related to restricted stock, RSUs and stock option awards for the three and nine months ended September 30, 2015 is presented below: Summary of the expense related to Restricted Stock and RSUs For the three months ended September 30, 2015 For the nine months ended September 30, 2015 Restricted Stock $ 390,000 $ 2,420,782 RSU’s 574,840 2,501,150 Stock options — 335,117 Common stock 74,333 74,333 Total $ 1,039,173 $ 5,331,382 On August 11, 2015, the Compensation Committee, with the Board’s approval, granted the Chairman of the Board a bonus of $371,666. The bonus is to be paid 20% in common stock of Medbox at $.0621 per share (the share price of the Company’s common stock on the date of grant) for a total grant of 1,196,988 shares, issued under the Medbox, Inc. 2014 Equity Incentive Plan. The remainder is to be paid in cash, including $50,000 which was paid in June and July, with the balance in monthly payments of $30,918 from August 2015 to March 2016.	NOTE 15 – RESTRICTED STOCK AND RESTRICTED STOCK UNITS (“RSUs”) On July 23, 2014, in connection with the election of a new Chairman, President and CEO, the Company entered into a two year employment contract with the new CEO. Under the employment contract, the CEO received an award of RSU’s, to be issued within 90 days of the effective date of the Employment Agreement, under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant. In October the Company granted 50,000 RSUs in accordance with the employee contract. The Company also agreed to make an equal stock award to the CEO on each anniversary date of the employment agreement. The RSU’s vest immediately during each year of the employment contract. During the third quarter of 2014, 20,000 additional shares were approved to increase the CEO’s first year RSU grant from 50,000 RSU’s to 70,000 RSU’s (see Note 16 for a more detailed discussion of the additional grant). As of December 31, 2014, the fair value of the grant was approximately $970,000 which is being amortized over the CEO’s one year service period. On August 21, 2014, the Compensation Committee of the Board of Directors granted Restricted Stock and RSU’s to two Board members who were elected to the Board on April 9, 2014. Under the award, the Directors received 346,875 shares of restricted stock and 121,875 RSU’s under which the holders have the right to receive 121,875 shares of common stock. The grant date fair value of the restricted stock was $3,607,500 and the grant date fair value of the RSU’s was $1,267,500. The restricted Stock and RSU’s vest over the remaining first year of the new Board members’ term ending on March 31, 2015. The fair value of the grant is being amortized over the period from the date of grant, August 21, 2014 to the end of the first year of the Board members’ term, March 31, 2015. Under the Board members’ contracts, additional grants will be made for the second year of the contract. During October 2014 the Compensation Committee of the Board of Directors granted 19,452 RSU’s to a new Board member who was elected to the Board on October 22, 2014. The Board member’s contract calls for grants of 100,000 RSU’s for each succeeding year of service beginning on April 1, 2015, which vest quarterly. A summary of the activity related to restricted stock and RSUs for the year ended December 31, 2014 is presented below: Restricted stock Total shares Grant date fair value Restricted stock non-vested at January 1, 2014 — $ — Restricted stock granted 346,875 10.40 Restricted stock vested (178,125 ) 10.40 Restricted stock forfeited — — Restricted stock non-vested at December 31, 2014 168,750 $ 10.40 Restricted stock units (RSU’s) Total shares Grant date fair value Restricted stock non-vested at January 1, 2014 — $ — Restricted stock granted 422,980 10.84 Restricted stock vested (223,396 ) 11.19 Restricted stock forfeited — — Restricted stock non-vested at December 31, 2014 199,584 $ 10.70 A summary of the expense related to restricted stock and RSUs for the year ended December 31, 2014 is presented below: Summary of the expense related to Restricted Stock and RSUs Year ended December 31, 2014 Restricted Stock $ 663,262 RSU’s 3,752,537 $ 4,415,799 There were not any restricted stock or RSU activity in the year ended December 31, 2013.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7 – RELATED PARTY TRANSACTIONS During the year ended December 31, 2014, the Company issued four notes payable to PVM International Inc. (“PVMI”), a related party which is 100% owned by a co-founder of the Company, in the amounts of $250,000, $100,000, $500,000, and $375,000. These notes were subsequently partially repaid leaving $284,488 outstanding as of June 30, 2014. On October 17, 2014 the Company entered into an assignment agreement with PVMI through which PVMI assigned all rights and titles for any opened escrow on real estate purchase agreements in San Diego in exchange for a related party notes payable from the Company. As of the signing date the agreement was valued at $190,400 which represented the value of escrow deposits paid by PVMI for eight different real estate agreements. All of the notes and amounts owed under the assignment agreement were repaid in full during the third quarter of 2015. On March 28, 2014, the Company entered into an agreement with a related party for territory rights in Colorado for $500,000. The agreement has a term of five years and in accordance with the Company’s revenue recognition policy, the revenue will be recognized over the five year term. Approximately $350,000 remains in deferred revenue as of September 30, 2015. During the third quarter of 2014, the Company created the following affiliated entities in connection with license applications: A. Hanna Growers, Inc., Herbal Choice of Illinois, Inc., Nature’s Treatment of Illinois, Inc., Green Blossom of Illinois, Inc., Midwestern Compassionate Care of Illinois, Inc., Midwestern Wellness Group of Illinois, Inc., Green Blossom, Inc., Nature’s Treatment, Inc. and Herbal Choice, Inc.	NOTE 16 – RELATED PARTY TRANSACTIONS The aggregate amount of outstanding payables to related parties as of December 31, 2014 and 2013 was $678,877 and $111,794, respectively. During 2012, the Company issued notes payable to a shareholder in the aggregate amount of $125,000 in exchange for the shareholder’s original investment in PVM common stock. The notes bear no interest and are due on demand. As of December 31, 2012, the outstanding balance on the notes was $94,000 and as of December 31, 2013, the notes were paid in full. On January 1, 2012, the Company issued a note payable to PVMI which is 100% owned by the founder of the Company in the amount of $1,000,000 along with the issuance of 4,000,000 shares of the Company’s common stock for 100% of PVMI Named Subsidiaries and for the exclusive use of patents related to PVMI’s dispensing systems. The note was secured with 1,000,000 shares of the Company’s common stock. The note was due on demand and bore interest at 10% of the outstanding balance beginning January 1, 2013. The balance at December 31, 2012 was $775,038 and as of December 31, 2013, the note was paid in full. The Company utilizes Kind Clinics, LLC, which is 100% owned by the former Chief Executive Officer of the Company, Dr, Bruce Bedrick, for management advisory and consulting services. During the year ended December 31, 2012, the Company incurred $113,613 in fees for these services. For the year ended December 31, 2012 the Company utilized AVT, Inc., for the procurement, manufacture and assembly of its dispensary units. During 2012, the Company incurred approximately $480,000 and $510,000 in manufacturing costs. In addition, the Company’s existing inventory of dispensary units was held at AVT, Inc.’s manufacturing facility in Corona, California on behalf of the Company. The Company believes that its transactions with AVT, Inc. during 2012 were completed on an arms-length basis. The Company utilizes Vincent Chase Inc., which is a related party and 100% owned by a co-founder of the Company for management advisory and consulting services. During the years ended December 31, 2014, 2013 and 2012, the Company incurred fees of $168,625, $262,500 and $230,706, respectively, for these services. The contract for the aforementioned services was terminated on December 8, 2014. During 2013, the Company issued two promissory notes payable to Vincent Chase Inc., on September 20, 2013, in the amount of $150,000 and on October 28, 2013 in the amount of $100,000. At December 31, 2013, the outstanding amount for the combined notes was $111,794. These notes were repaid in full during 2014. During the year ended December 31, 2014, the Company issued four notes payable to PVM International Inc. (“PVMI”), a related party which is 100% owned by a co-founder of the Company, in the amounts of $250,000, $100,000, $500,000, and $375,000. These notes were subsequently partially repaid leaving $388,477 outstanding as of December 31, 2014. On October 17, 2014 the Company entered into an assignment agreement with PVMI through which PVMI assigned all rights and titles for any opened escrow on real estate purchase agreements in San Diego in exchange for a related party notes payable from the Company. As of the signing date the agreement was valued at $190,400 which represented the value of escrow deposits paid by PVMI for eight different real estate agreements. On July 21, 2014, the Company also paid $75,000 to PVMI as a partial payment for advances made by PVMI for escrow deposits used to secure properties for possible license acquisition in the San Diego market area. On August 15, 2014, the Company issued a note payable to Vincent Chase, Inc., in the amount of $100,000. The notes bear no interest and are payable on demand. The Company utilized Dr. Bruce Consulting which is a related party and 100% owned by one of Company’s major shareholders and former Chief Executive Officer for management consulting and advisory service. During the year ended December 31, 2014, the Company incurred expenses in the amount of $43,750 for consulting and advisory services to Dr. Bruce Consulting. For the year ending December 31, 2013, the Company paid salary to Dr. Bruce Bedrick, the former Chief Executive Officer in the gross amount of $133,991. During the application process for dispensaries and cultivation centers in Illinois, which took place in September, 2014, Dr. Bruce Bedrick, a major shareholder, provided funding to the applicant entity in the amount of $500,000. This amount was returned by the applicant entity to Dr. Bruce Bedrick by September 30, 2014. During the third quarter of 2014, the CEO of the Company and the Chairman of the Board, Mr. Guy Marsala received 20,000 shares from the founder and major shareholder of the Company out of his personal holdings to compensate for his superior performance. On October 24, 2014 the Compensation Committee of the Board of Directors recommended that shares be returned to the founder and issued by the Company as part of the yearly RSU grant. In November 2014, Mr. Marsala returned 20,000 shares to founder and major shareholder and 20,000 additional shares were approved to increase Mr. Marsala’s first year RSU grant from 50,000 RSU’s to 70,000 RSU’s. Related parties contributed $810,000 and $561,000 in 2013 and 2012, respectively, to provide funding for growth for the Company. During the first quarter of 2014, the Company completed a contract with a related party and, a shareholder in the amount of $400,000 which was recognized as a Customer deposit in the Company’s balance sheet. In addition, the same related party paid the Company $150,000 for an amount owed to the Company by an unrelated third party to facilitate development at an existing dispensary where the unrelated party purchased an interest during the period. In addition on March 28, 2014 the Company entered into an agreement with a related party for territory rights in Colorado for $500,000. The agreement has a term of five years and in accordance with the Company’s revenue policy, the revenue will be recognized over the five year term. During the third quarter of 2014, the Company created the following affiliated entities in connection with license applications: A. Hanna Growers, Inc., Herbal Choice of Illinois, Inc., Nature’s Treatment of Illinois, Inc., Green Blossom of Illinois, Inc., Midwestern Compassionate Care of Illinois, Inc., Midwestern Wellness Group of Illinois, Inc., Green Blossom, Inc., Nature’s Treatment, Inc. and Herbal Choice, Inc.

Stockholder's Equity

Stockholder's Equity	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Equity [Abstract]
STOCKHOLDER'S EQUITY	NOTE 8 – STOCKHOLDER’S EQUITY Common Stock Authorized share increase On June 30, 2015, the Board of Directors of the Company and the holders of a majority of the Company’s voting securities approved by written consent an amendment to the Company’s Articles of Incorporation to increase the authorized number of shares of the Company’s common stock from 100,000,000 shares to 400,000,000 shares, par value of $0.001 per share. The Company’s Board of Directors approved the increase of authorized capital so that it will have sufficient shares of common stock available for issuance upon the conversion or exercise of currently outstanding convertible debt securities and warrants and for future capital raises. The Company filed a Schedule 14C Information Statement regarding the matter submitted to a vote of their security holders with the Securities and Exchange Commission. The increase of authorized capital approved by the stockholders became effective on October 27, 2015. Change of Control Effective August 24, 2015, Vincent Chase, Incorporated, which is owned by the former CEO of the Company, cancelled without consideration all of its 2 million shares of Preferred Stock and 3 million shares of Common Stock. As a result of this action, neither VM nor any of its affiliates holds a majority of the voting power of the Company, which to the Company’s knowledge is no longer held by a single person or entity or group thereof. For common shares which were issued upon conversion of the convertible debentures during the nine months ended September 30, 2015 see Note 5. During the nine months ended September 30, 2015 the Company issued 1,633,047 shares of its common stock, valued at approximately $365,000 as based on the market price of the common stock on the date of settlement, as a payment of certain accounts payables. In addition, in January, 2015, the Company issued 206,480 of their common stock upon exercise of the warrants held by various previous owners of VII.	NOTE 17 – STOCKHOLDER’S EQUITY Preferred Stock In November 2011, the Company issued 6,000,000 shares of $0.001 par value Series A convertible preferred stock to the founder and a shareholder of the Company. This preferred stock can be converted to common stock at a ratio of 1 (one) share of Series A Preferred Stock to 5 (five) shares of common stock. In October 2012, 3,000,000 shares of Series A Preferred Stock were returned to the Company by the shareholder and reissued to the founder. In January 2013, the founder returned to the Company the 3,000,000 shares of Series A Preferred Stock and they were immediately cancelled. As of September 30, 2014, there are 3,000,000 shares of Series A Preferred Stock outstanding. The Series A Preferred Stock has special voting rights when voting as a class with the Common Stock as follows: (i) the holders of Series A Preferred Stock shall have such number of votes as is determined by multiplying (a) the number of shares of Series A Preferred Stock held by such holder, (b) the number of issued and outstanding shares of the Corporation’s Series A Preferred Stock and Common Stock (collectively, the “Common Stock”) on a Fully-Diluted Basis (as hereinafter defined), as of the record date for the vote, or, if no such record date is established, as of the date such vote is taken or any written consent of stockholders is solicited, and (c) 0.00000025; and (ii) the holders of Common Stock shall have one vote per share of Common Stock held as of such date. “Fully-Diluted Basis” mean that the total number of issued and outstanding shares of the Company’s Common Stock shall be calculated to include (a) the shares of Common Stock issuable upon exercise and/or conversion of all of the following securities (collectively, “Common Stock Equivalents”): all outstanding (a) securities convertible into or exchangeable for Common Stock, whether or not then convertible or exchangeable (collectively, “Convertible Securities”), (b) subscriptions, rights, options and warrants to purchase shares of Common Stock, whether or not then exercisable (collectively, “Options”), and (c) securities convertible into or exchangeable or exercisable for Options or Convertible Securities and any such underlying Options and/or Convertible Securities. Common Stock On June 5, 2014 the Company entered into two separate sales agreements with an affiliate company owned by the co-founder of the Company. The first was for the sale of all of the Company’s Bio-Tech rights and claims, as consideration for which the Company received 30,000 shares of the Company’s common stock with a fair value of $604,800, as based on the market price of the common stock. The second was for the sale of all the MedVend rights and claims in exchange for 30,000 shares of the Company’s common stock, with a fair value of $604,800 as based on the market price of the common stock. These 60,000 shares of common stock received back by the Company are treated as treasury stock and can be reissued. During January, 2014, the Company issued 485,830 shares of its common stock at the price of $5.00 per share, resulting in net cash proceeds of $2,427,859. On December 18, 2013 the Company declared a two-for-one (2:1) forward stock split on its outstanding common stock, effectuated in the form of a common stock dividend. The stock dividend, aggregating in 14,762,875 common shares, was issued on and announced by the Financial Industry Regulatory Authority (FINRA) on February 3, 2014. Accordingly, the Company’s consolidated financial statements have been retroactively stated for all periods presented to reflect the 2:1 forward stock split. On September 8, 2014 the Company issued 93,751 shares of common stock to two board members from a total grant of 346,875 awarded by the Compensation Committee to board members. On October 7, 2014 additional 84,374 shares were issued to the same board members. During the fourth quarter of 2014 the Company issued 52,892 shares of its common stock, valued at $316,065 as based on the market price of the common stock, as a payment of certain accounts payables. During 2013, the Company issued 2,115,100 shares of common stock at an average price $2.23, resulting in net cash proceeds of $4,486,541. In addition, during 2013, the Company had non-cash additions to equity from the issuances of warrants and common stock in connection with the VII acquisition of $1,285,553. During 2012, the Company sold approximately 2,463,000 shares of common stock for proceeds of approximately $858,000. The balance of $153,250 for the remaining 74,100 shares is to be received in 2013. On January 1, 2012, the Company issued 4,000,000 shares of the Company’s common stock as consideration for 100% of certain named subsidiaries PVMI, a related party, and for the exclusive use of patents related to PVMI’s dispensing systems. (see Note 16)

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 18 – INCOME TAXES The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax basis of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. Deferred income taxes are provided for temporary differences arising from using the straight-line depreciation method for financial statement purposes and accelerated methods of depreciation for income taxes, including differences between book and tax for amortizing organization expenses. In addition, deferred income taxes are recognized for certain expense accruals, allowances and net operating loss carry forwards available to offset future taxable income, net of valuation allowances for potential expiration and other contingencies that could impact the Company’s ability to recognize the benefit. The Company is required to file federal and state income tax returns. Various taxing authorities may periodically audit the Company’s income tax returns. These audits would include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. The Company is in the process of an examination by the Internal Revenue Service of the year ended December 31, 2011. Management has performed its evaluation of all other income tax positions taken on all open income tax returns and has determined that there were no positions taken that do not meet the “more likely than not” standard. Accordingly, there are no provisions for income taxes, penalties or interest receivable or payable relating to uncertain income tax provisions in the accompanying consolidated financial statements. From time to time, the Company may be subject to interest and penalties assessed by various taxing authorities. These amounts have historically been insignificant and are classified as other expenses when they occur. Deferred tax assets and liabilities result from temporary differences in the recognition of income and expense for tax and financial reporting purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows at December 31: 2014 2013 Deferred tax assets: Customer deposits $ 295,000 $ 293,000 Deferred revenue 35,000 Share based compensation 1,760,000 NOL carryforward 5,400,000 2,377,000 Total deferred tax asset 7,490,000 2,670,000 Deferred tax liabilities: Deferred revenue — 285,000 Intangible asset amortization 20,000 20,000 285,000 7,470,000 2,385,000 Less: Valuation allowance (7,470,000 ) (2,385,000 ) $ — $ — A valuation allowance has been recorded against the realizability of the net deferred tax asset such that no value is recorded for the asset in the accompanying consolidated financial statements. The valuation allowance increased $5,085,000 between the year ended December 31, 2014 and 2013. The Company has net operating loss carryforwards available for federal and state tax purposes of approximately $13,510,000, at December 31, 2014, which expire in varying amounts through 2034. For the years ended December 31, 2014, 2013 and 2012, a reconciliation of the statutory rate and effective rate for the provisions for income taxes consists of the following: 2014 2013 2012 Federal Tax statutory rate 34.00 % 34.00 % 34.00 % State tax statutory rate 6.00 % 8.84 % 8.84 % Permanent differences (6.72 )% — % Valuation allowance (33.28 )% (42.84 )% (42.84 )% Effective rate 0.00 % 0.00 % 0.00 %

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES The Company leases property for its day to day operations and facilities for possible retail dispensary locations and cultivation locations as part of the process of applying for retail dispensary and cultivation licenses. Office Leases On August 1, 2011, the Company entered into a lease agreement for office space located in West Hollywood, California through June 30, 2017 at a monthly rate of $14,397. Starting July 1, 2014, the monthly rent increased by 3% to $14,828 per month. The Company moved to new offices in Los Angeles, CA in April 2015. The sublease on the new office has a term of 18 months and with monthly rent of $7,486. The Company plans to sublease the office in West Hollywood, CA. Total rent expense under operating leases for the three months ended September 30, 2015 and 2014 was approximately $90,000 and $53,000, respectively. Rent expense for the nine months ended September 30, 2015 and 2014 was approximately $211,000 and $157,000, respectively. Retail/Cultivation facility leases The Company’s business model of acquiring retail dispensary and cultivation licenses often requires us to acquire real estate either through lease arrangements or through purchase agreements in order to secure a possible license. On May 8, 2014, the Company entered into a lease agreement for the Portland dispensary for five years with a monthly payment of $7,400 in order to apply for a license and build-out of a location for a client. On July 22, 2014 one of the Company’s subsidiaries Medbox Property Investments, Inc., entered into a new lease for a facility which was to be used in the application process for both a dispensary and cultivation facility. The Company paid an initial security deposit of $30,000 and the lease was payable monthly at a rate of $20,000 per month. The lease had a five year term, but was contingent upon license approval which allowed for early termination of the lease after January 1, 2015 if the license was not granted. Due to the fact that the Company was unsuccessful in obtaining the license related to the mentioned facility the lease agreement was terminated in November 2014 and the Company forfeited the security deposit. The following table is a summary of our material contractual lease commitments as of September 30, 2015: Year Ending Office Rent Retail/Cultivation Facility Lease 2015 $ 66,942 $ 22,200 2016 245,310 88,800 2017 88,968 88,800 2018 — 88,800 2019 — 29,600 Total $ 401,220 $ 318,200 Real Estate Commitments Through December 31, 2014 the Company paid $930,000 either by deposit into twelve escrow accounts or direct payments to sellers, to secure the purchase and/or extend the closing dates on real estate to be used for future retail/cultivation facilities with an aggregate purchase price of $26,830,000. The real estate purchase agreements had closing dates varying between December 1, 2014 and February 10, 2015. During 2014, the Company entered into numerous real estate contracts to secure locations during the licensing process. The contracts allow the Company to demonstrate to licensing authorities that the locations are available for use as a dispensary or cultivation location. The contracts are generally structured with an escrow deposit, a deferred closing until a license is granted and periodic withdrawals from the deposit to compensate the seller for holding the property off the market in escrow during the pendency of the license application. The periodic transfers out of escrow to the seller are in some cases creditable towards the purchase price but in most cases represent charges in lieu of rent. The charges in lieu of rent and other non-refundable charges paid to property sellers have been recorded as expense of $195,712 for the nine months ended September 30, 2014 in the statement of operations. During the third quarter of 2014, one of the Company’s subsidiaries, MJ Property Investments, Inc., allowed the escrows to expire on two real estate purchase agreements with an aggregate purchase price of $2,500,000. As a result the Company forfeited $100,000 in earnest money due to unfavorable terms demanded by the sellers to extend the escrow and closing date. During the second quarter of 2014 one of the Company’s subsidiaries entered into a real estate purchase agreement in Washington state. The purchase transaction was closed during the third quarter of 2014 for a total purchase price of $399,594 partially financed by a promissory note for $249,000. The note was due January 30, 2015 and bore interest at twelve percent (12%). The Company did not repay the note on its maturity date, and is therefore is incurring the default interest rate of eighteen percent (18%). The property was classified as Assets held for resale as of December 31, 2014 because the Company’s plan was to sell the property to a third party to hold as a lessor to the operator of the dispensary. (See Note 10, Subsequent Events) On September 30, 2015, the Company, through its subsidiary, entered into an amendment to the Note Payable, whereby the maturity date was extended to April 1, 2017, with the interest at twelve percent (12%). During the nine months ended September 30, 2015 the Company recovered approximately $105,000 and forfeited approximately $280,000 out of escrow deposits outstanding as of December 31, 2014. As of September 30, 2015 the Company has only one open real estate agreement for a property in San Diego with a purchase price of $875,000 and related outstanding deposit of $15,000 Officers On June 30, 2015, Guy Marsala, President, Chief Executive Officer, and director of the Company since July 23, 2014, tendered his resignation as President and Chief Executive Officer of the Company and as a director on the Company’s board, effective immediately. Mr. Marsala confirmed that such resignation is not because of a disagreement with the Company on any matter relating to its operations, policies or practices. In connection with his resignation, the Company and Mr. Marsala entered into a Separation Agreement dated June 30, 2015. Pursuant to the terms of the Separation Agreement, Mr. Marsala is entitled to receive $500,000 in severance pay, payable in equal monthly installments of $30,000, and a grant of options to purchase up to $335,275 of shares of common stock at an exercise price based on the closing price of the Company’s common stock on June 30, 2015, in lieu of any rights under his employment agreement, which was terminated. Chief Operating Officer/Chief Executive Officer On April 22, 2015, the Board of Company appointed Jeffrey Goh as Chief Operating Officer, effective immediately. In connection with his appointment as Chief Operating Officer, Mr. Goh and the Company have agreed that Mr. Goh’s annual base salary will be $300,000, subject to annual increases of between 5% and 7% based upon performance goals and the Company’s financial results. Mr. Goh will be eligible to receive a cash bonus of up to a maximum of $150,000 per year (“Cash Bonus”), plus a bonus grant of restricted stock units convertible into Company common stock up to a maximum of $150,000 per year (“Equity Bonus”). Each of the Cash Bonus and Equity Bonus shall be determined based upon the achievement of performance goals to be mutually agreed upon amongst Mr. Goh and the Board of Directors for the given year. Mr. Goh shall also be entitled to receive an award of 100,000 restricted stock units convertible into Company common stock on each anniversary of the original date of his employment with the Company. In the event that Mr. Goh terminates his employment with or without cause or the Company terminates Mr. Goh’s employment without cause, Mr. Goh shall be entitled to receive a severance payment equivalent to 6, 12, or 18 months of base salary, based upon whether the length of Mr. Goh’s employment with the Company at the time of termination is less than 12 months, greater than 12 months but less than 24 months, or greater than 24 months, respectively. Effective June 30, 2015, Jeffrey Goh, was promoted to President and interim Chief Executive Officer of the Company. Voting Agreement On August 21, 2015, Medbox, P. Vincent Mehdizadeh (“VM”), PVM International, Inc., (“PVM”), and Vincent Chase, Incorporated, (“VC”) (VM, PVM and VC, collectively, the “VM Group”) and each member of the Board of Directors of the Company, namely, Ned Siegel, Mitch Lowe and Jennifer Love, entered into a certain Second Amendment to Voting Agreement, dated August 21, 2015 (the “Second Amendment”) amending in certain respects that certain Voting Agreement dated January 21, 2015 among such parties as previously amended by that certain First Amendment to Voting Agreement (the “First Amendment”) dated August 11, 2015 (collectively, the “Voting Agreement”). Pursuant to the First Amendment, the VM Group previously agreed (i) to extend the Expiration Date of the Voting Agreement from January 20, 2016 to July 20, 2016, provided the Company made certain pre-payments on the remaining $478,877 balance due to PVM on an outstanding promissory note (Note 7), and (ii) to forebear from exercising its rights to appoint a director to the Board of Directors of the Company (under Section 4 of that certain Settlement Agreement dated January 21, 2015 among the Company and the VM Group, the “Settlement Agreement”), until the Expiration Date of the Voting Agreement as extended by the First Amendment. Pursuant to the Second Amendment, the VM Group and the Company: (a) further extended the Expiration Date of the Voting Agreement to July 20, 2018, (b) provided that the Company would make certain accelerated pre-payments on the $328,877 balance under the Note consisting of: (i) three equal payments of principal in the amount of $82,220, together with accrued and unpaid interest, payable on each of August 24, 2015, August 31, 2015 and September 8, 2015, and (ii) one final payment on September 14, 2015 equal to the remaining principal and accrued and unpaid interest due under the Note (the payments have all been paid as of September 30, 2014); (c) provided that the VM Group would forebear from exercising its right to appoint a director to the Board of Directors of the Company (under Section 4 of that certain Settlement Agreement), until the Expiration Date of the Voting Agreement as extended by the Second Amendment; and (d) the VM Group executed, that certain Consent of Stockholders of Medbox, Inc. (the “Consent”) approving the following amendments of the Articles of Incorporation (the “Articles”) of the Company: (i) elimination of the provisions of Section IV of the Articles giving the holders of the Series A Convertible Preferred Stock of the Company (the “Preferred”) disproportionately greater voting rights than the holders of Common Stock and instead providing for the Preferred to have one vote per common share on an as- converted basis voting as a single class with the common shares upon any matter submitted to the stockholders for a vote, and (ii) to eliminate the provisions of Section V of the Articles providing the holders of a majority of the outstanding shares of Preferred the right to approve any corporate action except for: (1) actions which would adversely alter or change the rights, preferences, privileges or restrictions of the Preferred or increase the authorized number thereof, (2) any changes to the terms of the Preferred; (3) creation of any new class of shares having preferences over or being on a parity with the Preferred as to dividends or assets, unless the purpose of creation of such class is, and the proceeds to be derived from the sale and issuance thereof are to be used for, the retirement of all Preferred then outstanding; or, (4) any payment of dividends or other distributions or any redemption or repurchase of options or warrants to purchase stock of the Company, except for repurchases of options or stock issued under an equity incentive plan approved by the Board. Litigation On May 22, 2013, Medbox initiated litigation in the United States District Court in the District of Arizona against three shareholders of MedVend Holdings LLC (“Medvend”) in connection with a contemplated transaction that Medbox entered into for the purchase of an approximate 50% ownership stake in Medvend for $4.1 million. The lawsuit alleges fraud and related claims arising out of the contemplated transaction during the quarter ended June 30, 2013. The litigation is pending and Medbox has sought cancellation due to a fraudulent sale of the stock because the selling shareholders lacked the power or authority to sell their ownership stake in MedVend, and their actions were a breach of representations made by them in the agreement. On November 19, 2013 the litigation was transferred to United States District Court for the Eastern District of Michigan. MedVend recently joined the suit pursuant to a consolidation order executed by a new judge assigned to the matter. In the litigation, the selling shareholder defendants seek alternatively to have the transaction performed, or to have it unwound and be awarded damages and allege breach of the agreement by Medbox and that $600,000 was wrongfully retained by the Company. Medbox has denied liability with respect to any and all such counterclaims. A new litigation schedule was recently issued setting trial for September 2015. On June 5, 2014, the Company entered into a purchase and sale agreement (the “Medvend PSA”) with PVM International, Inc. (“PVMI”) concerning this matter. Pursuant to the Medvend PSA, the Company sold to PVMI the Company’s rights and claims attributable to or controlled by the Company against those three certain stockholders of Medvend, known as Kaplan, Tartaglia and Kovan (the “Medvend Rights and Claims”), in exchange for the return by PVMI to the Company of 30,000 shares of the Company’s common stock. PVMI is owned by Vincent Mehdizadeh, the Company’s largest stockholder. The Company will have the right, under the Medvend PSA, to purchase from PVMI, at any time, the Medvend Rights and Claims, for the consideration provided by PVMI, plus the sum of any of PVMI’s reasonable expenditures incurred in pursuit of the Medvend Rights and Claims. The court has not yet ruled on the substitution of PVMI as plaintiff in this matter. If necessary, the Company plans to vigorously defend against this matter. The case is in the discovery stage, and, at this time, the Company cannot determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can they reasonably estimate a range of potential loss, should the outcome be unfavorable. On February 20, 2015, Michael A. Glinter, derivatively and on behalf of nominal defendants Medbox, Inc. the Board and certain executive officers (Pejman Medizadeh, Matthew Feinstein, Bruce Bedrick, Thomas Iwanskai, Guy Marsala, J. Mitchell Lowe, Ned Siegel, Jennifer Love, and C. Douglas Mitchell) filed a suit in the Superior Court of the State of California for the County of Los Angeles. The suit alleges breach of fiduciary duties and abuse of control by the defendants. Relief is sought awarding damages resulting from breach of fiduciary duty and to direct the Company and the defendants to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. This action has been stayed pending the outcome of the actions filed in the United States District Court for the District of Nevada (Calabrese and Gray). Due to the early stages of this suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On January 21, 2015, Josh Crystal on behalf of himself and of all others similarly situated filed a class action lawsuit in the U.S. District Court for Central District of California against Medbox, Inc., and certain past and present members of the Board (Pejman Medizadeh, Bruce Bedrick, Thomas Iwanskai, Guy Marsala, and C. Douglas Mitchell). The suit alleges that the Company issued materially false and misleading statements regarding its financial results for the fiscal year ended December 31, 2013 and each of the interim financial periods that year. The plaintiff seeks relief of compensatory damages and reasonable costs and expenses or all damages sustained as a result of the wrongdoing. On April 23, 2015, the Court issued an Order consolidating the three related cases in this matter: Crystal v. Medbox, Inc., Gutierrez v. Medbox, Inc., and Donnino v. Medbox, Inc., and appointing a lead plaintiff. On July 27, 2015 Plaintiffs filed a Consolidated Amended Complaint. The Company must file a responsive pleading on or before December 4, 2015. The Company intends to vigorously defend against these suits. Due to the early stages of the suits the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On January 18, 2015, Ervin Gutierrez filed a class action lawsuit in the U.S. District Court for the Central District of California. The suit alleges violations of federal securities laws through public announcements and filings that were materially false and misleading when made because they misrepresented and failed to disclose that the Company was recognizing revenue in a manner that violated US GAAP. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses or all damages sustained as a result of the wrongdoing. On April 23, 2015, the Court issued an Order consolidating the three related cases in this matter: Crystal v. Medbox, Inc., Gutierrez v. Medbox, Inc., and Donnino v. Medbox, Inc., and appointing a lead plaintiff. On July 27, 2015 Plaintiffs filed a Consolidated Amended Complaint. The Company must file a responsive pleading on or before December 4, 2015. The Company intends to vigorously defend against this suit. Due to the early stages of the suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On January 29, 2015, Matthew Donnino filed a class action lawsuit in the U.S. District Court for Central District of California. The suit alleges that the Company issued materially false and misleading statements regarding its financial results for the fiscal year ended December 31, 2013 and each of the interim financial periods that year. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses or all damages sustained as a result of the wrongdoing. On April 23, 2015, the Court issued an Order consolidating the three related cases in this matter: Crystal v. Medbox, Inc., Gutierrez v. Medbox, Inc., and Donnino v. Medbox, Inc., and appointing a lead plaintiff. On July 27, 2015 Plaintiffs filed a Consolidated Amended Complaint. The Company must file a responsive pleading on or before December 4, 2015. The Company intends to vigorously defend against this suit. Due to the early stages of the suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On February 12, 2015, Jennifer Scheffer, derivatively on behalf of Medbox, Guy Marsala, Ned Siegel, Mitchell Lowe and C. Douglas Mitchell filed a lawsuit in the Eighth Judicial District Court of Nevada seeking damages for breaches of fiduciary duty regarding the issuance and dissemination of false and misleading statements and regarding allegedly improper and unfair related party transactions, unjust enrichment and waste of corporate assets. On April 17, 2015, Ned Siegel and Mitchell Lowe filed a Motion to Dismiss. On April 20, 2015, the Company filed a Joinder in the Motion to Dismiss. On July 27, 2015, the Court held a hearing on and granted the Motion to Dismiss without prejudice. Due to the early stages of the suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On March 10, 2015 Robert J. Calabrese, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the United States District Court for the District of Nevada against certain Company officers and/or directors (Ned L. Siegel, Guy Marsala, J. Mitchell Lowe, Pejman Vincent Mehdizadeh, Bruce Bedrick, and Jennifer S. Love). The suit alleges breach of fiduciary duties and gross mismanagement by issuing materially false and misleading statements regarding the Company’s financial results for the fiscal year ended December 31, 2013 and each of the interim financial periods. Specifically the suit alleges that defendants caused the Company to overstate the Company’s revenues by recognizing revenue on customer contracts before it had been earned. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Due to the early stages of the suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On March 27, 2015 Tyler Gray, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the United States District Court for the District of Nevada against the Company’s Board of Directors and certain executive officers (Pejman Vincent Mehdizadeh, Matthew Feinstein, Bruce Bedrick, Thomas Iwanski, Guy Marsala, J. Mitchell Lowe, Ned Siegel, Jennifer S. Love, and C. Douglas Mitchell). The suit alleges breach of fiduciary duties and abuse of control. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. Due to the early stages of this suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On May 20, 2015 Patricia des Groseilliers, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the United States District Court for the District of Nevada against the Company’s Board of Directors and certain executive officers (Pejman Vincent Mehdizadeh, Ned Siegel, Guy Marsala, J. Mitchell Lowe, Bruce Bedrick, Jennifer S. Love, Matthew Feinstein, C. Douglas Mitchell, and Thomas Iwanski). The suit alleges breach of fiduciary duties and unjust enrichment. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. Due to the early stages of this suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On June 3, 2015 Mike Jones, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the U.S. District Court for Central District of California against the Company’s Board of Directors and certain executive officers (Guy Marsala, J. Mitchell Lowe, Ned Siegel, Jennifer S. Love, C. Douglas Mitchell, Pejman Vincent Mehdizadeh, Matthew Feinstein, Bruce Bedrick, and Thomas Iwanski). The suit alleges breach of fiduciary duties, abuse of control, and breach of duty of honest services. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. On July 20, 2015, the Court issued an Order consolidating this litigation with those previously consolidated in the Central District (Crystal, Gutierrez, and Donnino). Due to the early stages of this suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On July 20, 2015 Kimberly Freeman, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the Eighth Judicial District Court of Nevada against the Company’s Board of Directors and certain executive officers (Pejman Vincent Mehdizadeh, Guy Marsala, Ned Siegel, J. Mitchell Lowe, Jennifer S. Love, C. Douglas Mitchell, and Bruce Bedrick). The suit alleges breach of fiduciary duties and unjust enrichment. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. Due to the early stages of this suit the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. On December 26, 2014, Medicine Dispensing Systems, a wholly-owned subsidiary of Medbox, filed a suit against Kind Meds, Inc. to collect fees of approximately $550,000 arising under a contract to establish a dispensary. Kind Meds, Inc. filed a cross complaint against Medicine Dispensing Systems for breach of contract and breach of implied covenant of good faith and fair dealing, claiming damages of not less than $500,000. We believe that the cross complaint is without merit. We will continue to pursue this Kind Meds for the amounts owed under the contract and will vigorously defend ourselves against the cross complaint. At this time the Company in unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. The Company commenced arbitration proceedings against a former employee on June 13, 2013 related to employment claims asserted by the employee. Thereafter, the employee filed a suit in Los Angeles County Superior Court. The suit was stayed pending the outcome of the arbitration and thereafter dismissed without prejudice. The Company obtained a favorable arbitration award. The Company then filed an Application to Confirm the Arbitration Award in Arizona Superior Court, Maricopa County. After being unable to serve the employee, the Company performed service by publication and filed proofs of publication for service on the employee on February 27, 2015 and March 2, 2015. If the arbitration award is not enforced, the employee’s claim can be re-filed in California. In October 2014, the Board of Directors of the Company appointed a special board committee (the “Special Committee”) to investigate a federal grand jury subpoena pertaining to the Company’s financial reporting which was served upon the Company’s accountants as well as certain alleged wrongdoing raised by a former employee of the Company. The Company was subsequently served with two SEC subpoenas in early November 2014. The Company is fully cooperating with the grand jury and the SEC. In connection with its investigation of these matters, the Special Committee in conjunction with the Audit Committee initiated an internal review by management and by an outside professional advisor of certain prior period financial reporting of the Company. The outside professional advisor reviewed the Company’s revenue recognition methodology for certain contracts for the third and fourth quarters of 2013. As a result of certain errors discovered in connection with the review by management and its professional advisor, the Audit Committee, upon management’s recommendation, concluded on December 24, 2014 that the consolidated financial statements for the year ended December 31, 2013 and for the third and fourth quarters therein, as well as for the quarters ended June 30, 2014, June 30, 2014 and September 30, 2014, should no longer be relied upon and would be restated to correct the errors. On March 6, 2015 the audit committee determined that the consolidated financial statements for the year ended December 31, 2012, together with all three, six and nine month financial information contained therein, and the quarterly information for the first two quarters of the 2013 fiscal year should also be restated. On March 11, 2015, the Company filed its restated Form 10 Registration Statement with the SEC with restated financial information for the years ended December 31, 2012 and December 31, 2013, and on March 16, 2015, the Company filed amended and restated quarterly reports on Form 10-Q, with restated financial information for the periods ended March 31, June 30 and September 30, 2014, respectively.	NOTE 19 – COMMITMENTS AND CONTINGENCIES The Company leases property for its day to day operations and has recently begun leasing facilities for possible retail dispensary locations and cultivation locations as part of the process of applying for retail dispensary and cultivation licenses. Office Leases On August 1, 2011, the Company entered into a lease agreement for office space located in West Hollywood, California through June 30, 2017 at a monthly rate of $14,397. Starting July 1, 2014, the monthly rent increased by 3% to $14,828 per month. In addition, the Company leased office facilities located at West Hills, California and Scottsdale, Arizona from unrelated third parties at a monthly rate of $1,300 and $1,420. The West Hills lease was on a month to month basis. The Arizona lease was a non-auto renewing lease with the most current agreement covering the period from May 1, 2014 to October 31, 2014. The Arizona lease term expired on October 31, 2014. The Company terminated the West Hills and Scottsdale leases effective November 1, 2014. On December 17, 2013 the Company’s subsidiary Vaporfection International Inc. entered into a 1 year non-cancelable office lease in Deerfield Beach, Florida. The lease started on January 1, 2014 at a monthly rate of $1,981. As of December 31, 2014 this lease was terminated. The Company rents virtual offices/meeting spaces in Seattle and Illinois on a month to month basis for an aggregate of approximately $705 per month. The payment is charged to rent expense as incurred. Total rent expense under operating leases for the year ended December 31, 2014, 2013 and 2012, was $ 204,726, $139,330 and $124,727, respectively Retail/Cultivation facility leases The Company’s business model of acquiring retail dispensary and cultivation licenses has made it important to acquire real estate either through lease arrangements or through purchase agreements in order to secure a possible license. On May 8, 2014, the Company entered into a lease agreement for five years with a monthly payment of $7,400 in order to apply for a license and build-out of a location for a client. Also, on July 22, 2014 one of the Company’s subsidiaries Medbox Property Investments, Inc., entered into a new lease for a facility which will be used in the application process for both a dispensary and cultivation facility. The Company paid an initial security deposit of $30,000 and the lease is payable monthly at a rate of $20,000 per month. The lease has a five year term, but is contingent upon license approval which allows for early termination of the lease after January 1, 2015 if the license is not granted. Due to the fact that the Company was unsuccessful in obtaining the license related to the mentioned facility the lease agreement was terminated in November 2014. The following table is a summary of our material contractual lease commitments as of December 31, 2014: Year Ending Office Rent Retail/ Facility Lease 2015 $ 177,936 $ 88,800 2016 177,936 88,800 2017 88,968 88,800 2018 — 88,800 2019 — 29,600 Total $ 444,840 $ 384,800 Real Estate Commitments As part of the changes in the Company’s business model, the Company entered in various real estate purchase agreements at various times in order to allow the filing of retail dispensary or cultivation facility licenses in certain states and localities. These purchase agreements generally provide for a period of due diligence and a termination clause in the event that the Company is unable to obtain a license for its client. The agreements generally also provide for some monthly payment from escrow in order to compensate the real estate owner for the passage of time until the sale transaction is complete. Most of these payment releases from escrow are nonrefundable but applicable towards the purchase price if the Company decides to proceed with the purchase. Subject to approval of the license for a dispensary or cultivation center, the Company intends to close on the real estate where purchase agreements have been signed, or to seek partners to replace the Company on each property purchased. During the year ended December 31, 2014, the Company paid $930,000, either by deposit into fifteen escrow accounts or direct payments to sellers, to secure the purchase and/or extend the closing dates on real estate to be used for future retail/cultivation facilities with an aggregate purchase price of $26,830,000. During the same period, the Company allowed the escrows to expire on three agreements with an aggregate purchase price of $3,195,000 and forfeited $140,000 in earnest money due to unfavorable terms demanded by the sellers to extend the escrow and closing date. The Company was not successful in obtaining licenses for another ten locations with an aggregated sales price of $21,515,000 and deposits in escrow totaling $685,000. As a result all escrow accounts were closed with $235,757 forfeited and $419,167 refunded to the Company in 2014, with an additional $30,076 of escrow deposits to be refunded in January 2015. The remaining two real estate purchase agreements have closing dates of March 31, 2015. During July, 2014, one of the real estate properties on which the Company opened escrow was foreclosed upon and the agreement was canceled and the escrow in the amount of $10,000 was reimbursed to the Company on July 28, 2014. During the second quarter of 2014 one of the Company’s subsidiaries entered into a real estate purchase agreement in Washington state. The purchase transaction was closed during the third quarter for a total purchase price of $399,594 partially financed by a promissory note for $249,000. A summary of open real estate purchase transactions as of December 31, 2014 is represented in the table below: Property Purchase price Closing date Net escrow balance Date escrow opened Additional rents/fees paid to extend closing date 1 $ 820,000 03/31/2015 55,000 06/28/2014 $ 9,808 2 1,300,000 03/30/2015 50,000 10/17/2014 3 — 265,400 07/21/2014 — Escrow deposits to be refunded 30,076 Total $ 2,120,000 $ 400,476 $ 9,808 Line 3 represents the advance on July 21, 2014 of $75,000 to PVMI, a related party, as a partial payment for advances made by PVMI for escrow deposits used to secure properties for possible license acquisition in the San Diego market area and $190,400 from the assignment agreement. On October 17, 2014, the Company entered into an assignment agreement with PVMI through which PVMI assigned all rights and titles for any opened escrow on real estate purchase agreements in San Diego in exchange for a related party notes payable from the Company. As of the signing date the agreement was valued at $190,400 which represented the value of escrow deposits paid by PVMI for eight different real estate agreements. Also on the date of the assignment agreement the Company paid $50,000 into an escrow account (line item 2 from the table above) for PVMI. The escrow was related to one of the eight real estate purchase agreements that were part of the assignment. Board of Directors and Officers On October 13, 2014, Mr. Vincent Mehdizadeh resigned as an officer of the Company. Mr. Mehdizadeh continued to serve as a consultant to the Company. In his new role, Mr. Mehdizadeh provided consulting services under the title of Founder and Senior Advisor. In connection therewith, on October 13, 2014, the Company entered into a consulting agreement with Mr. Mehdizadeh, pursuant to which the Company agreed to pay Mr. Mehdizadeh a monthly fee of $25,000 for consulting services to be performed by Mr. Mehdizadeh. The monthly consulting fee was reduced to $12,500 per month if Mr. Mehdizadeh is engaged in trading any of the Company’s securities at any time within the preceding 30 day period. The consulting agreement had a two-year term., and a total of $12,375 was paid to Mr. Mehdizadeh under this agreement. Mr. Mehdizadeh’s consulting agreement was terminated on December 8, 2014. On October 16, 2014, Thomas Iwanski resigned as Chief Financial Officer, and C. Douglas (“Doug”) Mitchell was elected as Chief Financial Officer of the Company and Corporate Secretary. Mr. Iwanski agreed to serve as a consultant to the Company for a transition period. The Company agreed to pay Mr. Iwanski $10,000 for services provided during the month of October 2014 and $200 per hour for consulting services rendered after October 31, 2014. The Company also agreed to issue Mr. Iwanski 100,000 Restricted Stock Units (“RSU’s”) for his service to the Company. In connection with Mr. Doug Mitchell’s election as Chief Financial Officer, on October 16, 2014, the Company entered into an employment agreement with Mr. Mitchell (the “Employment Agreement”). Pursuant to the Employment Agreement, the Company agreed to engage Mr. Mitchell, and Mr. Mitchell agreed to serve as the Company’s Chief Financial Officer, for a two-year term, which term will automatically be extended for successive additional one-year terms, unless either party provides written notice to the other 90 days prior to the expiration of the initial term or any successive term, that the Employment Agreement will not be renewed. The Company agreed to pay Mr. Mitchell a salary of $190,000 per year and to pay Mr. Mitchell $2,500 per month for living expenses in the West Hollywood, California area. Mr. Mitchell will also be entitled to an annual bonus of up to 35% of his salary, payable of up to 50% in cash and the balance payable in equity of the Company, subject to performance criteria and objectives to be established by mutual agreement of the CEO of the Company and Mr. Mitchell within 90 days of the effective date of the Employment Agreement, and thereafter from time to time by the CEO in consultation with Mr. Mitchell. Mr. Mitchell will also be entitled to an award of restricted stock units, to be issued within 90 days of the effective date of the Employment Agreement, under the Company’s Equity Incentive Plan, in the amount of 7,500 shares of common stock each calendar quarter Mr. Mitchell serves as Chief Financial Officer of the Company. The Company may terminate the Employment Agreement with or without Cause (as defined in the Employment Agreement) upon written notice to Mr. Mitchell. In the event the Company terminates the Employment Agreement without Cause, Mr. Mitchell terminates the Employment Agreement with Good Reason (as defined in the Employment Agreement), or the Employment Agreement is not renewed as a result of notice to Mr. Mitchell provided 90 days prior to expiration of the initial or a renewal term, Mr. Mitchell will be entitled to payment of one-half his annual salary. Termination by the Company within 365 days of a Change of Control (as defined in the Employment Agreement) in the absence of Cause will conclusively be deemed a termination by the Company without Cause. On October 22, 2014, Jennifer S. Love was elected to the board of directors of the Company. Ms. Love was also elected to serve as Chairperson of the Audit Committee. Jennifer Love was granted 19,452 RSU’s for 2014. Her contract calls for grants of 100,000 RSU’s for each succeeding year of service beginning on April 1, 2015. Contingencies – SEC investigation In October 2014 the Board of Directors of the Company appointed a special board committee (the “Special Committee”) to investigate a federal grand jury subpoena pertaining to the Company’s financial reporting which was served upon the Company’s then independent public accounting firm, as well as certain alleged wrongdoing raised by a former employee of the Company. Thereafter the Company was served with two subpoenas from the Securities and Exchange Commission in early November 2014. In connection with its investigation of these matters, the Special Committee in conjunction with the Audit Committee initiated an internal review by management and by an outside professional advisor of certain prior period financial reporting of the Company. As a result of this review, the Company determined there were errors in properly recording the revenue on certain customer contracts, capital contributions from related parties and improper capitalization of inventory costs. As a result, the Company restated the Company’s consolidated financial statements for the years ended December 31, 2012 and 2013 reported in the Company’s General Form of Registration of Securities on Form 10/A and the condensed consolidated financial statements as of and for the quarterly periods ended March 31, June 30, and September 30, 2014 and 2013. The SEC is trying to determine whether there have been any violations of the Federal Securities Laws. It said further that the fact of the investigation does not mean that it has concluded that the Company or anyone else has broken the law or that it has a negative opinion of any person, entity or security. The Company is cooperating with the SEC in the investigation. Registration Statement The registration rights agreement entered into in connection with the July and September 2014 purchase agreements required the Company to have a Form S-1 declared effective on or before November 18, 2014. Due to the restatement discussed above, the registration statement has been delayed. As a result of the withdraw of the Form S-1, in January 2015 the Company agreed with the lenders to adjust the conversion rate for the amortization payments and reduced the volume weighted average price for 20 days prior to the issuance to 51%. See Note 20 Subsequent Events for purchase agreement modifications finalized in January 2015. Litigation On May 22, 2013, Medbox initiated litigation in the United States District Court in the District of Arizona against three shareholders of MedVend Holdings LLC (“Medvend”) in connection with a contemplated transaction pursuant to which Medbox entered into for the purchase of an approximate 50% ownership stake in MedVend for $4,100,000. The Company paid an advance of $300,000 upon execution of the contract, and another $300,000 was disbursed as an additional investment to MedVend. The lawsuit alleges fraud and related claims arising out of the contemplated transaction during the quarter ended March 31, 2013. The litigation is pending and Medbox has sought cancellation of the agreement due to a fraudulent sale of the stock because the selling shareholders lacked power or authority to sell their ownership stake in MedVend, and their actions were a breach of representations made by them in the agreement. On November 19, 2013 the litigation was transferred to United States District Court for the Eastern District of Michigan. MedVend recently joined the suit pursuant to a consolidation order executed by a new judge assigned to the matter. In the litigation, the selling shareholder defendants seek alternatively to have the transaction performed, or to have it unwound and seek damages. Medbox has denied liability with respect to any and all such counterclaims. A new litigation schedule was recently issued setting trial for September 2015. On June 5, 2014, the Company entered into a purchase and sale agreement (the “Medvend PSA”) with PVM International, Inc. (“PVMI”) concerning this matter. Pursuant to the Medvend PSA, the Company assigned to PVMI the Company’s rights and claims attributable to or controlled by the Company against those three certain selling stockholders of Medvend, known as Kaplan, Tartaglia and Kovan, (the “Medvend Rights and Claims”) in exchange for the return by PVMI to the Company of 30,000 shares of the Company’s common stock. PVMI is owned by Vincent Mehdizadeh, the Company’s largest stockholder. The Company will have the right, under the Medvend PSA, to purchase from PVMI, at any time, the Medvend Rights and Claims, for the consideration provided by PVMI, plus the sum of any of PVMI’s reasonable expenditures incurred in pursuit of the Medvend Rights and Claims. The Court has not yet ruled on the substitution of PVMI as plaintiff in this matter. If necessary, the Company plans to vigorously defend against this matter. The case is in the discovery stage, and, at this time, the Company cannot determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can they reasonably estimate a range of potential loss, should the outcome be unfavorable. In January 2015, three separate class action suits were been filed against the Company, certain past and present members of management, and the Company’s Board of Directors. These suits allege that the Company violated federal securities laws by allegedly making materially false and misleading statements regarding the Company’s financial results. The Company has only been served with a complaint on one of these cases, Crystal v. Medbox, Inc., Mehdizadeh, Bedrick, Iwanski, Marasala, and Mitchell. On February 12, 2015, the Court issued an Order Extending Time to Respond to Complaint until such time “any related actions are consolidated, a lead plaintiff and lead counsel are appointed by the Court, the lead plaintiff serves an operative complaint,” and certain other events. The Company intends to vigorously defend itself against these suits. Due to the early stages of the suits, the Company is unable to determine whether the likelihood of an unfavorable outcome of these suits is probable or remote, nor can it reasonably estimate a range of potential loss, including coverage by the Company’s insurance carrier, should the outcome be unfavorable. On February 20, 2015, a derivative claim was filed, entitled Glitner v. Medbox, wherein the Company was named as both a nominal plaintiff and a defendant and all members of the Company’s Board of Directors were named as individual defendants. The lawsuit seeks damages for breach of fiduciary duties and abuse of control. The Company intends to vigorously defend itself against these suits. Due to the early stages of the suits, the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable. The Company has accrued an additional $500,000 in legal fees to represent amounts they are expecting to pay in excess of the defense costs paid by their insurance Company. The Company also is the plaintiff in a legal action with a customer to collect past due balances in the amount of approximately $550,000 from the customer. The customer filed a cross complaint for breach of contract and breach of implied covenant of good faith and fair dealing in which the customer claims damages of not less than $500,000. The Company does not believe the cross complaint is meritorious and intends to continue to pursue the amounts due from the customer, and to vigorously defend itself against the claim. At this time, the Company is unable to determine whether the likelihood of an unfavorable outcome of the dispute is probable or remote, nor can it reasonably estimate a range of potential loss, should the outcome be unfavorable.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 – SUBSEQUENT EVENTS Share purchase and transfer On March 5, 2015, Mr. Mehdizadeh announced that an agreement has been executed with Lizada Capital LLC, an investor in the field of legal cannabis products, that would result in the transfer of the majority of Mr. Mehdizadeh’s shares of the Company to that firm. As of September 30, 2015, the prospective buyer has cancelled this agreement. October 2015 Debentures On October 14, 2015, the Company issued seven debentures in the aggregate of $2,000,000 to a service provider (the “October 2015 Investor”) as consideration for services previously rendered to the Company on the same terms as the August 14 Debentures and August 14 Purchase Agreement (the “October 2015 Debentures” and “October 2015 Purchase Agreement”, respectively) except that the October 2015 Purchase Agreement does not provide for registration rights to the October 2015 Investor with regard to the shares underlying the October 2015 Debentures. The service provider has agreed with the Company not to convert the October 2015 Debentures for any amount in excess of fees payable for services previously rendered to the Company at the time of conversion. To the extent that the sale of shares underlying the October 2015 Debentures do not satisfy outstanding amounts payable to the service provider, such amounts will remain payable to the service provider by the Company. Lease On October 14, 2015, one of the Company’s subsidiaries entered into a lease regarding a property in Washington state (Note 9). The lease has a five year term, with monthly lease payments of $2,500. The property had been classified as Asset held for resale during previous periods, but as management’s plans regarding the property have changed, as evidenced by the subsequent period lease, it was reclassified as Property and equipment as of September 30, 2015. Settlements As disclosed in Note 9, class actions and derivative lawsuits were filed against and purportedly on behalf of the Company captioned (1) Josh Crystal v. Medbox, Inc., et al. , Matthew Donnino v. Medbox, Inc., et al. , Ervin Gutierrez v. Medbox, Inc., et al., Mike Jones v. Guy Marsala, et al. , Jennifer Scheffer v. P. Vincent Mehdizadeh, et al. , Kimberly Y. Freeman v. Pejman Vincent Mehdizadeh, et al., Tyler Gray v. Pejman Vincent Mehdizadeh, et al. , Robert J. Calabrese v. Ned L. Siegel, et al. , Patricia des Groseilliers v. Pejman Vincent Mehdizadeh, et al. , Michael A. Glinter v. Pejman Vincent Mehdizadeh, et al. , On October 16, 2015, solely to avoid the costs, risks, and uncertainties inherent in litigation, the parties to the class actions and derivative lawsuits entered into settlements, that collectively effect a global settlement of all claims asserted in the class actions and the derivative actions. The global settlement provides, among other things, for the release and dismissal of all asserted claims. The global settlement is contingent on final court approval, respectively, of the settlements of the class actions and derivative actions. As a result of amounts already reflected in the Company’s financial statements, and the coverage by the Company’s insurance carrier, the final terms of the settlements are not expected to have a material adverse effect on the Company’s financial position or results of operations. Board of Directors appointment On October 15, 2015, Jeff Goh, 51, President and Interim Chief Executive Officer of the Company was elected to the board of directors of the Company. The Farm Operating Agreement On November 4, 2015, the Company signed an operating agreement with an independent contractor to perform cultivating services at the Farm. The independent operator will receive 10% of the profits of the Farm, after deduction of direct expenses. The term of the agreement is five years from the date of the agreement, with the parties permitted to extend the term through mutual agreement by successive two year terms. New Litigation On October 27, 2015, Richard Merritts, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the Superior Court of the State of California for the County of Los Angeles against the Board and certain executive officers (Guy Marsala, J. Mitchell Lowe, Ned Siegel, Jennifer S. Love, C. Douglas Mitchell, Pejman Vincent Mehdizadeh, Matthew Feinstein, Bruce Bedrick, Jeff Goh, and Thomas Iwanski). The suit alleges breach of fiduciary duties by the defendants. Relief is sought awarding damages resulting from breach of fiduciary duty and to direct the Company and the defendants to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. Merritts’ lawsuit has not been served.	NOTE 20 – SUBSEQUENT EVENTS Litigation On or about January 9, 2015, PVM International, Inc., Vincent Chase, Inc., and Vincent Mehdizadeh, in his individual capacity, (collectively the “VM Parties”) jointly executed that certain “Action by Written Consent of the Stockholders of Medbox, Inc.” (the “Written Consent”) seeking to appoint four successor directors the Company’s board of directors (the “Board”) as of January 29, 2015. On January 16, 2015, the Company filed a complaint in Los Angeles Superior Court disputing the legal effectiveness of the Written Consent (the “Complaint”). On January 21, 2015, the Company, P. Vincent Mehdizadeh, PVM International, Inc., (“PVM”), and Vincent Chase, Incorporated, (“VC”) entered into an agreement pursuant to which (1) the VM Parties acknowledged that the Written Consent was cancelled and withdrawn, (2) the parties agreed to enter into a Voting Agreement to vote in favor of and to not remove directors Ned L. Siegel (“Siegel”), Mitch Lowe (“Lowe”), Jennifer Love (“Love”) and Guy Marsala (“Marsala”) for a period of 12 months (the “Voting Agreement”), (3) the Company would dismiss the Complaint with prejudice, (4) the Board would meet with Mr. Mehdizadeh on specified dates during the term of the agreement to discuss and to hear matters of interest or concern of Mr. Mehdizadeh, as a stockholder of the Company (the “Agreement”). Each of the directors of the Company are also parties to the Voting Agreement. Pursuant to the terms of the Agreement, the VM Parties may on or before January 25, 2015, present a term sheet to the Company from an accredited investor to invest in not less than $1,000,000 in restricted common stock of the Company on terms as reasonably agreed to by the Board (the “Private Placement”). In addition, either as part of the closing of the Private Placement or otherwise at the request of Mr. Mehdizadeh, Mr. Mehdizadeh shall have the right to appoint a person nominated by Mr. Mehdizadeh with industry experience and reasonably acceptable to the Board as the fifth director of the Company. Amendment and Modification of the July 2014 Financing On July 21, 2014, Medbox, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with accredited investors (the “Investors”) pursuant to which the Company agreed to sell, and the Investors agreed to purchase, convertible debentures (the “Debentures”) in the aggregate principal amount of $3,000,000, in three tranches, each in the amount of $1,000,000. The initial closing under the Purchase Agreement, for Debentures in the aggregate principal amount of $1,000,000 occurred on July 21, 2014. See the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on July 25, 2014. The Investors subscribed for an additional $1,000,000 on August 25, 2014, an additional $500,000 on September 24, 2014, and an additional $250,000 on November 24, 2014 (collectively, with the July 21 Debenture, the “Original Debentures”). On January 30, 2015, the Company and the Investors entered into an Amendment, Modification and Supplement to the Purchase Agreement (the “Purchase Agreement Amendment”) pursuant to which the Investors will purchase an additional $1,800,000 in seven Modified Closings: (1) $200,000 was funded at the Closing of the Purchase Agreement Amendment; (2) $100,000 will be funded within thirty (30) days of the Closing; (3) $100,000 will be funded within two days following the filing of a registration statement with the SEC to register the shares underlying the Debentures (the “Registration Statement”) and of the Company having filed with the SEC a restatement of the Company’s consolidated financial statements as described in the Company’s Current Report on Form 8-K filed with the SEC on December 22, 2014; (4) $100,000 will be funded within two days of receipt of the first comment letter from the SEC with regard to the Registration Statement; (5) $500,000 will be funded within two days of the date that the Registration Statement is declared effective by the SEC; (6) $500,000 will be funded within five days of the date that the Registration Statement is declared effective by the SEC; and (7) $100,000 will be funded within each of 90, 120, 150, and 180 days from the Closing of the Purchase Agreement Amendment. The Parties entered into a Modified Debenture Agreement for the $200,000 that was funded at the Closing and agreed to use the same form of Modified Debenture for each of the other foregoing Modified Closings (collectively, the “Modified Debentures”). The parties also entered into a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price (the “Reference Price”) equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, at an exercise price equal to the Reference Price, with a three year term. The Company also entered into a Debenture Amendment Agreement and an Amended and Restated Debenture for the amount outstanding under the original Debenture, (1) reflecting the terms set forth above, (2) providing for accrued and unpaid interest to be payable upon conversion or maturity rather than on specified payment dates and (3) amending the conversion price of the Debenture to be equal to the lower of $5.00 or 51% of the lowest volume weighted average price for the 20 consecutive trading days prior to the applicable conversion date. In connection with the Purchase Agreement Amendment, the Company is also required to open a new dispensary in Portland, Oregon during the first calendar quarter of 2015, as a condition to closing the fourth, fifth and sixth Modified Closings set forth above. With respect to each of the Modified Closings, the Company will pay a fee to the Investors in the amount equal to 5% of the Subscription Amount of the applicable Modified Closing. The Company must also file the Registration Statement by April 30, 2015 (as amended), and it must be declared effective by June 15, 2015 in order to avoid default and acceleration under the Amended and Restated Debenture. On March 13, 2015 the Company and the Investors entered into a further amendment (“March 2015 Amendment”) to the July 21, 2014, 10% Convertible debentures, as amended January 30, 2015, whereby the fixed conversion rate was lowered to $1.83, and the anti-dilution reset provision on all previous debentures was triggered. In addition, the March 2015 Amendment modified the filling date requirement for the Registration Statement to be April 30, 2015. Amendment and Modification of September 2014 Financing On September 19, 2014, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”) pursuant to which the Company agreed to sell, and the Investor agreed to purchase, convertible debentures (the “Debentures”) in the aggregate principal amount of $2,500,000, in two tranches, the first in the amount of $1,000,000, and the second in the amount of $1,500,000. The initial closing under the Purchase Agreement, for a Debenture in the principal amount of $1,000,000, occurred on September 19, 2014. See the Company’s Current Report on Form 8-K filed with the SEC on September 24, 2014. On January 28, 2015, the Company and the Investors entered into an Amendment, Modification and Supplement to the September 19, 2014 Purchase Agreement (Note (the “Purchase Agreement Amendment”) pursuant to which the remaining $1,500,000 will be funded in four Modified Closings: (1) $100,000 was funded at the Closing of the Purchase Agreement Amendment; (2) $100,000 will be funded within two days following the filing of a registration statement with the SEC to register the shares underlying the Debentures (the “Registration Statement”) and of the Company having filed with the SEC a restatement of the Company’s consolidated financial statements as described in the Company’s Current Report on Form 8-K filed with the SEC on December 22, 2014; (3) $100,000 will be funded within two days of receipt of the first comment letter from the SEC with regard to the Registration Statement; and (4) $1,200,000 will be funded within two days of the date that the Registration Statement is declared effective by the SEC. The Parties entered into a Modified Debenture Agreement for the $100,000 that was funded at the Closing and agreed to use the same form of Modified Debenture for each of the other foregoing Modified Closings (collectively, the “Modified Debentures”). The parties also entered into a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price (the “Reference Price”) equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, at an exercise price equal to the Reference Price, with a three year term. The Company also entered into a Debenture Amendment Agreement and an Amended and Restated Debenture for the amount outstanding under the original Debenture, (1) reflecting the terms set forth above, (2) providing for accrued and unpaid interest to be payable upon conversion or maturity rather than on specified payment dates and (3) amending the conversion price of the Debenture to be equal to the lower of $5.00 or 51% of the lowest volume weighted average price for the 20 consecutive trading days prior to the applicable conversion date. In connection with the Purchase Agreement Amendment, the Company is also required to open a new dispensary in Portland, Oregon during the first calendar quarter of 2015, as a condition to closing the second, third and fourth Modified Closings set forth above. With respect to each of the Modified Closings, the Company will pay a fee to the Investors in the amount equal to 5% of the Subscription Amount of the applicable Modified Closing. The Company must also file the Registration Statement by April 30, 2015 (as amended), and it must be declared effective by June 15, 2015 in order to avoid default and acceleration under the Amended and Restated Debenture. In connection with the Closing of the Purchase Agreement Amendments for the July 2014 Financing and the September 2014 Financing, Mr. Ned L. Siegel, the chairman of the Company’s Board, entered into two separate subordinated convertible promissory notes with the Company on January 5, 2015 and January 30, 2015, respectively, each in the principal amount of $50,000 and having a three year term and an interest rate of 8% per annum (the “Siegel Notes”). In addition, Mr. Mitchell Lowe, a member of the Board, entered into one subordinated convertible promissory note with the Company on February 2, 2015 in the principal amount of $50,000 and having a three year term and an interest rate of 8% per annum (the “Lowe Note”). Mr. Siegel and Mr. Lowe are entitled to receive a warrant, exercisable for a period of five (5) years from the date of grant, to purchase an amount of Company Common Stock equal to 50% of the principal sum under each of the Siegel Notes and the Lowe Note, respectively, at an exercise price equal to 200% of the applicable Conversion Price (the “Warrants”). The Conversion Price of the Warrants is either (i) 85% of the volume-weighted average price of the Common Stock for the thirty trading days prior to notice of Conversion or (ii) 85% of the per share price of the Company’s next common stock offering of not less than $2 million. Mr. Siegel and Mr. Lowe also received registration rights for the shares underlying the Siegel Notes and the Lowe Notes, respectively. Notes payable During February 2015 the Company entered into a modified loan agreement with the holder of a $249,000 note payable when they were unable to repay the note on its maturity date. Under the revised loan agreement, the Company agreed with the lender to an extension of the maturity date to July 1, 2015, and increased the interest rate to 18% plus a late charge in the amount of 5% of the principal balance of the note. Shares issued On January 15, 2015 the Company issued 206,480 shares to satisfy the conversion of remaining warrants related to the settlement with various previous owners of Vapor Systems International, LLC. Share purchase and transfer On March 5, 2015 Mr. Mehdizadeh announced that an agreement has been executed with Lizada Capital LLC, an investor in the field of legal cannabis products, that would result in the transfer of the majority of Mr. Mehdizadeh’s shares of the Company to that firm. Under the agreement, Lizada would purchase 22,160,000 shares, representing 2,000,000 preferred shares and 12,160,000 common shares of Medbox for consideration of approximately $15 million. A total of $5 million of the funds have been designated for purchase of restricted shares of the Company’s common stock, directly from the Company, at $2 per share in the name of Mr. Mehdizadeh’s holding company, PVM International, Inc. The transaction has 6 separate closings over the course of 18 months, with each of the first five closings being in the amount of $2 million dollars to be paid to Mehdizadeh’s holding company and Medbox equally, or $1 million to each party, to satisfy the $5 million dollar direct investment component of the transaction. The 6th and final closing has a performance contingency and is in the amount of $5 million dollars paid directly to Mehdizadeh’s holding company. A representative of Lizada will join Medbox’s Board of Directors within the next 90 days, after the first closing is set to occur.

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Medbox, Inc. and its wholly owned subsidiaries: • Prescription Vending Machines, Inc., a California corporation, d/b/a Medicine Dispensing Systems in the State of California (“MDS”), which distributes our Medbox™ product and provides related consulting services described further below. • Vaporfection International, Inc., a Florida corporation through which we distribute our medical vaporizing products and accessories. • Medbox Property Investments, Inc., a California corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers. • MJ Property Investments, Inc., a Washington corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers in the state of Washington. • Medbox Management Services, Inc., a California corporation specializing in providing management oversight and compliance services to state-licensed dispensaries for cultivation, dispensing, and marijuana infused products (MIPS). • EWSD I, LLC, an Arizona corporation that owns property in Colorado. All intercompany transactions, amounts and balances have been eliminated.	Principles of Consolidation The consolidated financial statements include the accounts of Medbox, Inc. and its wholly owned subsidiaries, as named in Note 1 above. All intercompany transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the condensed consolidated financial statements as well as the reported expenses during the reporting periods. The Company’s significant estimates and assumptions include the valuation of the Company’s common stock used in the valuation of goodwill, accounts receivable and note receivable collectability, inventory, advances on investments, the valuation of restricted stock and warrants received from customers, the amortization and recoverability of capitalized patent costs and useful lives of long-lived assets, the derivative liability, and income tax expense. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from these estimates.	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the consolidated financial statements as well as the reported expenses during the reporting periods. The Company’s significant estimates and assumptions include the valuation of the Company’s common stock used in the valuation of goodwill, accounts receivable and note receivable collectability, inventory, advances on investments, the valuation of restricted stock and warrants received from customers, the amortization and recoverability of capitalized patent costs and useful lives of long-lived assets the derivative liability, and income tax expense. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from these estimates.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company maintains cash balances at several financial institutions in California, Illinois, and Florida. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. At September 30, 2015 and December 31, 2014, the Company’s uninsured balances totaled $22,504 and $0, respectively. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.	Concentrations of Credit Risk The Company maintains cash balances at several financial institutions in the Portland, Oregon, Los Angeles, California area and Florida. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible. Three customers, one of which is a related party through the entity’s stock ownership in the Company (customer C) represented 72.1% of the total revenue of $629,132 for the year ended December 31, 2014. Customer December 31, 2014 January -December 2014 December 31, 2013 January -December 2013 Accounts Receivable Revenue Accounts Receivable Revenue Amount, $ % Amount, $ % Amount, $ % Amount, $ % A $ — — % $ 203,165 32.3 % $ 150,000 44.20 % $ 325,000 15.8 % B — — 175,000 27.8 115,200 33.9 — — C — — 75,301 12.0 — — — — Subtotal — 0.0 453,466 72.1 265,200 78.1 $ 325,000 15.8 % Total $ 8,774 100 % $ 629,132 100.00 % $ 339,735 100 % $ 2,062,083 100.00 %
Advertising and Marketing Costs	Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred. The Company incurred advertising and marketing costs of approximately $0 and $319,000 for the three months ended September 30, 2015 and 2014, respectively and approximately $0 and $749,000 for the nine months ended September 30, 2015 and 2014, respectively.	Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred. The Company incurred advertising and marketing costs of $933,627, $644,383 and $806,221 for the years ended December 31, 2014, 2013 and 2012, respectively.
Research and Development		Research and Development Research and development expenses are charged to operations as incurred. The Company incurred research and development costs of $242,232, $74,861 and $176,964 for the years ended December 31, 2014 2013 and 2012, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Pursuant to ASC No. 825, Financial Instruments Warrants and other financial assets received as a payment for the services provided are recorded as “Marketable securities” under the current assets if they are expected to be realized within 12 months. The Company uses the Black-Scholes model to measure the value of the warrants. At each reporting date the Company will reevaluate the value of marketable securities and record any changes in value to other comprehensive income (loss) under “Unrealized gain or losses from marketable securities”. Embedded derivative – The Company’s convertible notes payable include embedded features that require bifurcation and are accounted for as a separate embedded derivative (see Note 5). The Company has estimated the fair market value of the embedded derivative of the Notes based on a weighted probability model. The key valuation assumptions used consist of the price of the Company’s stock, a risk free interest rate based on the average yield of a one year Treasury note and expected volatility of the Company’s common stock all as of the measurement dates, and various estimated reset exercise prices allocated by probability. The Company considers these inputs Level 3 assumptions. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the liabilities that are measured at fair value on a recurring basis. Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) September 30, 2015 Marketable securities $ 94,817 $ 21,650 $ — $ 73,167 Derivative liability 4,885,286 — — 4,885,286 Total $ 4,980,103 $ 21,650 $ — $ 4,958,453 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the nine months ended September 30, 2015 Total Balance at January 1, 2015 $ 3,691,853 Additions 5,531,201 Reclassified to equity upon conversion (3,828,711 ) Change in fair value of conversion feature (509,057 ) Ending balance $ 4,885,286	Fair Value of Financial Instruments Pursuant to ASC No. 825, Financial Instruments Warrants and other financial assets received as a payment for the services provided are recorded as “Marketable securities” under the current assets if they are expected to be realized within 12 months. The Company uses the Black-Scholes model to measure the value of the warrants. At each reporting date the Company will reevaluate the value of marketable securities and record any changes in value to other comprehensive income (loss) under “Unrealized gain or losses from marketable securities”. Unrealized gain or loss from marketable securities occurs in the process of the reevaluation of the warrants or other financial assets after their initial recognition valuation. At each reporting date the Company reevaluates the value of marketable securities and reflects the change in the statement of changes in equity under other comprehensive income (loss). Embedded derivative – The Company’s convertible notes payable include embedded features that require bifurcation due to a reset provision and are accounted for as a separate embedded derivative (see Note 13). The Company has estimated the fair market value of the embedded derivative of the Notes based on a weighted probability model. The key valuation assumptions used consist of the price of the Company’s stock, a risk free interest rate based on the average yield of a one year Treasury note and expected volatility of the Company’s common stock all as of the measurement dates, and various estimated reset exercise prices allocated by probability. The Company considers these inputs Level 3 assumptions, based on the application of the estimated probability rate being considered an unobservable input. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring basis. Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2014 Marketable securities $ 94,776 $ $ $ 94,776 Derivative liability 3,691,853 — — 3,691,853 Total $ 3,786,629 $ $ — $ 3,786,629 Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2013 Marketable securities $ 184,800 $ 184,800 $ — $ — Total $ 184,800 $ 184,800 $ — $ — The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the year ended December 31, 2014 Total Beginning balance $ — Initial recognition of conversion feature 1,885,863 Change in fair value of conversion feature 1,805,990 Ending balance $ 3,691,853
Revenue Recognition	Revenue Recognition We enter into transactions with clients who require our expertise and are interested in being granted the right to have us engage exclusively with them in certain territories (which we describe as territory rights) to obtain the necessary licenses to operate a dispensary or cultivation center for the location, and to consult in daily operations of the dispensary or cultivation center. Terms for each deal are varied and the sales arrangements typically include the delivery of our dispensing technology and dispensary location build-out and/or consultation on the location, licensing, build out and operation of a cultivation center. Medbox machines retail for approximately $50,000 for each machine set (including the POS system), and normally our contracts include the sale of the dispensary units within the scope of options to be provided that might also include location build out costs. Currently, our standard contracts have a five year term, call for an upfront, non-refundable consulting fee, and contain options including acquiring a Medbox dispensary machine and having the Company perform the buildouts for the location, at set prices. The Company has determined these optional purchases each constitute a separate purchasing decision, and therefore are considered a separate arrangement for revenue recognition purposes. Revenue on each of these options are evaluated for recognition when and if the customer decides to enter into the arrangement. Based on these contracts, and other auxiliary agreements, our current revenue model consists of the following income streams: Consulting fee revenues and build-outs Consulting fee revenues is a consistent component of our current and anticipated future revenues and is negotiated at the time we enter into a contract. Consulting revenue consists of providing ongoing consulting services over the life of the contract, to the established business in the areas of regulatory compliance, security, operations and other matters to operate the dispensary. The majority of the consulting fees arise from the upfront, non-refundable consulting fee in our standard contract, and is recognized using the straight line method over the life of the contract. Consulting fee revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonably assured. Revenue for the build-outs of the dispensary or cultivation center, if the customer chooses to have it performed by the Company, is recognized after issuance of a certificate of occupancy for the newly completed facility. This consists of a complete interior build-out of the retail store front including necessary construction (not to include installation of plumbing, electrical, HVAC systems and masonry), furniture fixtures and security system. Due to the uncertainties inherent in the emerging industry, the Company deferred recognition of revenue for sale of completed dispensaries with licenses until the issuance of a certificate of occupancy by the municipality. The certificate of occupancy is the final approval to open a dispensary in the customer’s community, at which time all criteria for revenue recognition, including delivery and acceptance, has been met. Additionally, at the time of the issuance of the certificate of occupancy, under the contract terms, all payments owed by the customer have been received by the Company. Similarly, recognition of revenue for sale of completed cultivation center is deferred until all licensing and permitting is completed and approved. Unbilled costs and associated fees related to the build-outs are recorded in inventory and are subject to valuation testing at each quarter end for net realizable value (lower of cost or market) and collectability. Other revenue includes sales of territory, location, and management rights The Company at times enters into specific contracts to assign exclusive location and management rights, for a dispensary, that the Company has been granted through a license approved by local authorities. These rights are transferred under a management rights agreement to an operator for retail, dispensary, or cultivation centers. The Company also has one agreement with a related party in which they granted the related party the exclusive rights to a certain territory. Other revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonably assured. In the sale of the territory rights to the related party, the revenue is being recognized over the term of the agreement. Revenues on VII product sales. Revenue from referral fees.	Revenue Recognition Our current revenue model consists of the following income streams: Consulting fee revenues. Consulting fee revenues. This revenue stream is a consistent component of our current and anticipated future revenues and is negotiated at the time we enter into a contract. In jurisdictions where there is intense competition for a limited number of dispensing or cultivating licenses, we believe the Medbox model, with its incorporated security measures, promotes a distinct advantage in the application selection process for such licenses, especially in the states where an applicant is graded on the ability to demonstrate compliance with applicable law. Consulting fee revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. Revenues on dispensary unit and vaporizer sales Revenue on dispensary unit sales is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. The contract terms are broken down in specific milestones with specific attributable revenue to be earned upon successful completion of the milestone terms. (i.e. if a milestone is completing construction on a client dispensary, the condition for the revenue to be recorded is after issuance of a certificate of occupancy for the newly completed facility. The Company will record a specified amount of revenue attributable to this milestone based on the contract). Equipment sales not associated with a consulting contract are recognized as the product is shipped and title passes. Vaporizer sales are recognized as the product is shipped. Other revenue includes sales of territory rights, sales/leases of management rights of newly awarded dispensary licenses, and sales/leases of management rights of newly acquired dispensary licenses and physical locations. Other revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. The contract terms are broken down in specific milestones with specific attributable revenue to be earned upon successful completion of the milestone terms. (i.e. if a milestone is completing construction on a client dispensary, the condition for the revenue to be recorded is after issuance of a certificate of occupancy for the newly completed facility. The Company will record a specified amount of revenue attributable to this milestone based on the contract. Advance payments from clients in advance of work performed are recorded as customer deposits on the balance sheet. Revenue from referral fees and revenue sharing from real estate transactions with partners. Referral fee and revenue sharing revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. If all required deliverables are complete, the referral fee will be recognized when the customer closes on the subject transaction. Revenue from providing monthly compliance and accountability support to dispensary operators. Monthly compliance and accountability support revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonable assured. Revenue is recognized monthly as the services are delivered to clients.
Cost of Revenue	Cost of Revenue Cost of revenue consists primarily of expenses associated with the delivery and distribution of our products and services. These include expenses related to the manufacture of our dispensary units, construction expense related to the customer dispensary, site selection and establishment of licensing requirements, and consulting expense for the continued management of the dispensary unit build out, server and security equipment, rent expense, energy and bandwidth costs, and support and maintenance costs prior to when the client moves in. We only begin capitalizing costs when we have obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses then the excess cost above net realizable value is written off to cost of revenues. In addition, cost of revenue related to our vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfilment, shipping, inventory storage and inventory management costs.	Cost of Revenue Cost of revenue consists primarily of expenses associated with the delivery and distribution of our products and services. These include expenses related to the manufacture of our dispensary units, construction expense related to the customer dispensary, site selection and establishment of licensing requirements, and consulting expense for the continued management of the dispensary unit build out, server and security equipment, rent expense, energy and bandwidth costs, and support and maintenance costs prior to when the client moves in. We only begin capitalizing costs when we have obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses then the excess cost above net realizable value is written off to cost of revenues. In addition, cost of revenue related to our vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfilment, shipping, inventory storage and inventory management costs.
Inventory	Inventory Inventory is stated at the lower of cost or market value. Cost is determined on a cost basis that approximates the first-in, first-out (FIFO) method. Work in process and related capitalized costs includes costs to build out a dispensary in Portland Oregon that opened in the second quarter of 2015. Costs include tenant improvements to the facility, furniture, fixtures and Medbox dispensary units to be used by the licensed operator. The costs related to the Portland dispensary have been classified in deferred costs until the related revenue is recognized.	Inventory Inventory is stated at the lower of cost or market value. Cost is determined on a cost basis that approximates the first-in, first-out (FIFO) method. Work in process and related capitalized costs includes costs to build out a dispensary in Portland Oregon that is expected to open in the second quarter of 2015. Costs include tenant improvements to the facility, furniture, fixtures and Medbox dispensary units to be used by the licensed operator. It is anticipated this dispensary will be operated by a Medbox licensed operator and revenue and related cost of revenue will be recorded in the statement of operations in the second quarter of 2015.
Basic and Diluted Net Loss Per Share	Basic and Fully Diluted Net Income/Loss Per Share Basic net income/loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share includes the effects of any outstanding options, warrants and other potentially dilutive securities. The Company did not consider any potential common shares in the computation of diluted loss per share for the three and nine months ending September 30, 2015 and 2014, due to the net loss, as they would have an anti-dilutive effect on EPS. As of September 30, 2014, the Company had 3,000,000 shares of Series A preferred stock outstanding with par value of $0.001 that could have been converted into 15,000,000 shares of the Company’s common stock. On August 24, 2015, 2 million shares of Series A preferred stock was cancelled, leaving 1 million shares outstanding at September 30, 2015 . Additionally the Company has approximately 14,084,000 warrants to purchase common stock outstanding as of September 30, 2015. The Company also has approximately $4,994,000 in convertible debentures outstanding at September 30, 2015, whose underlying shares were not included that are convertible at the holders’ option at a conversion price of the lower of $0.75 or 51% of the VWAP over the last 40 days prior to conversion (subject to reset upon a future dilutive financing).	Basic and Diluted Net Loss Per Share Basic net income/loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share include the effects of any outstanding options, warrants and other potentially dilutive securities. The Company did not consider any potential common shares in the computation of diluted loss per share for the periods ending December 31, 2014, 2013 and 2012, due to the net loss, as they would have an anti-dilutive effect on EPS. As of December 31, 2014 and 2013, the Company has 3,000,000 shares of Series A preferred stock outstanding with par value of $0.001 that could be converted into 15,000,000 shares of the Company’s common stock. As of December 31, 2012 there were 6,000,000 shares of Series A preferred stock outstanding, which could be converted into 30,000,000 shares. Additionally the Company has 206,480 warrants to purchase common stock outstanding as of December 31, 2014. The Company also has $3,750,000 in convertible debentures outstanding at December 31, 2014, whose underlying shares were not included as they are convertible at the holders’ option at an initial fixed conversion price of $11.75.
Accounts Receivable and Allowance for Bad Debts		Accounts Receivable and Allowance for Bad Debts The Company is subject to credit risk as it extends credit to our customers for work performed as specified in individual contracts. The Company extends credit to its customers, mostly on an unsecured basis after performing certain credit analysis. Our typical terms require the customer to pay a portion of the contract price up front and the rest upon certain agreed milestones. The Company’s management periodically reviews the creditworthiness of its customers and provides for probable uncollectible amounts through a charge to operations and a credit to an allowance for doubtful accounts based on our assessment of the current status of individual accounts. Accounts still outstanding after the Company has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts. As of December 31, 2014 and December 31, 2013, the Company’s management considered all accounts outstanding fully collectible.
Property and Equipment		Property and Equipment Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses accelerated depreciation methods for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows: Vehicles 5 years Furniture and Fixtures 5 years Office equipment 3 years
Assets Held for Resale		Assets Held for Resale During 2014, the Company has entered into various real estate purchase agreements to support the filing of retail dispensary or cultivation facility licenses in certain states and localities. The cost of the acquired real estate is included in Assets Held for Resale on the consolidated balance sheet. The Company intends to sell the real estate to a long term investor after the license is granted. The Company does not depreciate assets held for resale.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC No. 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorizes. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes. An IRS audit is still open on the year ended December 31, 2011, in which the Company received a notice of deficiency for the amount of approximately $60,000. The Company is in discussions with the IRS to set up a payment plan for the amount owed.	Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorizes. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes.
Commitments and Contingencies	Commitments and Contingencies Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.	Commitments and Contingencies Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. The Company accrues all legal costs expected to be incurred per event, up to the amount of their deductible.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entities Ability to Continue as a Going Concern In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for annual reporting periods for public business entities beginning after December 15, 2017, including interim periods within that reporting period. The new standard permits the use of either the retrospective or cumulative effect transition method. The Company is currently evaluating the effect that ASU 2014-09 will have on its financial statements and related disclosures. The Company has not yet selected a transition method nor determined the effect of the standard on its ongoing financial reporting.	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. Generally Accepted Accounting Principles when it becomes effective. The new standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The new standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting.
Management's Evaluation of Subsequent Events		Management’s Evaluation of Subsequent Events The Company evaluates events that have occurred after the balance sheet date of December 31, 2014, through the date which the consolidated financial statements were issued. Based upon the review, other than described in Note 20 – Subsequent Events, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements.
Going Concern	Going Concern The accompanying unaudited interim financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of approximately $47,199,000 as of September 30, 2015. During the nine months ended September 30, 2015, the Company had a net loss of approximately $25,120,000, negative cash flow from operations of approximately $6,124,000 and negative working capital of approximately $15,685,000. The Company will need to raise capital in order to fund its operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement a business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. On August 14, 2015 and August 20, 2015, the Company entered into two Securities Purchase Agreements with two separate investors, in the aggregate principal amount of up to approximately $5,480,000 (collectively the “August 2015 Debentures”), of which approximately $2,729,000 was funded during the third quarter of 2015, with up to a remaining $2,751,000 still to be funded. Management is actively seeking additional financing and expects to complete additional financing arrangements in the next few months. The Company expects that these plans will provide it the necessary liquidity to continue operations for the next 12 months. To address its financing requirements, the Company will continue to execute on its business model by attempting to raise additional capital through the sales of debt or equity securities or other means. It is uncertain the Company can obtain financing to fund operating deficits until profitability is achieved. This need may be adversely impacted by: uncertain market conditions, approval of sites and licenses by regulatory bodies and adverse operating results. The outcome of these matters cannot be predicted at this time.	Going Concern The Company recently revised its business model and completed a restatement of its financial statements. The revision to the business model which plans for long term contracts to manage dispensaries or cultivation centers tends to defer revenue and cash flow while expensing the costs to develop markets currently. The recently completed restatements and the on-going investigations by the SEC and the Department of Justice have added general and administrative expenses. The Company also operates in a new, emerging industry where business models are still developing and finalizing new deals can take longer than in more mature industries. The financial statements were prepared on a going concern basis. The going concern basis assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the year ended December 31, 2014, the Company had a net loss of approximately $16.5 million, negative cash flow from operations of $6.3 million and negative working capital of $10.0 million. The Company will need to raise capital in order to fund its operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement a business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. As disclosed in our Form 8-K dated January 28, 2015, our lenders have committed to an additional $3.3 million in funding as our annual SEC filings are completed and the Form S-1 filed with the SEC. Due diligence is in process between an investor and our majority shareholder to sell his majority position which would also yield $5 million in new equity capital for the Company over the next 18 months (see Note 20). Management is committed to conducting a road show after the Form S-1 is declared effective to raise additional equity capital in 2015. The Company expects that these plans will provide it the necessary liquidity through the first quarter of 2016. To address its financing requirements, the Company will seek financing through debt and equity financings. It is uncertain the Company can obtain financing to fund operating deficits until profitability is achieved. This need may be adversely impacted by: uncertain market conditions, approval of sites and licenses by regulatory bodies and adverse operating results. The outcome of these matters cannot be predicted at this time.
Basis of Presentation	Basis of Presentation The accompanying unaudited interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. The results for the three and nine months ended September 30, 2015 are not necessarily indicative of results to be expected for a full year, any other interim periods or any future year or period. The accompanying unaudited interim financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our company’s audited financial statements and related notes included in our company’s Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC on March 26, 2015. The condensed consolidated balance sheet data as of December 31, 2014 was derived from audited consolidated financial statements. The Company has performed a review of all subsequent events through the date the unaudited interim financial statements were issued, and has determined that no additional disclosures are necessary.

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Schedules of Concentration of Risk, by Risk Factor		Three customers, one of which is a related party through the entity’s stock ownership in the Company (customer C) represented 72.1% of the total revenue of $629,132 for the year ended December 31, 2014. Customer December 31, 2014 January -December 2014 December 31, 2013 January -December 2013 Accounts Receivable Revenue Accounts Receivable Revenue Amount, $ % Amount, $ % Amount, $ % Amount, $ % A $ — — % $ 203,165 32.3 % $ 150,000 44.20 % $ 325,000 15.8 % B — — 175,000 27.8 115,200 33.9 — — C — — 75,301 12.0 — — — — Subtotal — 0.0 453,466 72.1 265,200 78.1 $ 325,000 15.8 % Total $ 8,774 100 % $ 629,132 100.00 % $ 339,735 100 % $ 2,062,083 100.00 %
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the liabilities that are measured at fair value on a recurring basis. Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) September 30, 2015 Marketable securities $ 94,817 $ 21,650 $ — $ 73,167 Derivative liability 4,885,286 — — 4,885,286 Total $ 4,980,103 $ 21,650 $ — $ 4,958,453	The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring basis. Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2014 Marketable securities $ 94,776 $ $ $ 94,776 Derivative liability 3,691,853 — — 3,691,853 Total $ 3,786,629 $ $ — $ 3,786,629 Total Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2013 Marketable securities $ 184,800 $ 184,800 $ — $ — Total $ 184,800 $ 184,800 $ — $ —
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the nine months ended September 30, 2015 Total Balance at January 1, 2015 $ 3,691,853 Additions 5,531,201 Reclassified to equity upon conversion (3,828,711 ) Change in fair value of conversion feature (509,057 ) Ending balance $ 4,885,286	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the year ended December 31, 2014 Total Beginning balance $ — Initial recognition of conversion feature 1,885,863 Change in fair value of conversion feature 1,805,990 Ending balance $ 3,691,853

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
Property And Equipment [Member]
Property, Plant and Equipment	Property and equipment at December 31, 2014 and 2013 consists of: Property and Equipment December 31, 2014 December 31, 2013 Office equipment $ 22,421 $ 17,192 Furniture and fixtures 74,404 73,567 Website development 46,922 46,922 Product tooling 64,763 24,100 208,510 161,781 Less accumulated depreciation (50,192 ) (21,123 ) Property and equipment, net $ 158,318 $ 140,658
Estimated Useful Lives [Member]
Property, Plant and Equipment	The estimated useful lives for significant property and equipment categories are as follows: Vehicles 5 years Furniture and Fixtures 5 years Office equipment 3 years

ACQUISITION (Tables)

ACQUISITION (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Purchase Price Allocation	The purchase price is comprised of: Cash deposit $ 500,000 Note Payable to Southwest 3,670,000 Note Payable to EWSD (Seller) 830,000 $ 5,000,000	The total value of the acquisition was approximately $1,635,000 and the purchase price has been allocated as per the Company’s independent valuation as follows: Machinery and equipment $ 70,000 IP and related technology 287,000 Amortizable intangible assets: Customer contracts and related relationships 314,000 Trade name, trademark, and domain name 46,000 Non-compete covenants 23,000 Goodwill 895,000 Total assets acquired 1,635,000 Fair value of liabilities assumed (469,000 ) Net fair value $ 1,166,000
Schedule of Principal Payments Due	Principal payments due on the notes are as follows: Secured Unsecured Total 2015 $ 8,851 301,658 310,509 2016 54,691 27,299 81,990 2017 58,007 30,635 88,642 2018 3,536,670 467,952 4,004,622

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	The consolidated inventories at September 30, 2015 and December 31, 2014 consist of the following: September 30, 2015 December 31, 2014 Work in process and related capitalized costs $ — $ 308,867 Deposits on dispensing machines — 325,973 Vaporizers and accessories 187,844 154,930 Dispensing machines — 171,466 Total inventory, net $ 187,844 $ 961,236	Inventory at December 31, 2014 and 2013 consists of the following: December 31, 2014 December 31, 2013 Work in process and related capitalized costs $ 308,867 $ 242,488 Deposits on dispensing machines 325,973 138,423 Vaporizers and accessories 154,930 193,575 Dispensing machines 171,466 58,500 Total inventory, net $ 961,236 $ 632,986

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2014
Estimated Useful Lives [Member]
Schedule of Finite-Lived Intangible Assets	The estimated useful lives for significant intangible assets are as follows: Distributor Relationship 10 years Domain Names 10 years IP/Technology/Patents 10 years Non-Compete covenants 3 years
Finite-Lived Intangible Assets [Member]
Schedule of Finite-Lived Intangible Assets	Intangible assets December 31, 2014 December 31, 2013 Distributor relationship $ 314,000 $ 314,000 IP/technology/patents 324,653 332,179 Domain names 131,000 46,000 Non-compete covenants 23,000 23,000 Subtotal 792,653 715,179 Less accumulated amortization (83,500 ) (32,750 ) Intangible assets, net $ 709,153 $ 682,429

MARKETABLE SECURITIES (Tables)

MARKETABLE SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2014
Marketable Securities	Marketable securities of the Company represent the shares received as a payment from clients for services provided. Marketable securities Value as of December 31, 2014 Value as of December 31, 2013 Shares received as a payment from client $ — $ 184,800 Securities from MJ Holdings, Inc. 94,776 — Total marketable securities $ 94,776 $ 184,800
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The Company uses a Black-Scholes model to measure the value of the warrants. The following assumptions were used by the Company for the Black-Scholes model valuation of the warrants as of their initial valuation: Black-Scholes Calculator Data Initial Valuation and Recognition #1 #2 #3 #4 #5 #6 Warrant Stock price, $ 8.69 4.00 8.00 6.15 2.01 2.02 Exercise price, $ 6.42 8.45 7.87 6.95 3.53 2.56 Time to maturity, Years 0.5 0.5 0.5 0.5 1.0 1.0 Annual risk-free rate, % 0.05 0.05 0.05 0.05 0.04 0.11 Annualized volatility, % 70.0 70.0 70.0 70.0 70.0 70.0 Black-Scholes Value per warrant, $ 2.876 0.080 1.616 0.918 0.214 0.391 Number of warrants/shares 33,333 33,333 33,333 33,333 33,333 33,333 Total value of warrants/shares, $ 95,866 2,666 53,867 30,600 7,133 13,033 The following data were used by the Company for the Black-Scholes model valuation of the warrants as of December 31, 2014: Fair Value of Warrants As of December 31, 2014 #2 #3 #4 #5 #6 Warrant Stock price, $ 2.00 2.00 2.00 2.00 2.00 Exercise price, $ 8.45 7.87 6.95 3.53 2.56 Time to maturity, Years 1.0 1.0 1.0 1.0 1.0 Annual risk-free rate, % 0.22 0.22 0.22 0.22 0.22 Annualized volatility, % 120.0 120.0 120.0 120.0 120.0 Black-Scholes Value per warrant, $ 0.25 0.27 0.31 0.60 0.77 Number of warrants/shares 33,333 33,333 33,333 33,333 33,333 Total value of warrants/shares, $ 8,179 8,920 10,318 20,053 25,656
Warrant [Member]
Marketable Securities	The following table represents the initial recognition value and subsequent adjustment as of reporting date: Warrants Initial Fair Value Fair Value at Conversion Gain or (Loss) Fair Value as of December 31, 2014 Warrant #1 $ 95,866 $ (94,719 ) $ (1,147 ) $ — Warrant #2 2,666 5,513 8,179 Warrant #3 53,867 (44,947 ) 8,920 Warrant #4 30,600 (20,282 ) 10,318 Warrant #5 7,133 12,920 20,053 Warrant #6 13,033 12,623 25,656 Total $ 203,165 $ (94,719 ) $ (35,320 ) $ 73,126

CUSTOMER DEPOSITS (Tables)

CUSTOMER DEPOSITS (Tables)	12 Months Ended
	Dec. 31, 2014
Banking and Thrift [Abstract]
Customer Advances And Deposits, Current	Advance payments from customers are recorded as customer deposits on the consolidated balance sheet. Customer deposits December 31, 2014 December 31, 2013 Advance payments from customers $ 1,450,770 $ 710,225 Advance payments for vaporizers 75,038 75,636 Total customer deposits $ 1,525,808 $ 785,861

PREPAID EXPENSES AND OTHER CU36

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure	Prepaid expenses and other currents assets consisted of: December 31, 2014 December 31, 2013 Rent $ — $ 3,962 Directors & officers insurance 31,491 — Professional fees 10,000 52,739 Other vendors 24,729 32,540 Prepaid expenses and other current assets $ 66,220 $ 89,241

RESTRICTED STOCK AND RESTRICT37

RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the activity related to restricted stock and RSUs for the nine months ended September 30, 2015 is presented below: Restricted stock Total shares Grant date fair value Restricted stock non-vested at January 1, 2015 168,750 $ 10.40 Restricted stock granted 150,000 — Restricted stock vested (206,250 ) 10.40 Restricted stock forfeited — — Restricted stock non-vested at September 30, 2015 112,500 $ 10.40 Restricted stock units (RSU’s) Total shares Grant date fair RSU’s non-vested at January 1, 2015 199,584 $ 10.70 RSU’s granted 698,522 $ 0.51 - $6.07 RSU’s vested (590,502 ) $ 0.51 - $6.07 RSU’s forfeited (50,000 ) RSU’s non-vested September 30, 2015 257,604 $ 0.51 - $10.70	A summary of the activity related to restricted stock and RSUs for the year ended December 31, 2014 is presented below: Restricted stock Total shares Grant date fair value Restricted stock non-vested at January 1, 2014 — $ — Restricted stock granted 346,875 10.40 Restricted stock vested (178,125 ) 10.40 Restricted stock forfeited — — Restricted stock non-vested at December 31, 2014 168,750 $ 10.40 Restricted stock units (RSU’s) Total shares Grant date fair value Restricted stock non-vested at January 1, 2014 — $ — Restricted stock granted 422,980 10.84 Restricted stock vested (223,396 ) 11.19 Restricted stock forfeited — — Restricted stock non-vested at December 31, 2014 199,584 $ 10.70
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	A summary of the expense related to restricted stock, RSUs and stock option awards for the three and nine months ended September 30, 2015 is presented below: Summary of the expense related to Restricted Stock and RSUs For the three months ended September 30, 2015 For the nine months ended September 30, 2015 Restricted Stock $ 390,000 $ 2,420,782 RSU’s 574,840 2,501,150 Stock options — 335,117 Common stock 74,333 74,333 Total $ 1,039,173 $ 5,331,382	A summary of the expense related to restricted stock and RSUs for the year ended December 31, 2014 is presented below: Summary of the expense related to Restricted Stock and RSUs Year ended December 31, 2014 Restricted Stock $ 663,262 RSU’s 3,752,537 $ 4,415,799

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Significant Components of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows at December 31: 2014 2013 Deferred tax assets: Customer deposits $ 295,000 $ 293,000 Deferred revenue 35,000 Share based compensation 1,760,000 NOL carryforward 5,400,000 2,377,000 Total deferred tax asset 7,490,000 2,670,000 Deferred tax liabilities: Deferred revenue — 285,000 Intangible asset amortization 20,000 20,000 285,000 7,470,000 2,385,000 Less: Valuation allowance (7,470,000 ) (2,385,000 ) $ — $ —
Reconciliation of Statutory Rate and Effective Rate for Provisions for Income Taxes	For the years ended December 31, 2014, 2013 and 2012, a reconciliation of the statutory rate and effective rate for the provisions for income taxes consists of the following: 2014 2013 2012 Federal Tax statutory rate 34.00 % 34.00 % 34.00 % State tax statutory rate 6.00 % 8.84 % 8.84 % Permanent differences (6.72 )% — % Valuation allowance (33.28 )% (42.84 )% (42.84 )% Effective rate 0.00 % 0.00 % 0.00 %

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Summary of Material Contractual Lease Commitments	The following table is a summary of our material contractual lease commitments as of September 30, 2015: Year Ending Office Rent Retail/Cultivation Facility Lease 2015 $ 66,942 $ 22,200 2016 245,310 88,800 2017 88,968 88,800 2018 — 88,800 2019 — 29,600 Total $ 401,220 $ 318,200	The following table is a summary of our material contractual lease commitments as of December 31, 2014: Year Ending Office Rent Retail/ Facility Lease 2015 $ 177,936 $ 88,800 2016 177,936 88,800 2017 88,968 88,800 2018 — 88,800 2019 — 29,600 Total $ 444,840 $ 384,800
Summary of Open Real Estate Purchase Transactions		A summary of open real estate purchase transactions as of December 31, 2014 is represented in the table below: Property Purchase price Closing date Net escrow balance Date escrow opened Additional rents/fees paid to extend closing date 1 $ 820,000 03/31/2015 55,000 06/28/2014 $ 9,808 2 1,300,000 03/30/2015 50,000 10/17/2014 3 — 265,400 07/21/2014 — Escrow deposits to be refunded 30,076 Total $ 2,120,000 $ 400,476 $ 9,808

Convertible Notes Payable and40

Convertible Notes Payable and Derivative Liability (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Summary of Warrants Issued in Connection with Modified Debentures	The warrants issued in the nine months ended September 30, 2015 in connection with all the Modified Debentures detailed above, and the August 2015 Securities Purchase Agreement (“August 2015 Debentures”) discussed below, are summarized below: Date issued Number of warrants Exercise price Fair Value July 2014 Modified Debentures January 30, 2015 40,552 $ 4.93 $ 159,601 February 26, 2015 45,537 2.20 79,904 March 13, 2015 21,151 2.36 39,965 March 16, 2015 10,575 2.36 19,981 March 20, 2015 41,946 1.79 59,942 March 27, 2015 75,758 1.98 119,888 April 2, 2015 60,386 1.66 74,025 April 2, 2015 30,193 1.66 37,012 April 10, 2015 107,914 1.39 112,460 April 17, 2015 41,667 1.20 37,680 April 24, 2015 127,119 1.18 112,635 April 24, 2015 21,186 1.18 18,772 May 1, 2015 156,250 .96 113,133 May 7, 2015 134,615 .78 79,234 May 8, 2015 42,000 .75 23,768 May 15, 2015 200,000 .75 113,365 May 22, 2015 250,000 .60 113,366 May 29, 2015 258,621 .58 112,537 June 5, 2015 288,462 .52 120,738 June 12, 2015 930,233 .43 303,246 June 19, 2015 3,448,276 .29 751,159 September 2014 Modified Debentures January 28, 2015 18,038 5.54 80,156 February 13, 2015 57,870 1.73 96,689 April 2, 2015 181,159 1.66 222,109 April 24, 2015 90,579 1.10 80,548 May 15, 2015 200,000 .75 113,365 June 12, 2015 1,744,186 .43 570,248 August 2015 Debentures August 24, 2015 6,666,667 .06 321,757 September 18, 2015 588,235 .17 82,804 Directors January 5, 2015 129,305 .40 39,901 January 30, 2015 129,250 .40 39,916 February 2, 2015 237,778 .22 16,619 Total $ 16,375,508 $ 4,266,522

Business Organization, Nature41

Business Organization, Nature of Operations - Additional Information (Detail)	Mar. 22, 2013USD ($)shares	Sep. 30, 2015USD ($)	Dec. 31, 2014	Dec. 31, 2012USD ($)shares	Jun. 30, 2015USD ($)	Apr. 01, 2013
BUSINESS ORGANIZATION, NATURE OF OPERATIONS (Details) [Line Items]
Notes Issued		$ 5,000,000
Note receivable, allowance		$ 350,000
Operating Agreement [Member]
BUSINESS ORGANIZATION, NATURE OF OPERATIONS (Details) [Line Items]
Agreement term		5 years
Agreement renewal term		5 years
Procurement fee paid upon execution and delivery of agreement		$ 50,000
Procurement fee due amount		350,000
Minimum monthly payment		$ 5,000
Note receivable, allowance					$ 350,000
Procurement fee payment terms		If the procurement fees are not paid within six months, the payment terms become a minimum monthly payment of $5,000.
Ownership percentage, by parent		51.00%
Ownership percentage		49.00%
Annual licensor fee		5.00%
Operating Agreement [Member] | Maximum [Member]
BUSINESS ORGANIZATION, NATURE OF OPERATIONS (Details) [Line Items]
Deferred revenue		$ 400,000
Operating Agreement [Member] | Minimum [Member]
BUSINESS ORGANIZATION, NATURE OF OPERATIONS (Details) [Line Items]
Deferred revenue					$ 50,000
Vaporfection International Inc. [Member]
BUSINESS ORGANIZATION, NATURE OF OPERATIONS (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares	260,854
Business Acquisition, Percentage of Voting Interests Acquired	100.00%					100.00%
Contributed Contribution Commitment	$ 1,600,000
Other Commitment	$ 175,000
Class of Warrant or Rights, Granted | shares	5,000
Number of Subsidiaries			6
PVM International Inc. (PVMI) [Member]
BUSINESS ORGANIZATION, NATURE OF OPERATIONS (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares				2,000,000
Notes Issued				$ 1,000,000

Summary of Significant Accoun42

Summary of Significant Accounting Policies - Additional Information (Detail)	Aug. 24, 2015USD ($)	Jan. 30, 2015USD ($)$ / shares	Jan. 28, 2015USD ($)	Jan. 31, 2015$ / shares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)$ / sharesshares	Sep. 30, 2015USD ($)d$ / sharesshares	Sep. 30, 2014USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2012USD ($)shares	Aug. 20, 2015USD ($)	Aug. 14, 2015USD ($)	Mar. 13, 2015$ / shares	Sep. 19, 2014USD ($)	Jul. 21, 2014USD ($)
Summary Of Significant Accounting Policies [Line Items]
Cash, FDIC Insured Amount					$ 250,000		$ 250,000		$ 250,000
Advertising Expense					0	$ 319,000	0	$ 749,000	933,627	$ 644,383	$ 806,221
Research and Development Expense						61,623		136,656	242,232	74,861	176,964
Revenues					$ 314,153	$ 173,076	$ 464,910	$ 524,192	$ 629,132	$ 2,062,083	1,176,829
Preferred Stock, Shares Outstanding (in Shares) | shares					1,000,000		1,000,000		3,000,000	3,000,000
Warrants to purchase common stock outstanding | shares					14,084,000		14,084,000		206,480
Debt Instrument, Convertible, Conversion Price | $ / shares					$ 0.75	$ 11.75	$ 0.75	$ 11.75	$ 11.75
Net loss					$ (9,291,949)	$ (3,796,532)	$ (25,120,496)	$ (6,802,926)	$ (16,541,334)	$ (3,791,440)	(1,758,237)
Net cash used in operating activities							(6,124,372)	$ (4,651,145)	(6,319,400)	$ (3,743,397)	$ (1,444,871)
Working capital					(15,685,000)		(15,685,000)		(10,000,000)
Cash, Uninsured Amount					$ 22,504		$ 22,504		$ 0
Cash, Uninsured Amount Description							The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.
Preferred stock, par value (in Dollars per share) | $ / shares					$ 0.001		$ 0.001		$ 0.001	$ 0.001
Conversion, percentage of weighted average price							51.00%
Accumulated deficit					$ (47,198,689)		$ (47,198,689)		$ (22,078,193)	$ (5,536,859)
Internal Revenue Service (IRS) [Member]
Summary Of Significant Accounting Policies [Line Items]
Tax deficiency amount							$ 60,000
Open tax year							2,011
July 2014, September 2014, August 2015 Modified Debentures [Member]
Summary Of Significant Accounting Policies [Line Items]
Period of volume weighted average price calculation | d							40
August 2015 Debentures [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Face Amount												$ 5,480,000	$ 5,480,000
Principal amount of debt funded amount					2,729,000		$ 2,729,000
Principal amount of debt yet to be funded amount					2,751,000		2,751,000
Convertible Debt [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Face Amount			$ 1,500,000		$ 4,994,000		$ 4,994,000		$ 3,750,000						$ 2,500,000	$ 3,500,000
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 5			$ 1.83		$ 1.83							$ 1.83
Conversion, percentage of weighted average price		51.00%					51.00%
Convertible Debt [Member] | August 2015 Debentures [Member]
Summary Of Significant Accounting Policies [Line Items]
Warrants to purchase common stock outstanding | shares					7,254,902		7,254,902
Debt Instrument, Face Amount					$ 200,000		$ 200,000					$ 1,500,000
Debt Instrument, Convertible, Conversion Price | $ / shares					$ 0.75		$ 0.75
Conversion, percentage of weighted average price							51.00%
Convertible Debt [Member] | Subsequent Event [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Face Amount		$ 1,800,000	1,500,000
Debt Instrument, Convertible, Conversion Price | $ / shares				$ 5										$ 1.83
Expected amount of new equity capital to be raised			5,000,000
Conversion, percentage of weighted average price				51.00%
Convertible Debt [Member] | Subsequent Event [Member] | Committed to fund as annual SEC filings are completed and the Form S-1 filed with the SEC [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Face Amount			$ 3,300,000
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage									72.10%
Gross revenue generated									$ 629,132
Series A Preferred Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Preferred Stock, Shares Outstanding (in Shares) | shares					1,000,000	3,000,000	1,000,000	3,000,000	3,000,000	3,000,000	6,000,000
Preferred Stock, No Par Value (in Dollars per share) | $ / shares									$ 0.001	$ 0.001
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares) | shares									15,000,000	15,000,000	30,000,000
Preferred stock, par value (in Dollars per share) | $ / shares						$ 0.001		$ 0.001
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares) | shares						15,000,000		15,000,000
Preferred stock, shares repurchased	$ 2,000,000
Dispensing machines [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenues							$ 50,000		$ 50,000

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Schedules of Concentration of Risk, by Risk Factor (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounts Receivable [Member] | Customer A [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount		$ 150,000
Concentration risk, percentage		44.20%
Accounts Receivable [Member] | Customer B [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount		$ 115,200
Concentration risk, percentage		33.90%
Accounts Receivable [Member] | Subtotal [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount		$ 265,200
Concentration risk, percentage	0.00%	78.10%
Accounts Receivable [Member] | Total [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount	$ 8,774	$ 339,735
Concentration risk, percentage	100.00%	100.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross revenue generated	$ 629,132
Concentration risk, percentage	72.10%
Sales Revenue, Net [Member] | Customer A [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross revenue generated	$ 203,165	$ 325,000
Concentration risk, percentage	32.30%	15.80%
Sales Revenue, Net [Member] | Customer B [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross revenue generated	$ 175,000
Concentration risk, percentage	27.80%
Sales Revenue, Net [Member] | Customer C [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross revenue generated	$ 75,301
Concentration risk, percentage	12.00%
Sales Revenue, Net [Member] | Subtotal [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross revenue generated	$ 453,466	$ 325,000
Concentration risk, percentage	72.10%	15.80%
Sales Revenue, Net [Member] | Total [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross revenue generated	$ 629,132	$ 2,062,083
Concentration risk, percentage	100.00%	100.00%

Summary of Significant Accoun44

Summary of Significant Accounting Policies - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 94,817	$ 94,776	$ 184,800
Derivative Liability	4,885,286	3,691,853
Total	4,980,103	3,786,629	184,800
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	21,650	0	184,800
Derivative Liability	0	0
Total	21,650	0	184,800
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0	0
Derivative Liability	0	0
Total	0	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	73,167	94,776	0
Derivative Liability	4,885,286	3,691,853
Total	$ 4,958,453	$ 3,786,629	$ 0

Summary of Significant Accoun45

Summary of Significant Accounting Policies - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Beginning balance	$ 3,691,853
Additions	5,531,201
Initial recognition of conversion feature		$ 1,885,863
Reclassified to equity upon conversion	(3,828,711)
Change in fair value of conversion feature	(509,057)	1,805,990
Ending balance	$ 4,885,286	$ 3,691,853

Summary of Significant Accoun46

Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2014
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years

Acquisition - Additional Inform

Acquisition - Additional Information (Detail) - USD ($)	Dec. 29, 2014	Mar. 22, 2013	Jan. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015	Sep. 30, 2015	May. 22, 2013	Apr. 01, 2013
ACQUISITION (Details) [Line Items]
Goodwill					$ 1,260,037	$ 1,090,037		$ 1,260,037
Legal expense on warrants					280,000
Average yield period					3 years
Deferred tax liability, amortizing intangible assets					$ 20,000	0
Vaporfection International Inc. [Member]
ACQUISITION (Details) [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired		100.00%								100.00%
Business Acquisition, Equity Interest Issued or Issuable, Description		The Company issued 260,854 warrants to shareholders of VII allowing them to purchase one (1) share of Medbox common stock at $.001 per share beginning April 1, 2013.
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)		260,854
Fair Value Assumptions, Exercise Price (in Dollars per share)		$ 4.47
Business Combination, Consideration Transferred, Liabilities Incurred		$ 470,000
Business Combination, Consideration Transferred		$ 1,635,000
Finite-Lived Intangible Asset, Useful Life		10 years
Goodwill		$ 895,000							$ 895,000
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities				$ 205,000
Goodwill, Period Increase (Decrease)					$ 10,000	$ 195,000
Warrants exercised			206,480		252,812
Business Combination, Contingent Consideration Arrangements, Description		In addition to the above warrants, the purchase agreement and associated consulting contract with the prior management company of the business unit calls for additional shares of common stock to be issued in the event that the performance of the business unit exceeds $11,818,140 of accumulated EBITDA over the subsequent 4 year operating period.
Vaporfection International Inc. [Member] | Finite-Lived Intangible Assets [Member]
ACQUISITION (Details) [Line Items]
Deferred tax liability, amortizing intangible assets					$ 160,000
Vaporfection International Inc. [Member] | Scenario Forecast [Member]
ACQUISITION (Details) [Line Items]
Goodwill							$ 1,260,037
Vaporfection International Inc. [Member] | Settlement With Former Shareholders [Member]
ACQUISITION (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)	50,000

Acquisition - Schedule of Recog

Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Detail) - USD ($)	Sep. 30, 2015	Jul. 24, 2015	Dec. 31, 2014	Dec. 31, 2013	May. 22, 2013	Mar. 22, 2013
Acquisition (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Goodwill	$ 1,260,037		$ 1,260,037	$ 1,090,037
Net fair value	$ 5,000,000	$ 500,000
Vaporfection International Inc. [Member]
Acquisition (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Machinery and equipment					$ 70,000
Goodwill					895,000	$ 895,000
Total assets acquired					1,635,000
Fair value of liabilities assumed					(469,000)
Net fair value					1,166,000
Customer Relationships [Member] | Vaporfection International Inc. [Member]
Acquisition (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets					314,000
Trademarks and Trade Names [Member] | Vaporfection International Inc. [Member]
Acquisition (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets					46,000
Noncompete Agreements [Member] | Vaporfection International Inc. [Member]
Acquisition (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets					23,000
IP and Related Technology [Member] | Vaporfection International Inc. [Member]
Acquisition (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets					$ 287,000

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($)	Jun. 05, 2014	Feb. 27, 2014	Mar. 12, 2013	Feb. 08, 2013	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	May. 22, 2013
INVESTMENTS (Details) [Line Items]
Investment Owned, at Cost							$ 1,200,000
Treasury Stock, Value					$ 1,209,600	$ 1,209,600
Treasury Stock, Shares (in Shares)						60,000
Bio-Tech Medical Software [Member]
INVESTMENTS (Details) [Line Items]
Equity Method Investment, Additional Information				The Company advanced $600,000 upon execution of this agreement for the right to purchase with the remaining balance of $900,000 due and payable in installments at various dates by August 25, 2013. On June 26, 2013, the Company notified Bio-Tech that it was canceling the agreement.
Payments to Acquire Trading Securities Held-for-investment				$ 600,000
Licensing Agreement, Term		5 years
Bio-Tech Medical Software [Member] | Maximum [Member]
INVESTMENTS (Details) [Line Items]
Investment, Authorized Shares Available for Purchase (in Shares)				833,333
Equity Method Investment, Ownership Percentage				25.00%
Investment, Purchase Price				$ 1,500,000
MedVend Holdings LLC [Member]
INVESTMENTS (Details) [Line Items]
Equity Method Investment, Additional Information			In May 2013, the three members of MedVend were named in a lawsuit by that entity's minority shareholders alleging improper conveyance of the three members' ownership interest in MedVend to the Company. Accordingly, also in May 2013, Medbox filed suit against MedVend and the three members of that entity that were involved in the transaction.
Equity Method Investment, Ownership Percentage			50.00%
Investment Owned, at Cost			$ 4,100,000
MedVend Holdings LLC [Member] | Amount Paid Upon Execution of the Contract [Member]
INVESTMENTS (Details) [Line Items]
Payments to Acquire Trading Securities Held-for-investment			300,000
MedVend Holdings LLC [Member] | Amount Disbursed as an Additional Investment [Member]
INVESTMENTS (Details) [Line Items]
Payments to Acquire Trading Securities Held-for-investment			$ 300,000
Affiliated Entity [Member]
INVESTMENTS (Details) [Line Items]
Treasury Stock, Shares (in Shares)						60,000
Affiliated Entity [Member] | Bio-Tech Medical Software [Member]
INVESTMENTS (Details) [Line Items]
Legal Fees	$ 4,800
Stock Repurchased During Period, Shares (in Shares)	30,000
Stock Repurchased During Period, Value	$ 604,800
Affiliated Entity [Member] | MedVend Holdings LLC [Member]
INVESTMENTS (Details) [Line Items]
Stock Repurchased During Period, Shares (in Shares)	30,000
Stock Repurchased During Period, Value	$ 604,800
Investment Owned, at Cost								$ 4,100,000

Inventories - Schedule of Inven

Inventories - Schedule of Inventory, Current (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Work in process and related capitalized costs		$ 308,867	$ 242,488
Inventory	$ 187,844	961,236	632,986
Deposits on dispensing machines [Member]
Inventory [Line Items]
Inventory		325,973	138,423
Vaporizers and Accessories [Member]
Inventory [Line Items]
Inventory	$ 187,844	154,930	193,575
Dispensing machines [Member]
Inventory [Line Items]
Inventory		$ 171,466	$ 58,500

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Inventory written down	$ 142,500	$ 329,154	$ 0	$ 0

Property and Equipment - Schedu

Property and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 208,510	$ 161,781
Less accumulated depreciation	$ (59,210)	(50,192)	(21,123)
Property and equipment, net	$ 573,470	158,318	140,658
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		22,421	17,192
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		74,404	73,567
Website Development [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		46,922	46,922
Product Development [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 64,763	$ 24,100

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property Plant And Equipment Capitalized Interest Costs [Abstract]
Depreciation expense	$ 29,000	$ 37,000	$ 30,000

Assets Held for Resale - Additi

Assets Held for Resale - Additional Information (Detail) - USD ($)	Jul. 28, 2014	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Assets Held For Sale [Line Items]
Assets held for resale			$ 399,594	$ 0
Land [Member]
Assets Held For Sale [Line Items]
Proceeds from Sale of Property, Plant, and Equipment		$ 399,594
Debt Instrument, Face Amount	$ 249,000	$ 249,000
Debt Instrument, Maturity Date	Jan. 30, 2015	Jan. 30, 2015
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail)	Apr. 01, 2013	Mar. 22, 2013
Vaporfection International Inc. [Member]
Intangible Assets [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%	100.00%

Intangible Assets - Schedule of

Intangible Assets - Schedule of Finite-Lived Intangible Assets (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross		$ 792,653	$ 715,179
Less accumulated amortization	$ (123,567)	(83,500)	(32,750)
Intangible assets, net		709,153	682,429
Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross		314,000	314,000
Patented Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross		324,653	332,179
Internet Domain Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross		131,000	46,000
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross		$ 23,000	$ 23,000

Intangible Assets - Schedule 57

Intangible Assets - Schedule of Finite-Lived Intangible Assets, Estimated Useful Life (Detail)	12 Months Ended
	Dec. 31, 2014
Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	10 years
Internet Domain Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	10 years
IP and Related Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	10 years
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	3 years

Accounts and Notes Receivable -

Accounts and Notes Receivable - Additional Information (Detail) - USD ($)	Oct. 20, 2014	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounts And Other Receivables [Line Items]
Bad debt expense		$ 75,000			$ 207,640
Note Receivable, Face Amount						$ 1,000,000
Note Receivable, Stated Interest Rate, Percentage						5.00%
Note Receivable, Maturity Date		Dec. 31, 2014				Dec. 10, 2018
Increase in notes receivable					40,000
Notes, Loans and Financing Receivable, Net, Current		$ 75,000		$ 75,000		$ 115,000
Accrued interest paid	$ 6,424		$ 1,151	$ 37,078	2,834	$ 2,106	$ 4,975
Notes Receivable [Member]
Accounts And Other Receivables [Line Items]
Bad debt expense					75,000
Accounts Receivable [Member]
Accounts And Other Receivables [Line Items]
Bad debt expense					132,640
Scenario, Adjustment [Member]
Accounts And Other Receivables [Line Items]
Notes, Loans and Financing Receivable, Net, Current					$ 155,000

Marketable Securities - Shares

Marketable Securities - Shares received as payment from clients (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Marketable Securities [Line Items]
Shares received as a payment from client		$ 0	$ 184,800
Marketable Securities, Current	$ 94,817	94,776	184,800
MJ Holdings [Member]
Marketable Securities [Line Items]
Marketable Securities, Current		$ 94,776	$ 0

Marketable Securities - Additio

Marketable Securities - Additional Information (Detail)	Sep. 05, 2014USD ($)shares	May. 19, 2014shares	Dec. 31, 2014USD ($)Trancheshares	Dec. 31, 2013USD ($)	Sep. 30, 2015shares
Schedule of Trading Securities and Other Trading Assets [Line Items]
Marketable Securities, Number of Shares Held as Deposit (in Shares) | shares	7,000,000
Marketable Securities, Value of Shares Held as Customer Deposit	$ 300,000
Fair Value Inputs, Discount Rate				12.00%
Marketable Securities, Restricted, Current			$ 0	$ 184,800
Class of Warrant or Right, Outstanding (in Shares) | shares			206,480		14,084,000
Endocan [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Customer deposit received as collateral description			The last filed financial statements show minimal assets and liabilities of over $1,000,000. Management concluded these factors were indications of impairment, and determined the shares were fully impaired, with the decline being other-than-temporary.
MJ Holdings [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Investment, Percentage of Profits Realized from Investment		50.00%
Investment, Term of Investment		6 months
Class of Warrant or Right, Outstanding (in Shares) | shares		33,333
Number of tranches of warrants received for services provided under agreement | Tranche			6
Class of Warrant or Rights, Exercised (in Shares) | shares			10,825
Class of Warrant or Rights, Fair Value Granted			$ 21,650
Unrealized loss on marketable securities			$ (73,069)

Marketable Securities - Schedul

Marketable Securities - Schedule of Marketable Securities (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Jun. 19, 2014	May. 19, 2014
MARKETABLE SECURITIES (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	$ 73,126	$ 203,165	$ (94,719)
Fair Value at Conversion	(35,320)
Warrant #1 [Member]
MARKETABLE SECURITIES (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	0	95,866	(94,719)
Fair Value at Conversion	(1,147)
Warrant #2 [Member]
MARKETABLE SECURITIES (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	8,179	2,666	0
Fair Value at Conversion	5,513
Warrant #3 [Member]
MARKETABLE SECURITIES (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	8,920	53,867	0
Fair Value at Conversion	(44,947)
Warrant #4 [Member]
MARKETABLE SECURITIES (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	10,318	30,600	0
Fair Value at Conversion	(20,282)
Warrant # 5 [Member]
MARKETABLE SECURITIES (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	20,053	7,133	0
Fair Value at Conversion	12,920
Warrant # 6 [Member]
MARKETABLE SECURITIES (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	25,656	$ 13,033	$ 0
Fair Value at Conversion	$ 12,623

Marketable Securities - Fair Va

Marketable Securities - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Detail) - USD ($)	May. 19, 2014	Dec. 31, 2014	Sep. 30, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Number of warrants/shares (in Shares)		206,480	14,084,000
Warrant #1 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$ 8.69
Exercise price, $	$ 6.42
Time to maturity, Years	6 months
Annual risk-free rate, %	0.05%
Annualized volatility, %	70.00%
Black-Scholes Value per warrant, $	$ 2.876
Number of warrants/shares (in Shares)	33,333
Total value of warrants/shares, $ (in Dollars)	$ 95,866
Warrant #2 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$ 4	$ 2
Exercise price, $	$ 8.45	$ 8.45
Time to maturity, Years	6 months	1 year
Annual risk-free rate, %	0.05%	0.22%
Annualized volatility, %	70.00%	120.00%
Black-Scholes Value per warrant, $	$ 0.080	$ 0.25
Number of warrants/shares (in Shares)	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	$ 2,666	$ 8,179
Warrant #3 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$ 8	$ 2
Exercise price, $	$ 7.87	$ 7.87
Time to maturity, Years	6 months	1 year
Annual risk-free rate, %	0.05%	0.22%
Annualized volatility, %	70.00%	120.00%
Black-Scholes Value per warrant, $	$ 1.616	$ 0.27
Number of warrants/shares (in Shares)	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	$ 53,867	$ 8,920
Warrant #4 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$ 6.15	$ 2
Exercise price, $	$ 6.95	$ 6.95
Time to maturity, Years	6 months	1 year
Annual risk-free rate, %	0.05%	0.22%
Annualized volatility, %	70.00%	120.00%
Black-Scholes Value per warrant, $	$ 0.918	$ 0.31
Number of warrants/shares (in Shares)	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	$ 30,600	$ 10,318
Warrant # 5 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$ 2.01	$ 2
Exercise price, $	$ 3.53	$ 3.53
Time to maturity, Years	1 year	1 year
Annual risk-free rate, %	0.04%	0.22%
Annualized volatility, %	70.00%	120.00%
Black-Scholes Value per warrant, $	$ 0.214	$ 0.60
Number of warrants/shares (in Shares)	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	$ 7,133	$ 20,053
Warrant # 6 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$ 2.02	$ 2
Exercise price, $	$ 2.56	$ 2.56
Time to maturity, Years	1 year	1 year
Annual risk-free rate, %	0.11%	0.22%
Annualized volatility, %	70.00%	120.00%
Black-Scholes Value per warrant, $	$ 0.391	$ 0.77
Number of warrants/shares (in Shares)	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	$ 13,033	$ 25,656

Customer Deposits - Customer Ad

Customer Deposits - Customer Advances and Deposits, Current (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Customer Advances and Deposits, Current [Abstract]
Advance payments from customers		$ 1,450,770	$ 710,225
Advance payments for vaporizers		75,038	75,636
Total customer deposits	$ 1,057,340	$ 1,525,808	$ 785,861

Short-Term Debt - Additional In

Short-Term Debt - Additional Information (Detail) - USD ($)	Jul. 28, 2014	Sep. 30, 2014	Dec. 31, 2014
Short-term Debt [Line Items]
Repayments of Notes Payable			$ 75,000
Land [Member]
Short-term Debt [Line Items]
Debt Instrument, Face Amount	$ 249,000	$ 249,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%
Debt Instrument, Date of First Required Payment	Aug. 1, 2014
Debt Instrument, Date of Final Required Payment	Jan. 1, 2015
Debt Instrument, Maturity Date	Jan. 30, 2015	Jan. 30, 2015
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum	18.00%
Debt Instrument, Interest Rate, late charge	5.00%
Notes Payable, Other Payables [Member]
Short-term Debt [Line Items]
Debt Instrument, Face Amount			$ 12,434
Debt Instrument, Interest Rate, Stated Percentage			5.99%
Debt Instrument, Date of First Required Payment			Sep. 5, 2014
Debt Instrument, Maturity Date			May 5, 2015
Debt Instrument, Periodic Payment, Interest			$ 2,524

Convertible Notes Payable and65

Convertible Notes Payable and Derivative Liability - Additional Information (Detail)	Sep. 18, 2015shares	Jul. 10, 2015USD ($)Tranches	Apr. 17, 2015USD ($)$ / shares	Apr. 14, 2015USD ($)	Apr. 11, 2015USD ($)	Apr. 09, 2015USD ($)	Feb. 27, 2015USD ($)	Jan. 30, 2015USD ($)$ / shares	Nov. 24, 2014USD ($)	Sep. 26, 2014USD ($)	Sep. 24, 2014USD ($)	Sep. 19, 2014USD ($)	Aug. 26, 2014USD ($)	Aug. 25, 2014USD ($)	Jul. 21, 2014USD ($)	Jan. 31, 2015$ / shares	Sep. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2015USD ($)	Sep. 30, 2014USD ($)$ / shares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)$ / shares	Dec. 31, 2014USD ($)$ / sharesshares	Oct. 14, 2015USD ($)	Aug. 20, 2015USD ($)	Aug. 14, 2015USD ($)	Mar. 26, 2015USD ($)	Mar. 20, 2015USD ($)	Mar. 16, 2015USD ($)	Mar. 13, 2015USD ($)$ / shares	Feb. 24, 2015USD ($)	Jan. 29, 2015USD ($)	Jan. 28, 2015USD ($)
Debt Conversion [Line Items]
Proceeds from convertible debt																				$ 7,432,128	$ 3,500,000	$ 3,475,000
Debt Instrument, Convertible, Conversion Price | $ / shares																	$ 0.75		$ 11.75	$ 0.75	$ 11.75	$ 11.75
Debt instrument, convertible, terms of conversion feature																				The Company may make the amortization payments on the debt in cash, prompting a 30% premium or, subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days.
Debt discount																	$ 266,497			$ 266,497		$ 1,225,573
Change in fair value of derivative liabilities																	(2,544,014)		$ 548,315	$ 509,057	$ 548,315	(1,805,990)
Conversion, percentage of weighted average price																				51.00%
Minimum percentage of change in present value of future cash flows																				10.00%
Maximum estimated percentage of resulted change in present value of future cash flows																				10.00%
Consecutive trading days																				20 days
Weighted probability model for the fair value			$ 3,287,000				$ 2,720,000
Derivative gain recognized							334,000
Derivative loss recognized			$ 1,764,000
Cash settlement provision for warrants classified in equity																	0			$ 0
Debt converted to common shares | shares																				67,475,000
Reclassified to equity upon conversion																				$ 3,828,711
Amortization of debt discount																	$ 2,071,898		$ 216,224	$ 8,121,537	$ 216,224	$ 935,290
Warrants to purchase common stock outstanding | shares																	14,084,000			14,084,000		206,480
Class of warrant or rights, outstanding																	$ 4,266,522			$ 4,266,522
Common Stock [Member]
Debt Conversion [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares																	$ 0.09			$ 0.09
Conversions of convertible debentures | shares																				67,475,105
Conversion of Convertible Debentures [Member]
Debt Conversion [Line Items]
Reclassified to equity upon conversion																				$ 4,519,000
Amortization of debt discount																				1,730,000
September 2014 Convertible Debentures [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount																	$ 1,710,000			$ 1,710,000
Debt Instrument, Convertible, Conversion Price | $ / shares																	$ 5			$ 5
Debt instrument, convertible, terms of conversion feature																				Modified Debentures have a fixed conversion price of the lower of $5.00 or 51% of the VWAP for the last 20 days prior to the conversion.
Conversion, percentage of weighted average price																				51.00%
Consecutive trading days																				20 days
Debt redemption amount																														$ 100,000	$ 100,000
Accrued interest of debt																				$ 49,000
Debt Instrument, Tranche Three [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount						$ 450,000
Debt Instrument, Due after filing						2 days
July 2014 Convertible Debentures [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount																	$ 4,420,000			$ 4,420,000
Debt redemption amount							$ 100,000																			$ 150,000	$ 75,000	$ 25,000	$ 50,000
July 2014 and September 2014 Convertible Debentures [Member]
Debt Conversion [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares																	$ 5			$ 5
August 2015 Debentures [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount																								$ 5,480,000	$ 5,480,000
Convertible Debt [Member]
Debt Conversion [Line Items]
Debt Instrument, Maturity Date												Sep. 19, 2015			Jul. 21, 2015
Debt Instrument, Face Amount												$ 2,500,000			$ 3,500,000		$ 4,994,000			$ 4,994,000		$ 3,750,000										$ 1,500,000
Proceeds from convertible debt									$ 250,000		$ 500,000	$ 1,000,000		$ 1,000,000	$ 1,000,000					$ 150,000
Debt Instrument, Interest Rate, Stated Percentage												5.00%			10.00%
Debt Instrument, Description																				In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement. Through subsequent modifications of the July 2014 Debentures and September 2014 Debentures, the required date to file the registration statement and the effective date of the registration statement have been changed to April 15, 2015 and July 15, 2015, respectively. The registration statement was filed on April 9, 2015, and became effective on June 11, 2015.		In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement. The registration statement was not declared effective within 120 days, and the amortization payment conversion rate was adjusted accordingly.
Debt Instrument, Convertible, Conversion Price | $ / shares								$ 5									$ 1.83			$ 1.83									$ 1.83
Debt instrument, convertible, terms of conversion feature																				They were originally convertible at a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 20 days prior to conversion.		Beginning four months (as subsequently amended) after the initial closing, the Company will begin making amortization payments on the debt in cash, prompting a 30% premium or, at their option and subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days. However, in the event the registration statement filed by the Company in connection with the respective purchase agreements is not effective within 120 days of the initial closing date under the July 2014 Purchase Agreement and 120 days of the initial closing date under the September 2014 Purchase Agreement, the July 2014 Purchase Agreement Debentures’ and the September 2014 Purchase Agreement Debentures’, respectively, conversion rate will be, during the period commencing 120 days after the initial closing date until the registration statement is effective, equal to 63% of the lowest volume weighted average price of the common stock for the 20 prior trading days. If the aforementioned registration statement is not effective within 160 days of the initial closing date, each of the debentures’ conversion rate will be, during the period commencing 160 days after the initial closing date until the registration statement is effective, equal to 60% of the lowest volume weighted average price of the common stock for the 20 prior trading days.
Debt discount															$ 275,000
Derivative Liability								$ 2,690,000							1,885,000		$ 132,175			$ 132,175
Change in fair value of derivative liabilities																				$ 1,072,000
Conversion, percentage of weighted average price								51.00%												51.00%
Consecutive trading days								20 days												20 days
Convertible debt instrument term																				3 years
Debt instrument effective percentage																	8.00%			8.00%
Warrant instrument grant agreement, description																				The Modified Debentures also included a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, with a three year term.		The parties also entered into a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price (the "Reference Price") equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, at an exercise price equal to the Reference Price, with a three year term.
Convertible Debt [Member] | Directors Debentures [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount																	$ 150,000			$ 150,000
Convertible Debt [Member] | Subsequent Event [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount								$ 1,800,000																								$ 1,500,000
Debt Instrument, Convertible, Conversion Price | $ / shares																$ 5													$ 1.83
Conversion, percentage of weighted average price																51.00%
Consecutive Trading Days																20 days
Convertible Debt [Member] | Funded at the Closing of the Purchase Agreement Amendment [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount								1,800,000
Convertible Debt [Member] | Funded within thirty (30) days of the closing [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount								200,000
Convertible Debt [Member] | Funded within two days following the filing of a registration statement with the SEC to register the shares underlying the debentures [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount								100,000
Convertible Debt [Member] | Funded within two days of receipt of the first comment letter from the SEC with regard to the Registration Statement [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount								100,000
Convertible Debt [Member] | Funded within two days of the date that the Registration Statement is declared effective by the SEC [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount								100,000
Convertible Debt [Member] | Funded within five days of the date that the Registration Statement is declared effective by the SEC [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount								500,000
Convertible Debt [Member] | Funded within each of 90, 120, 150, and 180 days from the Closing of the Purchase Agreement Amendment Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount								500,000
Convertible Debt [Member] | Funded at the Closing [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount								$ 100,000
Convertible Debt [Member] | September 2014 Convertible Debentures [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount																	$ 1,300,000			$ 1,300,000
Debt Instrument, Payment Terms																				The original agreement called for amortization payments, including accrued principal and accrued interest, due in nine monthly installments, commencing the fourth month after issuance.		Repayment, including accrued principal and accrued interest, due in nine monthly installments, commencing the fourth month after issuance.
Debt Instrument, Description																				The second closing, of $1,500,000, is to occur within 2 days of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the September 2014 Debentures.		The second closing, of $1,500,000, is to occur within 2 days of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the September 2014 Purchase Agreement Debentures.
Debt Instrument, Convertible, Conversion Price | $ / shares																	$ 0.88			$ 0.88
Debt instrument, convertible, terms of conversion feature																				Modified Debentures all have a fixed conversion price of the lower of $0.88 or 51% of the VWAP for the last 40 days prior to the conversion.
Conversion, percentage of weighted average price																				51.00%
Consecutive trading days																				40 days
Warrants to purchase shares common stock | shares	2,291,832
Percentage reduction of exercise price of warrants to purchase share of common stock	6.00%
Class of warrant or right, exercised | shares	2,292,000
Convertible Debt [Member] | Debt Instrument, Tranche One [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount												$ 1,000,000			1,000,000
Proceeds from convertible debt															1,000,000					$ 650,000
Convertible Debt [Member] | Debt Instrument, Tranche Two [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount												$ 1,500,000			1,000,000
Proceeds from convertible debt													$ 1,000,000							500,000
Convertible Debt [Member] | Debt Instrument, Tranche Three [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount															$ 1,000,000
Proceeds from convertible debt										$ 500,000										500,000
Convertible Debt [Member] | Debt Instrument, Tranche Four [Member]
Debt Conversion [Line Items]
Proceeds from convertible debt					$ 500,000				$ 250,000											700,000
Convertible Debt [Member] | Debt Instrument, Tranche Five [Member]
Debt Conversion [Line Items]
Proceeds from convertible debt				$ 500,000
Convertible Debt [Member] | July 2014 Convertible Debentures [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount																	$ 300,000			$ 300,000
Proceeds from convertible debt																		$ 2,811,500
Debt Instrument, Payment Terms																				The original agreement calling for amortization payments, including accrued principal and accrued interest, beginning on the eleventh day of the fourth month after issuance and will continue on the eleventh day of each following eight successive months thereafter.		Repayment, including accrued principal and accrued interest, beginning on the eleventh day of the fourth month after issuance and will continue on the eleventh day of each following 8 successive months thereafter.
Debt Instrument, Convertible, Conversion Price | $ / shares			$ 0.88														$ 1.83			$ 1.83
Debt instrument, convertible, terms of conversion feature																				The first $300,000 had a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 40 days prior to the conversion. The April 17, 2015 closing contained a fixed conversion price of the lower of $0.88 or 51% of the VWAP for the last 40 days prior to the conversion.
Conversion, percentage of weighted average price			51.00%																	51.00%
Consecutive trading days			40 days																	40 days
Warrants to purchase shares common stock | shares	6,332,441
Percentage reduction of exercise price of warrants to purchase share of common stock	6.00%
Class of warrant or right, exercised | shares																				0
Convertible Debt [Member] | July 2014 and September 2014 Convertible Debentures [Member]
Debt Conversion [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares																	$ 1.83			$ 1.83
Convertible Debt [Member] | August 2015 Debentures [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount																	$ 200,000			$ 200,000				$ 1,500,000
Proceeds from convertible debt																				$ 1,078,880
Debt Instrument, Interest Rate, Stated Percentage																	10.00%			10.00%
Debt Instrument, Description																				In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement. The pre-effective registration statement was filed with the SEC on October 16, 2015.
Debt Instrument, Convertible, Conversion Price | $ / shares																	$ 0.75			$ 0.75
Debt instrument, convertible, terms of conversion feature																				All amounts are convertible at any time, in whole or in part, at the option of the holders into shares of the Company's common stock at a fixed conversion price. The conversion price is the lower of (a) $0.75, or (b) a 49% discount to the lowest daily VWAP (as reported by Bloomberg) of the Common Stock during the 30 trading days prior to the conversion date. The Fixed Conversion Price is subject to adjustment for stock splits, combinations or similar events. If the Company makes any subsequent equity sales (subject to certain exceptions), under which an effective price per share is lower than the Fixed Conversion Price, then the conversion price will be reset to equal such price. The Company may prepay the Debentures in cash, prompting a 30% premium or, subject to certain conditions, in shares of common stock valued at 51% of the lowest volume weighted average price of the common stock for the 30 prior trading days. The premium will be recognized at such time as the Company may choose to prepay the Debentures.
Derivative Liability																	$ 2,345,000			$ 2,345,000
Conversion, percentage of weighted average price																				51.00%
Consecutive trading days																				30 days
Warrant instrument grant agreement, description																				The debenture entered into with the second investor on August 20, 2015 included a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Debenture divided by a price equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Debenture, with a three year term.
Percentage of discount to common stock valuation																				49.00%
Percentage of premium																				30.00%
Percentage of debenture conversion price on common stock price																				120.00%
Debenture conversion term																				3 years
Warrants to purchase common stock outstanding | shares																	7,254,902			7,254,902
Class of warrant or rights, outstanding																	$ 404,561			$ 404,561
Conversions of convertible debentures | shares																	0
Convertible Debt [Member] | August 2015 Debentures [Member] | Maximum [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount																	$ 3,979,877			3,979,877
Convertible Debt [Member] | Debt Instrument Tranche Seven [Member]
Debt Conversion [Line Items]
Proceeds from convertible debt																				250,000
Convertible Debt [Member] | Debt Instrument Tranche Eight [Member]
Debt Conversion [Line Items]
Proceeds from convertible debt																				1,250,000
Convertible Debt [Member] | Debt Instrument Tranche Nine [Member]
Debt Conversion [Line Items]
Proceeds from convertible debt																				$ 750,000
Convertible Debt [Member] | July 2015 Debenture [Member].
Debt Conversion [Line Items]
Debt Instrument, Face Amount		$ 500,000
Number of tranches | Tranches		5
Convertible Debt [Member] | July 2015 Debenture [Member]. | Subsequent Event [Member]
Debt Conversion [Line Items]
Debt Instrument, Face Amount																							$ 100,000

Prepaid Expenses And Other Cu66

Prepaid Expenses And Other Current Assets - Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Prepaid expenses and other current assets
Rent		$ 0	$ 3,962
Directors & officers insurance	$ 240,428	31,491	0
Professional fees		10,000	52,739
Other vendors		24,729	32,540
Prepaid expenses and other current assets	$ 172,039	34,729	$ 89,241
As Originally Presented [Member]
Prepaid expenses and other current assets
Prepaid expenses and other current assets		$ 66,220

Share Based Awards, Restricted

Share Based Awards, Restricted Stock and Restricted Stock Units ("RSUs") - Additional Information (Detail)

Sep. 24, 2015shares

Aug. 31, 2015$ / sharesshares

Aug. 26, 2015$ / sharesshares

Aug. 11, 2015USD ($)$ / sharesshares

Jun. 30, 2015USD ($)$ / sharesshares

May. 11, 2015USD ($)shares

Apr. 01, 2015shares

Feb. 10, 2015USD ($)shares

Jan. 15, 2015USD ($)shares

Sep. 08, 2014Person

Aug. 21, 2014USD ($)Personshares

Jul. 23, 2014USD ($)

Oct. 31, 2014shares

Sep. 30, 2015USD ($)

Jun. 30, 2015USD ($)

Sep. 30, 2014shares

Sep. 30, 2015$ / sharesshares

Dec. 31, 2014USD ($)$ / sharesshares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Employment Agreement, Term

2 years

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

Under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant.

Under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant.

Stock Issued During Period, Value, Restricted Stock Award, Gross | $

$ 711,500

$ 970,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period

1 year

Number of Board Members | Person

2

2

Stock compensation expense | $

$ 197,000

$ 353,000

2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Value of bonus share issued | $

$ 371,666

Number of bonus share issued

1,196,988

Percentage of bonus to be paid in common stock

20.00%

Per share price | $ / shares

$ 0.0621

Remainder bonus amount | $

$ 50,000

Monthly payments of bonus | $

$ 30,918

Officers and Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Grant date fair value of RSU's | $ / shares

$ 12,000

CFO [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares granted

156,250

Grant date fair value of RSU's | $ / shares

$ 25,000

Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Value, Restricted Stock Award, Gross | $

$ 1,267,500

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)

50,000

70,000

Number of shares granted

121,875

698,522

422,980

Number of shares underlying restricted stock

121,875

Unvested RSU's forfeited

50,000

50,000

0

Number of shares vested on grant date

590,502

223,396

Grant date fair value of RSU's | $ / shares

$ 10.84

Restricted Stock Units (RSUs) [Member] | Additional Award [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)

20,000

Restricted Stock Units (RSUs) [Member] | Former Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares granted

2,580,000

Shares granted in period, term

10 years

Shares granted in period, exercise price | $ / shares

$ 0.13

Fair value of shares granted | $

$ 335,117

$ 335,117

Restricted Stock Units (RSUs) [Member] | Officers and Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Value, Restricted Stock Award, Gross | $

$ 20,000

$ 114,000

Number of shares granted

79,917

38,600

100,174

Vesting period description

The RSU's vest every six months through December 31, 2016.

Number of shares vested on grant date

38,600

Restricted Stock Units (RSUs) [Member] | Board of Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares granted

100,000

19,452

Restricted Stock Units (RSUs) [Member] | Board of Directors [Member] | Scenario Forecast [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares granted

100,000

Restricted Stock Units (RSUs) [Member] | Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Value, Restricted Stock Award, Gross | $

$ 450,000

Number of shares granted

75,000

Vesting period description

Vest in 25,000 installments quarterly through July 15, 2015, beginning with 25,000 which vested immediately on the grant date.

Number of shares vested on grant date

25,000

Restricted Stock Units (RSUs) [Member] | New Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Value, Restricted Stock Award, Gross | $

$ 100,000

Number of shares granted

196,078

Vesting period description

The RSUs vest quarterly through May 11, 2016

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Value, Restricted Stock Award, Gross | $

$ 3,607,500

Number of shares granted

346,875

150,000

346,875

Unvested RSU's forfeited

0

0

Number of shares vested on grant date

206,250

178,125

Grant date fair value of RSU's | $ / shares

$ 0

$ 10.40

Share Based Awards, Restricte68

Share Based Awards, Restricted Stock and Restricted Stock Units ("RSUs") - Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Detail) - $ / shares	Sep. 24, 2015	Aug. 21, 2014	Sep. 30, 2015	Dec. 31, 2014
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock and RSUs non-vested at beginning of period			168,750	0
Restricted stock and RSUs granted		346,875	150,000	346,875
Restricted stock and RSUs vested			(206,250)	(178,125)
Restricted stock and RSUs forfeited			0	0
Restricted stock and RSUs non-vested at end of period			112,500	168,750
Restricted stock and RSUs non-vested at beginning of period			$ 10.40	$ 0
Restricted stock and RSUs granted			0	10.40
Restricted stock and RSUs vested			10.40	10.40
Restricted stock and RSUs forfeited			0	0
Restricted stock and RSUs non-vested at end of period			$ 10.40	$ 10.40
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock and RSUs non-vested at beginning of period			199,584	0
Restricted stock and RSUs granted		121,875	698,522	422,980
Restricted stock and RSUs vested			(590,502)	(223,396)
Restricted stock and RSUs forfeited	(50,000)		(50,000)	0
Restricted stock and RSUs non-vested at end of period			257,604	199,584
Restricted stock and RSUs non-vested at beginning of period			$ 10.70	$ 0
Restricted stock and RSUs granted				10.84
Restricted stock and RSUs vested				11.19
Restricted stock and RSUs forfeited				0
Restricted stock and RSUs non-vested at end of period				$ 10.70
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock and RSUs granted			0.51
Restricted stock and RSUs vested			0.51
Restricted stock and RSUs non-vested at end of period			0.51
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock and RSUs granted			6.07
Restricted stock and RSUs vested			6.07
Restricted stock and RSUs non-vested at end of period			$ 10.70

Share Based Awards, Restricte69

Share Based Awards, Restricted Stock and Restricted Stock Units ("RSUs") - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Detail) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	$ 1,039,173	$ 5,331,382	$ 1,031,640	$ 4,415,799
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	74,333	74,333
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	390,000	2,420,782		663,262
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	$ 574,840	2,501,150		$ 3,752,537
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation		$ 335,117

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)

Sep. 30, 2015USD ($)Agreement

Nov. 30, 2014shares

Nov. 01, 2014USD ($)shares

Oct. 17, 2014USD ($)Agreement

Sep. 08, 2014shares

Aug. 15, 2014USD ($)

Jul. 21, 2014USD ($)

Jan. 01, 2012USD ($)shares

Oct. 31, 2014shares

Sep. 30, 2014USD ($)

Dec. 31, 2014USD ($)shares

Sep. 30, 2014shares

Sep. 30, 2015USD ($)

Dec. 31, 2014USD ($)NotesPayable

Dec. 31, 2013USD ($)NotesPayable

Dec. 31, 2012USD ($)

Jun. 30, 2014USD ($)

Mar. 28, 2014USD ($)

Oct. 28, 2013USD ($)

Sep. 20, 2013USD ($)

Related Party Transactions [Line Items]

Notes Payable, Related Parties, Current

$ 678,877

$ 678,877

$ 111,794

Escrow Deposit

$ 15,000

400,476

$ 15,000

400,476

Number of real estate purchase agreements on which escrow deposits paid | Agreement

1

Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares) | shares

346,875

Contribution from related parties

810,000

$ 561,000

Deposits and other assets

$ 140,212

$ 104,726

$ 140,212

$ 104,726

98,726

Restricted Stock Units (RSUs) [Member]

Related Party Transactions [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares) | shares

50,000

70,000

Additional Award [Member] | Restricted Stock Units (RSUs) [Member]

Related Party Transactions [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares) | shares

20,000

Territory Rights Agreement [Member]

Related Party Transactions [Line Items]

Deposits and other assets

$ 500,000

Agreement term

5 years

Revenue recognition period

5 years

Deferred revenue

$ 350,000

$ 350,000

Investor [Member]

Related Party Transactions [Line Items]

Notes Payable, Related Parties, Current

94,000

Debt Instrument, Face Amount

$ 125,000

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Debt Instrument, Maturity Date, Description

due on demand

Affiliated Entity [Member]

Related Party Transactions [Line Items]

Manufacturing Costs

480,000

$ 510,000

Escrow Deposit

$ 190,400

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member]

Related Party Transactions [Line Items]

Notes Payable, Related Parties, Current

$ 775,038

Debt Instrument, Face Amount

$ 1,000,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Maturity Date, Description

due on demand

Equity Method Investment, Ownership Percentage

100.00%

100.00%

100.00%

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares) | shares

4,000,000

Debt Instrument, Collateral

secured with 1,000,000 shares of the Company's common stock

Number of Promissory Notes | NotesPayable

4

Due to Related Parties, Current

$ 388,477

$ 388,477

$ 284,488

Number of real estate purchase agreements on which escrow deposits paid | Agreement

8

Repayments of Related Party Debt

$ 75,000

Percentage of ownership by co-founder

100.00%

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #1 [Member]

Related Party Transactions [Line Items]

Debt Instrument, Face Amount

250,000

$ 250,000

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #2 [Member]

Related Party Transactions [Line Items]

Debt Instrument, Face Amount

100,000

100,000

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #3 [Member]

Related Party Transactions [Line Items]

Debt Instrument, Face Amount

500,000

500,000

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #4 [Member]

Related Party Transactions [Line Items]

Debt Instrument, Face Amount

$ 375,000

$ 375,000

Affiliated Entity [Member] | Kind Clinics, LLC [Member]

Related Party Transactions [Line Items]

Equity Method Investment, Ownership Percentage

100.00%

Related Party Transaction, Amounts of Transaction

$ 113,613

Affiliated Entity [Member] | Vincent Chase Inc. [Member]

Related Party Transactions [Line Items]

Debt Instrument, Face Amount

$ 100,000

$ 100,000

$ 150,000

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Debt Instrument, Maturity Date, Description

payable on demand

Equity Method Investment, Ownership Percentage

100.00%

100.00%

Related Party Transaction, Amounts of Transaction

$ 168,625

$ 262,500

$ 230,706

Number of Promissory Notes | NotesPayable

2

Due to Related Parties, Current

$ 111,794

Affiliated Entity [Member] | Dr. Bruce Consulting [Member]

Related Party Transactions [Line Items]

Equity Method Investment, Ownership Percentage

100.00%

100.00%

Related Party Transaction, Amounts of Transaction

$ 500,000

$ 43,750

$ 133,991

Former Chief Executive Officer [Member]

Related Party Transactions [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares) | shares

20,000

Stock Issued During Period, Value, Share-based Compensation, Forfeited

$ 20,000

Former Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]

Related Party Transactions [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares) | shares

50,000

70,000

Former Chief Executive Officer [Member] | Additional Award [Member] | Restricted Stock Units (RSUs) [Member]

Related Party Transactions [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares) | shares

20,000

Related Party And Shareholder [Member]

Related Party Transactions [Line Items]

Related Party Transaction, Amounts of Transaction

150,000

Deposits and other assets

$ 400,000

$ 400,000

$ 500,000

Agreement term

5 years

Revenue recognition period

5 years

Stockholder's Equity - Addition

Stockholder's Equity - Additional Information (Detail)	Aug. 24, 2015shares	Oct. 07, 2014shares	Sep. 08, 2014Personshares	Aug. 21, 2014Person	Jun. 05, 2014USD ($)shares	Feb. 03, 2014shares	Dec. 18, 2013	Jan. 01, 2012shares	Jan. 31, 2015shares	Jan. 31, 2014USD ($)$ / sharesshares	Jan. 31, 2013shares	Nov. 30, 2011$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2012USD ($)shares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2012USD ($)shares	Jun. 30, 2015$ / sharesshares	Apr. 01, 2013	Mar. 22, 2013
Stockholders Equity [Line Items]
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares													$ 0.001		$ 0.001		$ 0.001	$ 0.001
Preferred Stock, Shares Outstanding													3,000,000		1,000,000		3,000,000	3,000,000
Treasury Stock, Shares													60,000				60,000
Proceeds from Issuance of Common Stock (in Dollars) | $																$ 2,442,859	$ 2,442,859	$ 4,486,541	$ 858,415
Dividends Payable, Nature							two-for-one (2:1)
Common Stock Dividends, Shares						14,762,875
Stock Issued During Period, Shares, Share-based Compensation, Gross			346,875
Number of Board Members | Person			2	2
Stock Issued During Period, shares, as a payment of certain accounts payables													52,892		1,633,047
Stock Issued During Period, value, as a payment of certain accounts payables | $													$ 316,065		$ 364,728		$ 316,065	$ 119,553
Stock value to be received | $														$ 153,250					$ 153,250
Shares to be received														74,100					74,100
Common stock, authorized													100,000,000		100,000,000		100,000,000	100,000,000		100,000,000
Common stock, authorized after amendment																				400,000,000
Common stock, par value | $ / shares													$ 0.001		$ 0.001		$ 0.001	$ 0.001		$ 0.001
Increase of authorized capital approved by the stockholders, effective date															Oct. 27, 2015
Common Stock [Member]
Stockholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues																	485,830	2,115,100	2,463,366
Stock Issued During Period, shares, as a payment of certain accounts payables															1,633,047		54,392	43,506
Stock Issued During Period, value, as a payment of certain accounts payables | $															$ 1,633		$ 54	$ 44
Non-cash additions to equity from the issuances of warrants and common stock in connection with acquisition | $																			$ 4,000
Shares of common stock sold																			2,463,000
Proceed from issuance of common stock | $																			$ 858,000
Issuance of common stock for acquisition PVMI (in Shares)																			4,000,000
Cancelled shares															3,000,000
Issuance common stock upon exercise of the warrants held by various previous owners of VII															206,480		252,812
Common Stock [Member] | Vincent Chase [Member]
Stockholders Equity [Line Items]
Cancelled shares	3,000,000
Preferred Stock [Member]
Stockholders Equity [Line Items]
Stock Repurchased and Retired During Period, Shares																		3,000,000
Cancelled shares															2,000,000
Preferred Stock [Member] | Vincent Chase [Member]
Stockholders Equity [Line Items]
Cancelled shares	2,000,000
Series A Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares																$ 0.001
Preferred Stock, Shares Outstanding													3,000,000	6,000,000	1,000,000	3,000,000	3,000,000	3,000,000	6,000,000
Special voting right												The Series A Preferred Stock has special voting rights when voting as a class with the Common Stock as follows: (i) the holders of Series A Preferred Stock shall have such number of votes as is determined by multiplying (a) the number of shares of Series A Preferred Stock held by such holder, (b) the number of issued and outstanding shares of the Corporation’s Series A Preferred Stock and Common Stock (collectively, the “Common Stock”) on a Fully-Diluted Basis (as hereinafter defined), as of the record date for the vote, or, if no such record date is established, as of the date such vote is taken or any written consent of stockholders is solicited, and (c) 0.00000025; and (ii) the holders of Common Stock shall have one vote per share of Common Stock held as of such date. “Fully-Diluted Basis” mean that the total number of issued and outstanding shares of the Company’s Common Stock shall be calculated to include (a) the shares of Common Stock issuable upon exercise and/or conversion of all of the following securities (collectively, “Common Stock Equivalents”): all outstanding (a) securities convertible into or exchangeable for Common Stock, whether or not then convertible or exchangeable (collectively, “Convertible Securities”), (b) subscriptions, rights, options and warrants to purchase shares of Common Stock, whether or not then exercisable (collectively, “Options”), and (c) securities convertible into or exchangeable or exercisable for Options or Convertible Securities and any such underlying Options and/or Convertible Securities.
Series A Preferred Stock [Member] | Stock Issued to Founder and Shareholder [Member]
Stockholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues												6,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares												$ 0.001
Convertible Preferred Stock, Terms of Conversion												converted to common stock at a ratio of 1 (one) share of Series A Preferred Stock to 5 (five) shares of common stock
Series A Preferred Stock [Member] | Stock Issued To Shareholder [Member]
Stockholders Equity [Line Items]
Stock Repurchased During Period, Shares														3,000,000
Series A Preferred Stock [Member] | Stock Issued to Founder [Member]
Stockholders Equity [Line Items]
Stock Repurchased and Retired During Period, Shares											3,000,000
Common Stock Issuance [Member]
Stockholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues										485,830								2,115,100
Sale of Stock, Price Per Share (in Dollars per share) | $ / shares										$ 5								$ 2.23
Proceeds from Issuance of Common Stock (in Dollars) | $										$ 2,427,859								$ 4,486,541
Affiliated Entity [Member]
Stockholders Equity [Line Items]
Treasury Stock, Shares													60,000				60,000
Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member]
Stockholders Equity [Line Items]
Issuance of common stock for acquisition PVMI (in Shares)								4,000,000
Business Acquisition, Percentage of Voting Interests Acquired								100.00%
Affiliated Entity [Member] | Bio-Tech Medical Software [Member]
Stockholders Equity [Line Items]
Stock Repurchased During Period, Shares					30,000
Stock Repurchased During Period, Value (in Dollars) | $					$ 604,800
Affiliated Entity [Member] | MedVend Holdings LLC [Member]
Stockholders Equity [Line Items]
Stock Repurchased During Period, Shares					30,000
Stock Repurchased During Period, Value (in Dollars) | $					$ 604,800
Board Member [Member]
Stockholders Equity [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		84,374	93,751
Vaporfection International Inc. [Member]
Stockholders Equity [Line Items]
Non-cash additions to equity from the issuances of warrants and common stock in connection with acquisition | $																		$ 1,285,553
Business Acquisition, Percentage of Voting Interests Acquired																					100.00%	100.00%
Issuance common stock upon exercise of the warrants held by various previous owners of VII									206,480								252,812

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets
Customer deposits	$ 295,000	$ 293,000
Deferred revenue	35,000	0
Share based compensation	1,760,000	0
NOL carryforward	5,400,000	2,377,000
Total deferred tax asset	7,490,000	2,670,000
Deferred tax liabilities:
Deferred revenue	0	285,000
Intangible asset amortization	20,000	0
Total deferred tax liabilities	20,000	285,000
Net deferred tax assets	7,470,000	2,385,000
Less: Valuation allowance	(7,470,000)	(2,385,000)
Net	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014USD ($)
Income Tax Disclosure [Abstract]
Valuation allowance, change in amount	$ 5,085,000
Net operating loss carryforwards	$ 13,510,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory Rate and Effective Rate for Provisions for Income Taxes (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal Tax statutory rate	34.00%	34.00%	34.00%
State tax statutory rate	6.00%	8.84%	8.84%
Permanent differences	(6.72%)
Valuation allowance	(33.28%)	(42.84%)	(42.84%)
Effective rate	0.00%	0.00%	0.00%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)

Oct. 14, 2015USD ($)

Sep. 30, 2015USD ($)Agreement

Sep. 08, 2015USD ($)

Aug. 31, 2015USD ($)

Aug. 24, 2015USD ($)

Apr. 22, 2015USD ($)shares

Dec. 31, 2014USD ($)

Dec. 26, 2014USD ($)

Oct. 17, 2014USD ($)Agreement

Oct. 16, 2014USD ($)

Oct. 13, 2014USD ($)

Jul. 23, 2014

Jul. 22, 2014USD ($)

Jul. 01, 2014USD ($)

Jun. 05, 2014shares

May. 08, 2014USD ($)

Dec. 17, 2013USD ($)

May. 22, 2013USD ($)

Aug. 01, 2011USD ($)

Apr. 30, 2015USD ($)

Jan. 31, 2015USD ($)

Oct. 31, 2014USD ($)shares

Jul. 31, 2014USD ($)Agreement

Sep. 30, 2015USD ($)

Sep. 30, 2014USD ($)Agreement

Sep. 30, 2015USD ($)

Sep. 30, 2014USD ($)

Dec. 31, 2014USD ($)Agreementshares

Dec. 31, 2013USD ($)

Dec. 31, 2012USD ($)

Jul. 21, 2014USD ($)

Jun. 30, 2014USD ($)

Nov. 19, 2013USD ($)

Jun. 30, 2013

Mar. 31, 2013

Mar. 12, 2013USD ($)

Jan. 01, 2012

Other Commitments [Line Items]

Operating Leases, Rent Expense

$ 90,000

$ 53,000

$ 211,000

$ 157,000

$ 204,726

$ 139,330

$ 124,727

Escrow Deposits Related to Property Sales

$ 15,000

Payments to Acquire Real Estate

$ 50,000

500,000

399,594

399,594

Real Estate, Purchase Price

$ 875,000

$ 2,120,000

875,000

875,000

2,120,000

Number of Real Estate Purchase Agreements | Agreement

1

Earnest Money Forfeited

280,000

Notes Issued

5,000,000

Escrow Deposit

$ 15,000

400,476

15,000

$ 15,000

$ 400,476

Employment Agreement, Term

2 years

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

Under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant.

Under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant.

Investment Owned, at Cost

1,200,000

Charges in lieu of rent and other non refundable charges to property sellers

$ 195,712

Assets held for resale

399,594

$ 399,594

$ 0

Amount recovered out of escrow deposit

105,000

Amount retained by company

$ 600,000

Convertible Debt [Member]

Other Commitments [Line Items]

Debt Instrument, Payment Terms

Due to the restatement discussed above, the registration statement has been delayed. As a result of the withdraw of the Form S-1, in January 2015 the Company agreed with the lenders to adjust the conversion rate for the amortization payments and reduced the volume weighted average price for 20 days prior to the issuance to 51%. See Note 20 Subsequent Events for purchase agreement modifications finalized in January 2015.

Vaporfection International Inc. [Member]

Other Commitments [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

$ 1,981

Lessee Leasing Arrangements, Operating Leases, Term of Contract

1 year

President [Member]

Other Commitments [Line Items]

Severance payable

500,000

500,000

500,000

Monthly severance payments

$ 30,000

Chief Operating Officer [Member]

Other Commitments [Line Items]

Annual base salary

$ 300,000

Restricted stock units convertible into company common stock | shares

100,000

Severance payment term

Mr. Goh shall be entitled to receive a severance payment equivalent to 6, 12, or 18 months of base salary, based upon whether the length of Mr. Goh's employment with the Company at the time of termination is less than 12 months, greater than 12 months but less than 24 months, or greater than 24 months, respectively.

Maximum [Member] | President [Member]

Other Commitments [Line Items]

Option to purchase common stock, value

$ 335,275

Maximum [Member] | Chief Operating Officer [Member]

Other Commitments [Line Items]

Annual base salary increase, Percentage

7.00%

Cash bonus per year

$ 150,000

Annual equity bonus

$ 150,000

Minimum [Member] | Chief Operating Officer [Member]

Other Commitments [Line Items]

Annual base salary increase, Percentage

5.00%

Employment Termination Less Than Twelve Months [Member] | Chief Operating Officer [Member]

Other Commitments [Line Items]

Severance payment

6 months

Employment Termination Greater Than Twelve Months But Less Than Twenty Four Months [Member] | Chief Operating Officer [Member]

Other Commitments [Line Items]

Severance payment

12 months

Employment Termination Greater Than Twenty Four Months [Member] | Chief Operating Officer [Member]

Other Commitments [Line Items]

Severance payment

18 months

MedVend Holdings LLC [Member]

Other Commitments [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

Investment Owned, at Cost

$ 4,100,000

First Amendment [Member]

Other Commitments [Line Items]

Date of voting agreement

Jan. 21, 2015

Expiration date of agreement

Jan. 20, 2016

Extended expiration date of agreement

Jul. 20, 2016

First Amendment [Member] | PVM International Inc. (PVMI) [Member]

Other Commitments [Line Items]

Remaining balance due to related party

478,877

478,877

$ 478,877

Second Amendment [Member]

Other Commitments [Line Items]

Date of voting agreement

Aug. 21, 2015

Extended expiration date of agreement

Jul. 20, 2018

Second Amendment [Member] | PVM International Inc. (PVMI) [Member]

Other Commitments [Line Items]

Remaining balance due to related party

$ 328,877

$ 328,877

$ 328,877

Repayment of principal and accrued interest of promissory notes

$ 82,220

$ 82,220

$ 82,220

Pre-payment of promissory notes description

Company would make certain accelerated pre-payments on the $328,877 balance under the Note consisting of (i) three equal payments of principal in the amount of $82,220, together with accrued and unpaid interest, payable on each of August 24, 2015, August 31, 2015 and September 8, 2015, and (ii) one final payment on September 14, 2015 equal to the remaining principal and accrued and unpaid interest due under the Note

Affiliated Entity [Member]

Other Commitments [Line Items]

Escrow Deposit

$ 190,400

Affiliated Entity [Member] | MedVend Holdings LLC [Member]

Other Commitments [Line Items]

Claims damages

$ 500,000

Stock Repurchased During Period, Shares (in Shares) | shares

30,000

Investment Owned, at Cost

$ 4,100,000

Legal fees accrued

500,000

500,000

Plaintiff past due balance

$ 550,000

$ 550,000

Ownership stake percentage

50.00%

Affiliated Entity [Member] | MedVend Holdings LLC [Member] | Funded at the Closing of the Purchase Agreement Amendment [Member]

Other Commitments [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member]

Other Commitments [Line Items]

Number of Real Estate Purchase Agreements | Agreement

8

Equity Method Investment, Ownership Percentage

100.00%

100.00%

100.00%

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Remaining balance due to related party

$ 388,477

$ 388,477

$ 284,488

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Property 13 [Member]

Other Commitments [Line Items]

Escrow Deposit

$ 75,000

CFO [Member]

Other Commitments [Line Items]

Other Commitments, Description

Pursuant to the Employment Agreement, the Company agreed to engage Mr. Mitchell, and Mr. Mitchell agreed to serve as the Company's Chief Financial Officer, for a two-year term, which term will automatically be extended for successive additional one-year terms, unless either party provides written notice to the other 90 days prior to the expiration of the initial term or any successive term, that the Employment Agreement will not be renewed.

Employment Agreement, Term

2 years

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

Mitchell will also be entitled to an award of restricted stock units, to be issued within 90 days of the effective date of the Employment Agreement, under the Company's Equity Incentive Plan, in the amount of 7,500 shares of common stock each calendar quarter Mr. Mitchell serves as Chief Financial Officer of the Company.

CFO [Member] | Subsequent Event [Member]

Other Commitments [Line Items]

Employee Agreement, Description

Termination by the Company within 365 days of a Change of Control (as defined in the Employment Agreement) in the absence of Cause will conclusively be deemed a termination by the Company without Cause.

Vice President [Member] | Restricted Stock Units (RSUs) [Member]

Other Commitments [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures (in Shares) | shares

19,452

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in Shares) | shares

100,000

Amount Paid Upon Execution of the Contract [Member] | MedVend Holdings LLC [Member]

Other Commitments [Line Items]

Payments to Acquire Trading Securities Held-for-investment

300,000

Amount Disbursed as an Additional Investment [Member] | MedVend Holdings LLC [Member]

Other Commitments [Line Items]

Payments to Acquire Trading Securities Held-for-investment

$ 300,000

Kind Meds Inc [Member] | Medicine Dispensing Systems [Member]

Other Commitments [Line Items]

Claims damages

$ 500,000

Plaintiff past due balance

$ 550,000

Land and Building [Member]

Other Commitments [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

$ 20,000

$ 7,400

Lessee Leasing Arrangements, Operating Leases, Term of Contract

5 years

5 years

Security Deposit

$ 30,000

Real Estate, Purchase Price

399,594

399,594

Notes Issued

249,000

Land and Building [Member] | Subsequent Event [Member]

Other Commitments [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

$ 2,500

Lessee Leasing Arrangements, Operating Leases, Term of Contract

5 years

Land and Building [Member] | Potential Real Estate Purcahse Foreclosed Upon [Member]

Other Commitments [Line Items]

Number of Real Estate Purchase Agreements | Agreement

1

Proceeds from Other Deposits

$ 10,000

Land and Building [Member] | Agreement One [Member]

Other Commitments [Line Items]

Escrow Deposits Related to Property Sales

$ 930,000

Payments to Acquire Real Estate

26,830,000

Real Estate, Purchase Price

$ 2,500,000

2,500,000

Number of Real Estate Purchase Agreements | Agreement

2

Earnest Money Forfeited

$ 100,000

Land and Building [Member] | Agreement One [Member] | Forfeiture Of Earnest Money On Potential Purchase Of Real Estate [Member]

Other Commitments [Line Items]

Real Estate, Purchase Price

3,195,000

$ 3,195,000

Number of Real Estate Purchase Agreements | Agreement

3

Earnest Money Forfeited

$ 140,000

Land and Building [Member] | Real Estate Purchase Agreement [Member]

Other Commitments [Line Items]

Real Estate, Purchase Price

399,594

$ 399,594

Notes Issued

$ 249,000

Debt Instrument, Maturity Date before default

Jan. 30, 2015

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, default interest rate

18.00%

Assets held for resale

$ 399,594

399,594

Debt instrument, extended maturity date

Apr. 1, 2017

Debt Instrument, Interest Rate, Stated Percentage

12.00%

12.00%

12.00%

Office Lease, West Hollywood, California [Member]

Other Commitments [Line Items]

Operating Lease, Rent Increase, Percent

3.00%

Operating Leases, Rent Expense

$ 14,828

Lease Expiration Date

Jun. 30, 2017

Jun. 30, 2017

Operating Leases, Rent Expense, Minimum Rentals

$ 14,397

Office Facilities Lease, West Hills, California [Member]

Other Commitments [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

1,300

Office Facilities Lease, Scottsdale, Arizona [Member]

Other Commitments [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

1,420

Virtual offices/meeting spaces in Seattle and Illinois [Member]

Other Commitments [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

$ 705

Description of Lessee Leasing Arrangements, Operating Leases

month to month basis

Agreement Two [Member] | Land and Building [Member]

Other Commitments [Line Items]

Escrow Deposits Related to Property Sales

$ 685,000

Payments to Acquire Real Estate

21,515,000

Earnest Money Forfeited

235,757

Proceeds from Other Deposits

$ 419,167

Agreement Two [Member] | Land and Building [Member] | Subsequent Event [Member]

Other Commitments [Line Items]

Proceeds from Other Deposits

$ 30,076

Monthly Advisory and Consulting Service Fee [Member]

Other Commitments [Line Items]

Other Commitments, Description

The monthly consulting fee was reduced to $12,500 per month if Mr. Mehdizadeh is engaged in trading any of the Company's securities at any time within the preceding 30 day period.

Consulting agreement

$ 12,375

Other Commitment

$ 10,000

Hourly Advisory And Consulting Service Fee [Member]

Other Commitments [Line Items]

Other Commitment

$ 200

Advisory And Consulting Services [Member] | Restricted Stock Units (RSUs) [Member]

Other Commitments [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures (in Shares) | shares

100,000

Annual Salary [Member] | CFO [Member]

Other Commitments [Line Items]

Other Commitment

$ 190,000

Living Expenses [Member] | CFO [Member]

Other Commitments [Line Items]

Other Commitment

$ 2,500

Annual Bonus [Member] | CFO [Member] | Maximum [Member]

Other Commitments [Line Items]

Percentage of bonus on base salary

35.00%

Annual Cash Bonus [Member] | CFO [Member]

Other Commitments [Line Items]

Percentage of bonus in cash

50.00%

Office Lease Los Angeles California [Member]

Other Commitments [Line Items]

Operating Leases, Rent Expense

$ 7,486

Sublease term

18 months

Commitments and Contingencies76

Commitments and Contingencies - Summary of Material Contractual Lease Commitments (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Building [Member]
Property Subject to or Available for Operating Lease [Line Items]
2,015		$ 177,936
2,015	$ 66,942
2,016	245,310	177,936
2,017	88,968	88,968
2,018		0
2,019		0
Total	401,220	444,840
Land and Building [Member]
Property Subject to or Available for Operating Lease [Line Items]
2,015		88,800
2,015	22,200
2,016	88,800	88,800
2,017	88,800	88,800
2,018	88,800	88,800
2,019	29,600	29,600
Total	$ 318,200	$ 384,800

Commitments and Contingencies77

Commitments and Contingencies - Summary of Open Real Estate Purchase Transactions (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Sep. 30, 2015
Real Estate Properties [Line Items]
Purchase price	$ 2,120,000	$ 875,000
Net escrow balance	400,476
Additional rents/fees incurred to extend closing date	9,808
Property 1 [Member]
Real Estate Properties [Line Items]
Purchase price	$ 820,000
Closing date	Mar. 31, 2015
Net escrow balance	$ 55,000
Date escrow opened	Jun. 28, 2014
Additional rents/fees incurred to extend closing date	$ 9,808
Property 2 [Member]
Real Estate Properties [Line Items]
Purchase price	$ 1,300,000
Closing date	Mar. 30, 2015
Net escrow balance	$ 50,000
Date escrow opened	Oct. 17, 2014
Property 3 [Member]
Real Estate Properties [Line Items]
Purchase price	$ 0
Net escrow balance	$ 265,400
Date escrow opened	Jul. 21, 2014
Additional rents/fees incurred to extend closing date	$ 0
Escrow deposits to be refunded [Member]
Real Estate Properties [Line Items]
Net escrow balance	$ 30,076

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)

Nov. 04, 2015

Oct. 14, 2015USD ($)Debenture

Mar. 05, 2015USD ($)$ / sharesshares

Feb. 28, 2015USD ($)

Feb. 02, 2015USD ($)

Jan. 30, 2015USD ($)$ / shares

Jan. 15, 2015shares

Jan. 05, 2015USD ($)

Nov. 24, 2014USD ($)

Sep. 26, 2014USD ($)

Sep. 24, 2014USD ($)

Sep. 19, 2014USD ($)

Aug. 26, 2014USD ($)

Aug. 25, 2014USD ($)

Jul. 22, 2014USD ($)

Jul. 21, 2014USD ($)

May. 08, 2014USD ($)

Dec. 17, 2013USD ($)

Sep. 30, 2015USD ($)$ / sharesshares

Sep. 30, 2014USD ($)$ / shares

Dec. 31, 2014USD ($)Closings$ / shares

Dec. 31, 2012shares

Apr. 09, 2015USD ($)

Mar. 13, 2015$ / shares

Jan. 31, 2015$ / shares

Jan. 28, 2015USD ($)

Jan. 25, 2015USD ($)

Dec. 31, 2013USD ($)

Subsequent Event [Line Items]

Restricted common stock, amount

$ (15,000)

Proceeds from convertible debt

$ 7,432,128

$ 3,500,000

$ 3,475,000

Fixed conversion rate | $ / shares

$ 0.75

$ 11.75

$ 11.75

Debt instrument, convertible, terms of conversion feature

The Company may make the amortization payments on the debt in cash, prompting a 30% premium or, subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days.

Number of closings | Closings

6

Sixth Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

$ 5,000,000

Common Stock [Member]

Subsequent Event [Line Items]

Fixed conversion rate | $ / shares

$ 0.09

Conversion of warrants, shares | shares

67,475,105

Sale of stock, shares to be issued | shares

2,463,000

Vaporfection International Inc. [Member]

Subsequent Event [Line Items]

Lessee Leasing Arrangements, Operating Leases, Term of Contract

1 year

Operating Leases, Rent Expense, Minimum Rentals

$ 1,981

Notes Payable, Other Payables [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 12,434

Debt Instrument, Interest Rate, Stated Percentage

5.99%

Debt Instrument, Maturity Date

May 5, 2015

Note Warrant [Member]

Subsequent Event [Line Items]

Warrants exercisable period

5 years

Purchase an amount of Company Common Stock, as a percentage of principal amount of notes

50.00%

Warrants, exercise price as a percentage of conversion price

200.00%

Debt instrument, convertible, terms of conversion feature

The Conversion Price of the Warrants is either (i) 85% of the volume-weighted average price of the Common Stock for the thirty trading days prior to notice of Conversion or (ii) 85% of the per share price of the Company's next common stock offering of not less than $2 million. Mr. Siegel and Mr. Lowe also received registration rights for the shares underlying the Siegel Notes and the Lowe Notes, respectively.

Option One [Member] | First Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

$ 2,000,000

Option One [Member] | Second Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

2,000,000

Option One [Member] | Third Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

2,000,000

Option One [Member] | Fourth Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

2,000,000

Option One [Member] | Fifth Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

2,000,000

Option Two [Member] | First Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

1,000,000

Option Two [Member] | Second Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

1,000,000

Option Two [Member] | Third Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

1,000,000

Option Two [Member] | Fourth Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

1,000,000

Option Two [Member] | Fifth Closing [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

1,000,000

Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 2,500,000

$ 3,500,000

$ 4,994,000

$ 3,750,000

$ 1,500,000

Proceeds from convertible debt

$ 250,000

$ 500,000

$ 1,000,000

$ 1,000,000

$ 1,000,000

$ 150,000

Warrant instrument grant agreement, description

The Modified Debentures also included a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, with a three year term.

The parties also entered into a warrant instrument granting the Investor the right to purchase shares of common stock of the Company equal to the principal amount of the applicable Modified Debenture divided by a price (the "Reference Price") equal to 120% of the last reported closing price of the Common stock on the applicable closing date of the Modified Debenture, at an exercise price equal to the Reference Price, with a three year term.

Exercise price term

The Company also entered into a Debenture Amendment Agreement and an Amended and Restated Debenture for the amount outstanding under the original Debenture, (1) reflecting the terms set forth above, (2) providing for accrued and unpaid interest to be payable upon conversion or maturity rather than on specified payment dates and (3) amending the conversion price of the Debenture to be equal to the lower of $5.00 or 51% of the lowest volume weighted average price for the 20 consecutive trading days prior to the applicable conversion date.

Debenture fee percentage

5.00%

Fixed conversion rate | $ / shares

$ 5

$ 1.83

$ 1.83

Debt Instrument, Interest Rate, Stated Percentage

5.00%

10.00%

Debt instrument, convertible, terms of conversion feature

They were originally convertible at a fixed conversion price of the lower of $1.83 or 51% of the VWAP for the last 20 days prior to conversion.

Beginning four months (as subsequently amended) after the initial closing, the Company will begin making amortization payments on the debt in cash, prompting a 30% premium or, at their option and subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days. However, in the event the registration statement filed by the Company in connection with the respective purchase agreements is not effective within 120 days of the initial closing date under the July 2014 Purchase Agreement and 120 days of the initial closing date under the September 2014 Purchase Agreement, the July 2014 Purchase Agreement Debentures’ and the September 2014 Purchase Agreement Debentures’, respectively, conversion rate will be, during the period commencing 120 days after the initial closing date until the registration statement is effective, equal to 63% of the lowest volume weighted average price of the common stock for the 20 prior trading days. If the aforementioned registration statement is not effective within 160 days of the initial closing date, each of the debentures’ conversion rate will be, during the period commencing 160 days after the initial closing date until the registration statement is effective, equal to 60% of the lowest volume weighted average price of the common stock for the 20 prior trading days.

Debt Instrument, Maturity Date

Sep. 19, 2015

Jul. 21, 2015

Debentures [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 3,000,000

Debt Instrument, Tranche One [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 1,000,000

1,000,000

Proceeds from convertible debt

1,000,000

$ 650,000

Debt Instrument, Tranche Two [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 1,500,000

1,000,000

Proceeds from convertible debt

$ 1,000,000

500,000

Debt Instrument, Tranche Three [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 450,000

Debt Instrument, Tranche Three [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 1,000,000

Proceeds from convertible debt

$ 500,000

$ 500,000

Land and Building [Member]

Subsequent Event [Line Items]

Lessee Leasing Arrangements, Operating Leases, Term of Contract

5 years

5 years

Operating Leases, Rent Expense, Minimum Rentals

$ 20,000

$ 7,400

Subsequent Event [Member]

Subsequent Event [Line Items]

Sale of stock, shares to be issued | shares

22,160,000

Sale of stock, consideration

$ 15,000,000

Subsequent Event [Member] | Restricted Stock [Member] | PVM International Inc. (PVMI) [Member]

Subsequent Event [Line Items]

Sale of stock, consideration

$ 5,000,000

Sale of stock, price per share received | $ / shares

$ 2

Subsequent Event [Member] | Preferred Stock [Member]

Subsequent Event [Line Items]

Sale of stock, shares to be issued | shares

2,000,000

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Sale of stock, shares to be issued | shares

12,160,000

Subsequent Event [Member] | Vaporfection International Inc. [Member]

Subsequent Event [Line Items]

Conversion of warrants, shares | shares

206,480

Subsequent Event [Member] | Notes Payable, Other Payables [Member]

Subsequent Event [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18.00%

Notes payable

$ 249,000

Debt Instrument, Maturity Date

Jul. 1, 2015

Debt instrument late charge percentage on principal

5.00%

Subsequent Event [Member] | Minimum [Member] | Private Placement [Member]

Subsequent Event [Line Items]

Restricted common stock, amount

$ 1,000,000

Subsequent Event [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 1,800,000

1,500,000

Fixed conversion rate | $ / shares

$ 1.83

$ 5

Subsequent Event [Member] | Convertible Debt [Member] | Funded at the Closing of the Purchase Agreement Amendment [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

200,000

100,000

Subsequent Event [Member] | Convertible Debt [Member] | Funded within thirty (30) days of the closing [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

100,000

Subsequent Event [Member] | Convertible Debt [Member] | Funded within two days following the filing of a registration statement with the SEC to register the shares underlying the debentures [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

100,000

100,000

Subsequent Event [Member] | Convertible Debt [Member] | Funded within two days of receipt of the first comment letter from the SEC with regard to the Registration Statement [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

100,000

100,000

Subsequent Event [Member] | Convertible Debt [Member] | Funded within two days of the date that the Registration Statement is declared effective by the SEC [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

500,000

$ 1,200,000

Subsequent Event [Member] | Convertible Debt [Member] | Funded within five days of the date that the Registration Statement is declared effective by the SEC [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

500,000

Subsequent Event [Member] | Convertible Debt [Member] | Funded within each of 90, 120, 150, and 180 days from the Closing of the Purchase Agreement Amendment Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

100,000

Subsequent Event [Member] | Convertible Debt [Member] | Funded at the Closing [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

200,000

Subsequent Event [Member] | Convertible Subordinated Debt [Member] | Mr. Ned L. Siegel, the chairman of the Company's Board[Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 50,000

$ 50,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

8.00%

Subordinated convertible promissory notes, maturity period

3 years

3 years

Subsequent Event [Member] | Convertible Subordinated Debt [Member] | Directors [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 50,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Subordinated convertible promissory notes, maturity period

3 years

Subsequent Event [Member] | October 2015 Debentures [Member] | Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 2,000,000

Number of debentures issued | Debenture

7

Subsequent Event [Member] | Land and Building [Member]

Subsequent Event [Line Items]

Lessee Leasing Arrangements, Operating Leases, Term of Contract

5 years

Operating Leases, Rent Expense, Minimum Rentals

$ 2,500

Subsequent Event [Member] | Southwest [Member]

Subsequent Event [Line Items]

Profits after deduction of direct expenses

10.00%

Term of Agreement

5 years

Agreement extension terms

through mutual agreement by successive two year terms

Asset Acquisition - Additional

Asset Acquisition - Additional Information (Detail)	Jul. 24, 2015USD ($)aBuildingsInstallments	Sep. 30, 2015USD ($)a	Aug. 07, 2015a	Dec. 31, 2014USD ($)
Business Acquisition [Line Items]
Escrow Deposit		$ 15,000		$ 400,476
Fair value of acquired property	$ 5,000,000	500,000
Cash payment	500,000	$ 5,000,000
Purchase price allocation, land	4,945,000
Purchase price allocation, building and structures	$ 55,000
Number of buildings to be replaced | Buildings	2
EWSD [Member]
Business Acquisition [Line Items]
Business acquisition, percentage of equity interest	100.00%
Area of real estate property | a			320
Escrow Deposit	$ 500,000
Royalty percentage on adjusted gross revenues	3.00%
Royalty payment period	3 years
Percentage of royalty payable in cash	50.00%
Percentage of royalty payable in common stock	50.00%
EWSD [Member] | Leased Property [Member]
Business Acquisition [Line Items]
Area of real estate property | a		150
EWSD [Member] | Secured Promissory Note [Member]
Business Acquisition [Line Items]
Royalty payment terms		Company's future payments to Seller of a royalty of 3% of the adjusted gross revenue, if any, from operation of the Acquired Property (including sale of any portion of or interest in the Acquired Property less any applicable expenses) for the three-year period beginning on January 1, 2016. Such royalty payments shall be payable 50% in cash and 50% in Company common stock (the "Royalty Payment").
Debt Instrument, Face Amount	$ 3,670,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Debt instrument frequency description		Commencing on September 1, 2015 and continuing thereafter on the first day of each calendar month through and including July 1, 2018; and one final balloon payment of all unpaid principal and accrued but unpaid interest on August 1, 2018.
Debt Instrument, Payment Terms		The Note shall be payable by EWSD in thirty-five payments of principal and interest, which shall be calculated based upon an amortization period of thirty years
Amortization period of Debt instrument	30 years
Debt instrument frequency payments of principal and interest | Installments	35
EWSD [Member] | Unsecured Promissory Note [Member]
Business Acquisition [Line Items]
Acquisition date		Aug. 7, 2015
Debt Instrument, Face Amount	$ 830,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt instrument frequency description		Unsecured Note shall be payable by EWSD in thirty-five payments of principal and interest, which shall be calculated based upon a hypothetical amortization period of thirty years
Debt Instrument, Payment Terms		Commencing on September 1, 2015 and continuing thereafter on the first day of each calendar month through and including July 1, 2018; and one final balloon payment of all unpaid principal and accrued but unpaid interest on August 1, 2018.
Amortization period of Debt instrument	30 years
Debt instrument frequency payments of principal and interest | Installments	35
Balance amount owing to be paid		$ 4,485,763
Current maturities of long-term debt	$ 378,278
Southwest [Member]
Business Acquisition [Line Items]
Area of real estate property | a	320

Asset Acquisition - Schedule of

Asset Acquisition - Schedule of Principal Payments Due (Detail)	Sep. 30, 2015USD ($)
Debt Instrument [Line Items]
2,015	$ 310,509
2,016	81,990
2,017	88,642
2,018	4,004,622
Secured Promissory Note [Member]
Debt Instrument [Line Items]
2,015	8,851
2,016	54,691
2,017	58,007
2,018	3,536,670
Unsecured Promissory Note [Member]
Debt Instrument [Line Items]
2,015	301,658
2,016	27,299
2,017	30,635
2,018	$ 467,952

Asset Acquisition - Schedule 81

Asset Acquisition - Schedule of Purchase Price Allocation (Detail) - USD ($)	Sep. 30, 2015	Jul. 24, 2015
Business Acquisition [Line Items]
Cash deposit	$ 500,000	$ 5,000,000
Net fair value	5,000,000	$ 500,000
Southwest [Member]
Business Acquisition [Line Items]
Note Payable	3,670,000
EWSD [Member]
Business Acquisition [Line Items]
Note Payable	$ 830,000

Convertible Notes Payable and82

Convertible Notes Payable and Derivative Liability - Summary of Warrants Issued in Connection with Modified Debentures (Detail)	Sep. 30, 2015USD ($)$ / sharesshares
Class of Warrant or Right [Line Items]
Number of warrants | shares	16,375,508
Fair Value	$ 4,266,522
Directors [Member] | January 30, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	129,250
Exercise price | $ / shares	$ 0.40
Fair Value	$ 39,916
Directors [Member] | January 5, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	129,305
Exercise price | $ / shares	$ 0.40
Fair Value	$ 39,901
Directors [Member] | February 2, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	237,778
Exercise price | $ / shares	$ 0.22
Fair Value	$ 16,619
July 2015 Modified Debentures [Member] | January 30, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	40,552
Exercise price | $ / shares	$ 4.93
Fair Value	$ 159,601
July 2015 Modified Debentures [Member] | February 26, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	45,537
Exercise price | $ / shares	$ 2.20
Fair Value	$ 79,904
July 2015 Modified Debentures [Member] | March 13, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	21,151
Exercise price | $ / shares	$ 2.36
Fair Value	$ 39,965
July 2015 Modified Debentures [Member] | March 16, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	10,575
Exercise price | $ / shares	$ 2.36
Fair Value	$ 19,981
July 2015 Modified Debentures [Member] | March 20, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	41,946
Exercise price | $ / shares	$ 1.79
Fair Value	$ 59,942
July 2015 Modified Debentures [Member] | March 27, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	75,758
Exercise price | $ / shares	$ 1.98
Fair Value	$ 119,888
July 2015 Modified Debentures [Member] | April 2, 2015 First Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	60,386
Exercise price | $ / shares	$ 1.66
Fair Value	$ 74,025
July 2015 Modified Debentures [Member] | April 2, 2015 Second Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	30,193
Exercise price | $ / shares	$ 1.66
Fair Value	$ 37,012
July 2015 Modified Debentures [Member] | April 10, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	107,914
Exercise price | $ / shares	$ 1.39
Fair Value	$ 112,460
July 2015 Modified Debentures [Member] | April 17, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	41,667
Exercise price | $ / shares	$ 1.20
Fair Value	$ 37,680
July 2015 Modified Debentures [Member] | April 24, 2015 First Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	127,119
Exercise price | $ / shares	$ 1.18
Fair Value	$ 112,635
July 2015 Modified Debentures [Member] | April 24, 2015 Second Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	21,186
Exercise price | $ / shares	$ 1.18
Fair Value	$ 18,772
July 2015 Modified Debentures [Member] | May 1, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	156,250
Exercise price | $ / shares	$ 0.96
Fair Value	$ 113,133
July 2015 Modified Debentures [Member] | May 7, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	134,615
Exercise price | $ / shares	$ 0.78
Fair Value	$ 79,234
July 2015 Modified Debentures [Member] | May 8, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	42,000
Exercise price | $ / shares	$ 0.75
Fair Value	$ 23,768
July 2015 Modified Debentures [Member] | May 15, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	200,000
Exercise price | $ / shares	$ 0.75
Fair Value	$ 113,365
July 2015 Modified Debentures [Member] | May 22, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	250,000
Exercise price | $ / shares	$ 0.60
Fair Value	$ 113,366
July 2015 Modified Debentures [Member] | May 29, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	258,621
Exercise price | $ / shares	$ 0.58
Fair Value	$ 112,537
July 2015 Modified Debentures [Member] | June 5, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	288,462
Exercise price | $ / shares	$ 0.52
Fair Value	$ 120,738
July 2015 Modified Debentures [Member] | June 12, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	930,233
Exercise price | $ / shares	$ 0.43
Fair Value	$ 303,246
July 2015 Modified Debentures [Member] | June 19, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	3,448,276
Exercise price | $ / shares	$ 0.29
Fair Value	$ 751,159
September 2014 Modified Debentures [Member] | April 2, 2015 First Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	181,159
Exercise price | $ / shares	$ 1.66
Fair Value	$ 222,109
September 2014 Modified Debentures [Member] | April 24, 2015 First Issued [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	90,579
Exercise price | $ / shares	$ 1.10
Fair Value	$ 80,548
September 2014 Modified Debentures [Member] | May 15, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	200,000
Exercise price | $ / shares	$ 0.75
Fair Value	$ 113,365
September 2014 Modified Debentures [Member] | June 12, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	1,744,186
Exercise price | $ / shares	$ 0.43
Fair Value	$ 570,248
September 2014 Modified Debentures [Member] | January 28, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	18,038
Exercise price | $ / shares	$ 5.54
Fair Value	$ 80,156
September 2014 Modified Debentures [Member] | February 13, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	57,870
Exercise price | $ / shares	$ 1.73
Fair Value	$ 96,689
August 2015 Debentures [Member] | August 24, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	6,666,667
Exercise price | $ / shares	$ 0.06
Fair Value	$ 321,757
August 2015 Debentures [Member] | September 18, 2015 [Member]
Class of Warrant or Right [Line Items]
Number of warrants | shares	588,235
Exercise price | $ / shares	$ 0.17
Fair Value	$ 82,804